Viral vectors for the treatment of retinal dystrophy

ABSTRACT

The present invention relates to viral vectors that are capable of delivering a heterologous gene to the retina and in particular delivering RLBP1 to RPE and Müller cells of the retina. The invention also relates nucleic acids useful for producing viral vectors, compositions comprising the viral vectors and uses of the compositions and viral vectors. The invention also relates to methods of delivering and/or expressing a heterologous gene to the retina, improving the rate of dark adaption in a subject and treating RLBP1-associated retinal dystrophy.

RELATED APPLICATIONS

This application is a continuation of U.S. Application No. 16/725,081, filed Dec. 23, 2019, which is a divisional of U.S. Application No. 15/713,021, filed Sep. 22, 2017, now U.S. Pat. No. 10,550,404, which is a divisional of U.S. Application No. 14/881,960, filed Oct. 13, 2015, now U.S Pat. No. 9,803,217, which is a continuation of U.S. Application No. 13/873,558, filed Apr. 30, 2013, now U.S. Pat. No. 9,163,259, which claims priority to U.S. Provisional Application No. 61/642,630 filed May 4, 2012 and U.S. Provisional Application No. 61/776,167 filed Mar. 11, 2013, the contents of which are incorporated herein by reference in their entireties.

SEQUENCE LISTING

The instant application contains a Sequence Listing which was submitted in ASCII format via EFS-Web on Oct. 13, 2015, in U.S. Pat. Application No. 14/881,960, and is hereby incorporated by reference in its entirety.

BACKGROUND OF THE INVENTION

Retinitis pigmentosa (RP) refers to a group of inherited degenerations of the photoreceptor cells (rods and cones) of the retina leading to visual loss and blindness. Mutations in any of a wide variety of genes can cause RP, including genes encoding proteins that are involved in phototransduction (the process by which the energy of a photon of light is converted in the photoreceptor cell outer segment into a neuronal signal), the visual cycle (production and recycling of vitamin A in the retina), photoreceptor structure, and transcription factors (Phelan and Bok, 2000).

RLBP1-associated retinal dystrophy is a rare form of RP caused by mutations in the retinaldehyde binding protein 1 (RLBP1) gene on chromosome 15. Mutations in this gene cause absence of or dysfunction of cellular retinaldehyde-binding protein (CRALBP), a protein that is important in the visual cycle (He et al 2009). CRALBP is expressed in retinal pigment epithelium (RPE) and Muller cells, ciliary epithelium, iris, cornea, pineal gland and a subset of oligodendrocytes of the optic nerve and brain (Saari et al 1997). CRALBP accepts 11-cis-retinol from the isomerase RPE65 and acts as a carrier of this substrate for 11-cis-retinol dehydrogenase (RDH5) to convert the substrate into 11-cis-retinal. The rate of chromophore regeneration is severely reduced in the absence of functional CRALBP (Travis et al 2007). The function of CRALBP outside the RPE is not well understood, but it has been suggested that CRALBP in the Muller cells supports a cone-specific visual pathway that permits cone cells to quickly adapt to a wide range of light intensities (Wang and Kefalov 2011).

RLBP1-associated retinal dystrophy is characterized by early severe night blindness and slow dark adaptation, followed by progressive loss of visual acuity, visual fields and color vision leading to legal blindness typically around middle adulthood. The fundus appearance is characterized by yellow or white spots in the retina. The reduction in visual acuity and visual field significantly impacts patients’ quality of life (Burstedt and Mönestam, 2010).

The most common RLBP1 mutations leading to RLBP1-associated retinal dystrophy are recessive mutations, designated R234W and M226K (Golovleva I and Burstedt M 2012). RLBP1-associated retinal dystrophy caused by 1 or both of these recessive missense mutations is also known as Bothnia Dystrophy. Several other loss-of-function mutations in the RLBP1 gene have been reported to lead to RLBP1-associated retinal dystrophy. For example, splice-junction mutations in RLBP1 cause rod-cone dystrophy in Newfoundland. Currently there is no treatment available for RLBP1-associated retinal dystrophy (Eichers et al 2002).

The present invention is based in part on the discovery that expression of RLBP1 from recombinant adeno-associated viral vectors (rAAV) having a combination of selected promoter, AAV genome and capsid serotype provides a potent and efficacious treatment for RLBP1-associated retinal dystrophy.

SUMMARY OF THE INVENTION

The present invention relates generally to recombinant viral vectors and methods of using recombinant viral vectors to express proteins in the retina of subjects suffering from retinal diseases and blindness.

The present invention relates to viral vectors that are capable of delivering a heterologous gene to the retina. The present invention also relates to viral vectors that are capable of directing a heterologous gene to RPE and Müller cells of the retina. The present invention further relates to viral vectors that are recombinant adeno-associated viral vectors (rAAV). In certain embodiments the rAAV viral vector may be selected from among any AAV serotype known in the art, including, without limitation, AAV1-AAV12. In certain embodiments, the rAAV vector capsid is an AAV2 serotype. In certain other embodiments, the rAAV vector capsid is an AAV8 serotype.

The invention relates, in part, to viral vectors carrying a single stranded vector genome. In the single stranded viral vector, the vector genome can include a 5′ ITR, a recombinant nucleotide sequence comprising an RLBP1 coding sequence, and a 3′ ITR. The recombinant nucleic acid sequence of the vector genome can also include a promoter as described herein. In one aspect, the promoter is an RLBP1 (long) promoter (SEQ ID NO: 10), in another aspect the promoter is an RLBP1 (short) promoter (SEQ ID NO: 3). In certain specific aspects of the invention, the vector genome comprises, in the 5′ to 3′ direction, nucleic acid sequences selected from: a) SEQ ID NO: 2, 10, 5, 6, 8, and 9; b) SEQ ID NO: 2, 11, 5, 6, 8, 14, 9; c) SEQ ID NO: 2, 22, 5, 6, 8, 23, and 9; and d) SEQ ID NO: 2, 3, 4, 5, 6, 8, 23, and 9.

The invention also relates, in part, to viral vectors carrying a self-complementary genome. The self-complementary vector genome can include, from 5′ to 3′, a 5′ ITR, a first recombinant nucleotide sequence, a non-resolvable ITR (e.g.: ΔITR), a second recombinant nucleotide sequence, and a 3′ ITR, wherein the first and second recombinant nucleotide sequences are self-complementary. The second recombinant nucleotide sequence comprises in the 5′ to 3′ direction, a promoter, an RLBP1 coding sequence and an SV40 polyA sequence. The promoter can be an RLBP1 promoter and, further, can be the RLBP1 (short) promoter (SEQ ID NO: 3). In certain aspects of the invention, the second recombinant nucleotide sequence comprises nucleic acid sequences in the 5′ to 3′ direction of SEQ ID NO: 3, 4, 5, 6, and 8 and the first recombinant nucleotide sequence comprises sequences that are self-complementary to, or the reverse complement of, the second recombinant sequence, for example, SEQ ID NOs: 62, 63, 64, 65, and 66. The invention also relates to a viral vector comprising a self-complementary vector genome wherein the genome comprises, nucleic acid sequences in the 5′ to 3′ direction of: SEQ ID NOs: 36, 62, 63, 64, 65, 66, 1, 3, 4, 5, 6, 8, and 9. The self-complementary vector genome described above can be packaged in an AAV capsid that is selected from any AAV serotype known in the art, including but not limited to AAV1-12. In one aspect, the self- complementary genome is packaged in an AAV8 capsid. In another aspect, the self- complementary genome is packaged in an AAV2 capsid.

The present invention also relates to a viral vector capable of directing expression of a heterologous gene to RPE and Muller cells of the retina. It is contemplated that the viral vector capsid is an AAV2 or an AAV8 serotype capsid and that the viral vector comprises a vector genome, wherein the heterologous gene is operably linked to an RLBP1 promoter. It is further contemplated that the RLBP1 promoter is the RLBP1 (short) promoter (SEQ ID NO: 3) or the RLBP1 (long) promoter (SEQ ID NO: 10). In another aspect of the invention it is contemplated that the heterologous gene to be expressed in RPE and Muller cells is an RLBP1 coding sequence having for example, the sequence of SEQ ID NO: 6.

The present invention also relates to a viral vector capable of directing expression of a heterologous gene to RPE and Muller cells of the retina, wherein the viral vector capsid is an AAV8 serotype capsid and that the viral vector comprises a self-complementary vector genome wherein a heterologous gene is operably linked to an RLBP1 promoter. It is further contemplated that the RLBP1 promoter is the RLBP1 (short) promoter (SEQ ID NO: 3). In another aspect of the invention it is contemplated that the heterologous gene to be expressed in RPE and Muller cells is an RLBP1 coding sequence having for example, the sequence of SEQ ID NO: 6.

The invention also relates to a composition comprising a viral vector described herein, as well as viral vector compositions in combination with a pharmaceutically acceptable carrier. Specifically, the invention further relates to compositions comprising the viral vectors as described in Table 4. The invention still further relates to compositions comprising viral vectors that can be generated using the plasmids described in Table 2, in conjunction with rAAV production methods known in the art and described herein. The compositions described herein are useful for treating a subject having RLBP1 associated retinal dystrophy and/or improving the rate of dark adaption in a subject having RLBP1-associated retinal dystrophy.

The present invention also relates to nucleic acids that can be used, with the rAAV production methods known in the art and described herein, for the generation of the viral vectors described herein. The invention relates to nucleic acids comprising a gene cassette, wherein the gene cassette comprises, in the 5′ to 3′ direction: (i) a 5′ ITR or a non-resolvable ITR, (ii) a recombinant nucleotide sequence comprising an RLBP1 coding sequence, and (iii) a 3′ ITR. It is contemplated that the nucleic acid may comprise a gene cassette comprising a nucleic acid sequence selected from SEQ ID NOs: 51, 52, 53, 54, and 55. It is contemplated that the nucleic acids of the invention may be plasmids. It is further contemplated that the nucleic acid may be a plasmid comprising a nucleic acid sequence selected from SEQ ID NOs: 26, 27, 28, 29, 30 and 50.

In certain specific aspects of the invention, the nucleic acid can comprise a gene cassette comprising sequences in the 5′ to 3′ direction that are selected from: a) a) SEQ ID NO: 2, 10, 5, 6, 8, and 9, b) SEQ ID NO: 2, 11, 5, 6, 8, 14 and 9, c) SEQ ID NO: 2, 22, 5, 6, 8, 23 and 9, d) SEQ ID NO: 2, 3, 4, 5, 6, 8, 23 and 9, or e) SEQ ID NO: 1, 3, 4, 5, 6, 8, and 9.

The invention also relates to nucleic acids comprising a gene cassette, wherein the gene cassette comprises, in the 5′ to 3′ direction: (i) a 5′ ITR, (ii) a recombinant nucleotide sequence comprising a promoter operably linked to reporter gene, and (iii) a 3′ ITR. It is contemplated that the nucleic acid may comprise a gene cassette comprising a nucleic acid sequence selected from SEQ ID NOs: 56, 57, 59 and 60. It is further contemplated that nucleic acid may be a plasmid comprising a nucleic acid sequence selected from SEQ ID NOs: 31, 32, 34 and 35.

The invention also relates to methods of treating a subject having RLBP1-associated retinal dystrophy wherein the method comprises administering to a subject in need thereof, a composition comprising a viral vector as described herein.

The invention also relates to a method of improving the rate of dark adaption in a subject having RLBP1-associated retinal dystrophy, wherein the method comprises administering to a subject in need thereof, a composition comprising a viral vector as described herein.

The invention still further relates to a method of directing expression of an RLBP1 coding sequence in RPE and Muller cells in the retina of a subject having RLBP1-associated retinal dystrophy, wherein the method comprises the step of contacting the retina of the subject, with a viral vector comprising an AAV8 or AAV2 serotype capsid and a vector genome comprising an RLBP1 coding sequence operably linked to an RLBP1 promoter, such as, for example, the RLBP1(short) (SEQ ID NO: 3) or RLBP1(long) (SEQ ID NO: 10) promoters as described herein.

The invention still further relates to a method of delivering an RLBP1 coding sequence in RPE and Muller cells in the retina of a subject having RLBP1-associated retinal dystrophy, wherein the method comprises the step of contacting the retina of the subject, with a viral vector comprising an AAV8 or AAV2 serotype capsid and a vector genome comprising an RLBP1 coding sequence operably linked to an RLBP1 promoter, such as, for example, the RLBP1(short) (SEQ ID NO: 3) or RLBP1(long) (SEQ ID NO: 10) promoters as described herein.

The invention also includes a viral vector as described in Table 1, or 4, as well as a plasmid described in Table 2.

DEFINITIONS

Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by those of ordinary skill in the art to which this invention pertains.

The term “capsid” refers to the protein coat of the virus or viral vector. The term “AAV capsid” refers to the protein coat of the adeno-associated virus (AAV), which is composed of a total of 60 subunits; each subunit is an amino acid sequence, which can be viral protein 1(VP1), VP2 or VP3 (Muzyczka N and Berns KI 2001).

The term “gene cassette” refers to a manipulatable fragment of DNA carrying, and capable of expressing, one or more genes, or coding sequences, of interest between one or more sets of restriction sites. A gene cassette can be transferred from one DNA sequence (often in a plasmid vector) to another by ‘cutting’ the fragment out using restriction enzymes and ligating it back into a new context, for example into a new plasmid backbone.

The term “heterologous gene” or “heterologous nucleotide sequence” will typically refer to a gene or nucleotide sequence that is not naturally-occurring in the virus. Alternatively, a heterologous gene or nucleotide sequence may refer to a viral sequence that is placed into a non-naturally occurring environment (e.g.: by association with a promoter with which it is not naturally associated in the virus).

The terms “ITR” or “inverted terminal repeat” refer to the stretch of nucleic acid sequences that exist in Adeno-Associated Viruses (AAV) and/or recombinant Adeno-Associated Viral Vectors (rAAV) that can form a T-shaped palindromic structure, that is required for completing AAV lytic and latent life cycles (Muzyczka N and Berns KI 2001). The term “non-resolvable ITR” refers to a modified ITR such that the resolution by the Rep protein is reduced. A non-resolvable ITR can be an ITR sequence without the terminal resolution site (TRS) which leads to low or no resolution of the non-resolvable ITR and would yield 90-95% of self-complementary AAV vectors (McCarty et al 2003). A specific example of a non-resolvable ITR is “ΔITR”, having a sequence of SEQ ID NO: 1.

The term “operably linked” refers to a functional relationship between two or more polynucleotide (e.g., DNA) segments. Typically, the term refers to the functional relationship of a transcriptional regulatory sequence to a sequence to be transcribed. For example, a promoter or enhancer sequence is operably linked to a coding sequence if it stimulates or modulates the transcription of the coding sequence in an appropriate host cell or other expression system. Generally, promoter transcriptional regulatory sequences that are operably linked to a transcribable sequence are contiguous to the transcribable sequence, i.e., they are cis-acting. However, some transcriptional regulatory sequences, such as enhancers, need not be physically contiguous or located in close proximity to the coding sequences whose transcription they enhance.

The term “promoter” refers to a sequence that regulates transcription of an operably-linked gene, or nucleotide sequence encoding a protein, etc. Promoters provide the sequence sufficient to direct transcription, as well as, the recognition sites for RNA polymerase and other transcription factors required for efficient transcription and can direct cell specific expression. In addition to the sequence sufficient to direct transcription, a promoter sequence of the invention can also include sequences of other regulatory elements that are involved in modulating transcription (e.g.: enhancers, kozak sequences and introns). Examples of promoters known in the art and useful in the viral vectors described herein, include the CMV promoter, CBA promoter, smCBA promoter and those promoters derived from an immunoglobulin gene, SV40, or other tissue specific genes (e.g: RLBP1, RPE, VMD2). Specific promoters may also include those described in Table 1, for example, the “RLBP1 (short)” promoter (SEQ ID NO: 3), the “RLBP1 (long)” promoter (SEQ ID NO: 10), RPE65 promoter (SEQ ID NO: 11), VMD2 promoter (SEQ ID NO: 12), and the CMV enhancer+CBA promoter (SEQ ID NO: 22) . In addition, standard techniques are known in the art for creating functional promoters by mixing and matching known regulatory elements. “Truncated promoters” may also be generated from promoter fragments or by mix and matching fragments of known regulatory elements; for example the smCBA promoter is a truncated form of the CBA promoter.

The term “RLBP1” refers to the “Retinaldehyde Binding Protein 1”. The human RLBP1 gene is found on chromosome 15 and has the nucleic acid coding sequence as set out in Table 1: SEQ ID NO: 6. The “RLBP1 gene product” is also known as, “cellular retinaldehyde binding protein” or “CRALBP” and is the protein encoded by the RLBP1 gene. The human RLBP1 gene product (hCRALBP) has the amino acid sequence as set out in Table 1: SEQ ID NO: 7. Examples of RLBP1 coding sequences and RLBP1 gene products from other species can be found in Table 1 (e.g.: SEQ ID NOs: 37-48). The term “RLBP1 coding sequence” or “RLBP1 GENE CDS” or “RLBP1 CDS” refers to the nucleic acid sequence that encodes the RLBP1 gene product. One of skill in the art would understand that an RLBP1 coding sequence may include any nucleic acid sequence that encodes an RLBP1 gene product. The RLBP1 coding sequence may or may not include intervening regulatory elements (e.g.: introns, enhancers, or other non-coding sequences).

The term “subject” includes human and non-human animals. Non-human animals include all vertebrates (e.g.: mammals and non-mammals) such as, non-human primates (e.g.: cynomolgus monkey), mice, rats, sheep, dogs, cows, chickens, amphibians, and reptiles. Except when noted, the terms “patient” or “subject” are used herein interchangeably.

As used herein, the term “treating” or “treatment” of any disease or disorder (e.g., retinitis pigmentosa, RBLP1-associated retinal dystrophy) refers, to ameliorating the disease or disorder such as by slowing or arresting or reducing the development of the disease or at least one of the clinical symptoms thereof. “Treating” or “treatment” can also refer to alleviating or ameliorating at least one physical parameter including those which may not be discernible by the patient. “Treating” or “treatment” can also refer to modulating the disease or disorder, either physically, (e.g., stabilization of a discernible symptom), physiologically, (e.g., stabilization of a physical parameter), or both. More specifically, “treatment” of RLBP1-associated retinal dystrophy means any action that results in the improvement or preservation of visual function and/or regional anatomy in a subject having RLBP1-associated retinal dystrophy. “Preventing” or “prevention” as used herein, refers to preventing or delaying the onset or development or progression of the disease or disorder. “Prevention” as it relates to RLBP1-associated retinal dystrophy means any action that prevents or slows a worsening in visual function, retinal anatomy, and/or an RLBP1-associated retinal dystrophy disease parameter, as described below, in a patient with RLBP1-associated retinal dystrophy and at risk for said worsening. Methods for assessing treatment and/or prevention of disease are known in the art and described herein below.

The term “virus vector” or “viral vector” is intended to refer to a non-wild-type recombinant viral particle (e.g.: a parvovirus, etc.) that functions as a gene delivery vehicle and which comprises a recombinant viral genome packaged within a viral (e.g.: AAV) capsid. A specific type of virus vector may be a “recombinant adeno-associated virus vector”, or “rAAV vector”. The recombinant viral genome packaged in the a viral vector is also referred to herein as the “vector genome”.

BRIEF DESCRIPTION OF THE DRAWINGS

FIGS. 1A-1B. Relative expression of vector-mediated human RLBP1 mRNA compared to endogenous mouse RLBP1 mRNA in eyes injected with various viral vectors at the dosage of 1×10⁹ (1A) and 1×10⁸ (1B) vector genome (vg) particles per eye.

FIG. 2 . Dark adaptation in RLBP1 KO (-/-) and wild-type (+/+) mice.

FIGS. 3A-3D. Measurement of rate of dark adaptation of RLBP1 KO mice treated with various viral vectors: NVS1 (3B), NVS3 (3A and 3C), NVS3 (3B and 3D), NVS4 (3A and 3C) and NVS5 (3B and 3D).

FIGS. 4A-4B. Measurement of increased rate of dark adaptation of RLBP1 KO mice treated with various doses of NVS2 and NVS11 is shown in panel 4A. Panel 4B illustrates treatment efficacy of NVS2. Horizontal axis doses are indicated in scientific notation (for example, 3E6 = 3×10⁶).

FIGS. 5A-5B. Measurement of increased rate of dark adaptation of RLBP1 KO mice treated with various doses of NVS4 and NVS11 is shown in panel 5A. Panel 5B illustrates treatment efficacy of NVS4. Horizontal axis doses are indicated in scientific notation (for example, 3E6 = 3×10⁶).

FIG. 6 . Measurement of increased rate of dark adaptation of RLBP1 KO mice treated with NVS2 prepared with different purification methods.

DETAILED DESCRIPTION

The present invention is based, in part, on the discovery of viral vectors that express a heterologous gene in RPE and Muller cells of the retina. The invention also relates both to single stranded and self-complementary viral vectors with a heterologous gene expressing the RLBP1 gene product (CRALBP).

Accordingly, the present invention provides recombinant viral vectors that direct expression of the RLBP1 coding sequence to the retina, viral vector compositions, plasmids useful for generating the viral vectors, methods of delivering an RLBP1 coding sequence to the retina, methods of expressing an RLBP1 coding sequence in RPE and Muller cells of the retina, and methods of use of such viral vectors.

Except as otherwise indicated, standard methods known to those skilled in the art may be used for the construction of recombinant parvovirus and rAAV vectors, using recombinant plasmids carrying a viral gene cassette, packaging plasmids expressing the parvovirus rep and/or cap sequences, as well as transiently and stably transfected packaging cells. Such techniques are known to those skilled in the art. (e.g.: SAMBROOK et al., MOLECULAR CLONING: A LABORATORY MANUAL 2nd Ed. (Cold Spring Harbor, N.Y., 1989); Choi VW et al. CURRENT PROTOCOLS IN MOLECULAR BIOLOGY (2007)).

1. Viral Vectors

The present invention is related to viral vectors that direct expression of a heterologous gene to the retina. In certain aspects of the invention, expression is directed to RPE and Muller cells of the retina. A variety of viral vectors known in the art may be adapted by one of skill in the art for use in the present invention, for example, recombinant adeno-associated viruses, recombinant adenoviruses, recombinant retroviruses, recombinant poxviruses, recombinant baculoviruses, etc.

In particular, it is contemplated that the viral vector of the invention may be a recombinant adeno-associated (rAAV) vector. AAVs are small, single-stranded DNA viruses which require helper virus to facilitate efficient replication (Muzyczka N and Berns KI 2001). The viral vector comprises a vector genome and a protein capsid. The viral vector capsid may be supplied from any of the AAV serotypes known in the art, including presently identified human and non-human AAV serotypes and AAV serotypes yet to be identified (See: Choi VW et al 2005, Schmidt et al 2008). Virus capsids may be mixed and matched with other vector components to form a hybrid viral vector, for example the ITRs and capsid of the viral vector may come from different AAV serotypes. In one aspect, the ITRs can be from an AAV2 serotype while the capsid is from, for example, an AAV2 or AAV8 serotype. In addition, one of skill in the art would recognize that the vector capsid may also be a mosaic capsid (e.g.: a capsid composed of a mixture of capsid proteins from different serotypes), or even a chimeric capsid (e.g.: a capsid protein containing a foreign or unrelated protein sequence for generating markers and/or altering tissue tropism). It is contemplated that the viral vector of the invention may comprise an AAV2 capsid. It is further contemplated that the invention may comprise an AAV8 capsid.

The invention relates, in part, to viral vectors wherein the vector genome is single stranded. In certain aspects, the invention is related to a single stranded vector genome comprising, in the 5′ to 3′ direction: (i) a 5′ ITR, (ii) a recombinant nucleotide sequence comprising an RLBP1 coding sequence, and (iii) a 3′ ITR. In certain aspects of the invention the recombinant nucleotide sequence comprises in the 5′ to 3′ direction: (i) a promoter, (ii) an RLBP1 coding sequence, and (iii) an SV40 polyA sequence. In certain aspects, the promoter may be an RLBP1 (short) promoter, an RLBP1 (long) promoter, or a truncated promoter of RLBP1. In particular, the invention relates to a single stranded vector genome comprising a recombinant nucleotide sequence comprising in the 5′ to 3′ direction: an RLBP1 (long) promoter (SEQ ID NO:10), an RLBP1 coding sequence, and an SV40 polyA sequence. In addition, the invention also relates to a single stranded vector genome comprising a recombinant nucleotide sequence comprising in the 5′ to 3′ direction: an RLBP1 (short) promoter (SEQ ID NO: 3), an RLBP1 coding sequence, and an SV40 polyA sequence. Certain aspects of the invention further relate to a single stranded vector genome comprising a recombinant nucleotide sequence packaged in an AAV2 or AAV8 capsid.

In certain aspects of the invention the viral vector comprises an AAV2 capsid (encoded by SEQ ID NO: 18) and a vector genome comprising in the 5′ to 3 direction nucleotide sequences selected from the following: a) SEQ ID NO: 2, 10, 5, 6, 8, and 9; b) SEQ ID NO: 2, 11, 5, 6, 8, 14, 9; c) SEQ ID NO: 2, 22, 5, 6, 8, 23, and 9; and d) SEQ ID NO: 2, 3, 4, 5, 6, 8, 23, and 9. In certain aspects the AAV2 capsid comprises capsid proteins VP1, VP2 and VP3 having an amino acid sequence of SEQ ID NO: 19, 68, and 69, respectively. In certain other aspects the AAV2 capsid may comprise subcombinations of capsid proteins VP1, VP2 and/or VP3.

In certain aspects of the invention the viral vector comprises an AAV8 capsid (encoded by SEQ ID NO: 20) and a vector genome comprising in the 5′ to 3′ direction nucleotide sequences selected from the following: a) SEQ ID NO: 2, 10, 5, 6, 8, and 9; b) SEQ ID NO: 2, 11, 5, 6, 8, 14, 9; c) SEQ ID NO: 2, 22, 5, 6, 8, 23, and 9; and d) SEQ ID NO: 2, 3, 4, 5, 6, 8, 23, and 9. In certain aspects the AAV8 capsid comprises capsid proteins VP1, VP2 and VP3 having an amino acid sequence of SEQ ID NO: 21, 70, and 71. In certain other aspects the AAV8 capsid may comprise subcombinations of capsid proteins VP1, VP2 and/or VP3.

The viral vector can also be an AAV vector comprising a self-complementary genome. Self-complementary rAAV vectors have been previously described in the art (US7465583 and McCarty 2008) and may be adapted for use in the present invention. A self-complementary genome comprises a 5′ ITR and a 3′ ITR (i.e.: resolvable ITR or wild-type ITR) at either end of the genome and a non-resolvable ITR (e.g.: ΔITR, as described herein) interposed between the 5′ and 3′ ITRs. Each portion of the genome (i.e. between each resolvable ITR and non-resolvable ITR) comprises a recombinant nucleotide sequence, wherein each half (i.e.: the first recombinant nucleotide sequence and the second recombinant nucleotide sequence) is complementary to the other, or self-complementary. In other words, the self-complementary vector genome is essentially an inverted repeat with the two halves joined by the non-resolvable ITR. In certain aspects the invention is related to a self-complementary vector genome comprising, in the 5′ to 3′ direction, (i) a 5′ ITR, (ii) a first recombinant nucleotide sequence, (iii) a non-resolvable ITR, (iv) a second recombinant nucleotide sequence, and (v) a 3′ ITR. In a certain aspect of the invention the second recombinant nucleotide sequence of the vector genome comprises, an RLBP1 promoter, an RLBP1 coding sequence, and an SV40 polyA sequence and the first recombinant nucleotide sequence is self-complementary to the second nucleotide sequence. In certain specific aspects the RLBP1 promoter has the nucleotide sequence of SEQ ID NO: 3. In certain aspects of the invention, the second recombinant nucleptide sequence comprises nucleic acid sequences in the 5′ to 3′ direction of SEQ ID NO: 3, 4, 5, 6, and 8 and the first recombinant nucleotide sequence comprises sequences that are self-complementary to, or the reverse complement of, the second recombinant sequence, for example, SEQ ID NOs: 62, 63, 64, 65, and 66. It is also contemplated that the viral vector of the invention may comprise a self-complementary genome wherein the first recombinant nucleotide sequence of the vector genome comprises, an RLBP1 promoter, an RLBP1 coding sequence, and an SV40 polyA sequence and the second recombinant nucleotide sequence is self-complementary to the first recombinant nucleotide sequence.

In certain aspects of the invention the self-complementary viral vector comprises an AAV2 capsid (encoded by SEQ ID NO: 18) and a vector genome comprising a nucleotide sequence comprising sequences in the 5′ to 3′ direction SEQ ID NO: 36, SEQ ID NO: 62, SEQ ID NO: 63, SEQ ID NO: 64, SEQ ID NO: 65, SEQ ID NO: 66, SEQ ID NO: 1, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 8, and SEQ ID NO: 9. In certain aspects the AAV2 capsid comprises capsid proteins VP1, VP2 and VP3 having an amino acid sequence of SEQ ID NO: 19, 68, and 69, respectively. In certain other aspects the AAV2 capsid may comprise subcombinations of capsid proteins VP1, VP2 and/or VP3.

In certain aspects of the invention the self-complementary viral vector comprises an AAV8 capsid (encoded by SEQ ID NO: 20) and a vector genome comprising a nucleotide sequence comprising sequences in the 5′ to 3′ direction SEQ ID NO: 36, SEQ ID NO: 62, SEQ ID NO: 63, SEQ ID NO: 64, SEQ ID NO: 65, SEQ ID NO: 66, SEQ ID NO: 1, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 8, and SEQ ID NO: 9. In certain aspects the AAV8 capsid comprises capsid proteins VP1, VP2 and VP3 having an amino acid sequence of SEQ ID NO: 21, 70, and 71. In certain other aspects the AAV8 capsid may comprise subcombinations of capsid proteins VP1, VP2 and/or VP3.

Thus, the invention also relates to viral vectors as described herein, comprising a truncated promoter of RLBP1.

The invention further relates to a viral vector that directs expression of a heterologous gene to RPE and Muller cells of the retina, wherein the viral vector comprises an AAV8 capsid and a vector genome comprising an RLBP1 (short) promoter (SEQ ID NO:3) operably linked to a heterologous gene. In certain aspects of the invention, the vector genome is a self-complementary genome.

The invention also relates to methods of expressing RLBP1 in RPE cells and Muller cells of the retina. In certain aspects of the invention the method comprises contacting the retinal cells with a viral vector comprising an AAV capsid and a vector genome comprising an RLBP1 coding sequence operably linked to an RLBP1 promoter, which may be an RLBP1 (short) promoter (SEQ ID NO:3). In certain aspects of the invention the AAV capsid is AAV2. In certain other aspects, the AAV capsid is AAV8. In other aspects of the invention the method comprises contacting the retinal cells with a viral vector comprising an AAV capsid and a vector genome comprising an RLBP1 coding sequence operably linked to an RLBP1 promoter, which may be an RLBP1 (long) promoter (SEQ ID NO: 10). In certain aspects of the invention the AAV capsid is AAV2. In certain other aspects, the AAV capsid is AAV8.

Methods for generating viral vectors are well known in the art and would allow for the skilled artisan to generate the viral vectors of the invention (see, e.g., U.S. Pat. No. 7,465,583), including the viral vectors described in Table 4, using the plasmids described in Table 2 and the Examples.

In general, methods of producing rAAV vectors are applicable to producing the viral vectors of the invention; the primary difference between the methods is the structure of the genetic elements to be packaged. To produce a viral vector according to the present invention, sequences of the genetic elements and plasmids as described in table 2 can be used to produce the encapsidated viral genome.

The genetic elements as described in table 2 are in the context of a circular plasmid, but one of skill in the art will appreciated that a DNA substrate may be provided in any form known in the art, including but not limited to a plasmid, naked DNA vector, bacterial artificial chromosome (BAC), yeast artificial chromosome (YAC) or a viral vector (e.g., adenovirus, herpesvirus, Epstein-Barr Virus, AAV, baculoviral, retroviral vectors, and the like). Alternatively, the genetic elements in table 2 necessary to produce the viral vectors described herein may be stably incorporated into the genome of a packaging cell.

The viral vector particles according to the invention may be produced by any method known in the art, e.g., by introducing the sequences to be replicated and packaged into a permissive or packaging cell, as those terms are understood in the art (e.g., a “permissive” cell can be infected or transduced by the virus; a “packaging” cell is a stably transformed cell providing helper functions).

In one embodiment, a method is provided for producing an RLBP1 viral vector, wherein the method comprises providing to a cell permissive for parvovirus replication: (a) a nucleotide sequence containing the genetic elements for producing a vector genome of the invention (as described in detail below and in table 2); (b) nucleotide sequences sufficient for replication of the vector genome sequence in (a) to produce a vector genome; (c) nucleotide sequences sufficient to package the vector genome into a parvovirus capsid, under conditions sufficient for virus vectors comprising the vector genome encapsidated within the parvovirus capsid to be produced in the cell. Preferably, the parvovirus replication and/or capsid coding sequences are AAV sequences.

Any method of introducing the nucleotide sequence carrying the gene cassettes described below into a cellular host for replication and packaging may be employed, including but not limited to, electroporation, calcium phosphate precipitation, microinjection, cationic or anionic liposomes, and liposomes in combination with a nuclear localization signal.

Viral vectors described herein may be produced using methods known in the art, such as, for example, triple transfection or baculovirus mediated virus production. Any suitable permissive or packaging cell known in the art may be employed to produce the vectors. Mammalian cells are preferred. Also preferred are trans-complementing packaging cell lines that provide functions deleted from a replication-defective helper virus, e.g., 293 cells or other E1 a trans-complementing cells. Also preferred are mammalian cells or cell lines that are defective for DNA repair as known in the art, as these cell lines will be impaired in their ability to correct the mutations introduced into the plasmids described herein.

The gene cassette may contain some or all of the parvovirus (e.g., AAV) cap and rep genes. Preferably, however, some or all of the cap and rep functions are provided in trans by introducing a packaging vector(s) encoding the capsid and/or Rep proteins into the cell. Most preferably, the gene cassette does not encode the capsid or Rep proteins. Alternatively, a packaging cell line is used that is stably transformed to express the cap and/or rep genes (see, e.g., Gao et al., (1998) Human Gene Therapy 9:2353; Inoue et al., (1998) J. Virol. 72:7024; U.S. Pat. No. 5,837,484; WO 98/27207; U.S. Pat. No. 5,658,785; WO 96/17947).

In addition, helper virus functions are preferably provided for the virus vector to propagate new virus particles. Both adenovirus and herpes simplex virus may serve as helper viruses for AAV. See, e.g., BERNARD N. FIELDS et al., VIROLOGY, volume 2, chapter 69 (3d ed., Lippincott-Raven Publishers). Exemplary helper viruses include, but are not limited to, Herpes simplex (HSV) varicella zoster, cytomegalovirus, and Epstein-Barr virus. The multiplicity of infection (MOI) and the duration of the infection will depend on the type of virus used and the packaging cell line employed. Any suitable helper vector may be employed. Preferably, the helper vector is a plasmid, for example, as described by Xiao et al., (1998) J. Virology 72:2224. The vector can be introduced into the packaging cell by any suitable method known in the art, as described above.

Vector stocks free of contaminating helper virus may be obtained by any method known in the art. For example, recombinant single stranded or self complementary virus and helper virus may be readily differentiated based on size. The viruses may also be separated away from helper virus based on affinity for a heparin substrate (Zolotukhin et al. (1999) Gene Therapy 6:973). Preferably, deleted replication-defective helper viruses are used so that any contaminating helper virus is not replication competent. As a further alternative, an adenovirus helper lacking late gene expression may be employed, as only adenovirus early gene expression is required to mediate packaging of the duplexed virus. Adenovirus mutants defective for late gene expression are known in the art (e.g., ts100K and ts149 adenovirus mutants).

One method for providing helper functions employs a non-infectious adenovirus miniplasmid that carries all of the helper genes required for efficient AAV production (Ferrari et al., (1997) Nature Med. 3:1295; Xiao et al., (1998) J. Virology 72:2224). The rAAV titers obtained with adenovirus miniplasmids are forty-fold higher than those obtained with conventional methods of wild-type adenovirus infection (Xiao et al., (1998) J. Virology 72:2224). This approach obviates the need to perform co-transfections with adenovirus (Holscher et al., (1994), J. Virology 68:7169; Clark et al., (1995) Hum. Gene Ther. 6:1329; Trempe and Yang, (1993), in, Fifth Parvovirus Workshop, Crystal River, Fla.).

Other methods of producing rAAV stocks have been described, including but not limited to, methods that split the rep and cap genes onto separate expression cassettes to prevent the generation of replication-competent AAV (see, e.g., Allen et al., (1997) J. Virol. 71:6816), methods employing packaging cell lines (see, e.g., Gao et al., (1998) Human Gene Therapy 9:2353; Inoue et al., (1998) J. Virol. 72:7024; U.S. Pat. No. 5,837,484; WO 98/27207; U.S. Pat. No. 5,658,785; WO 96/17947), and other helper virus free systems (see, e.g., U.S. Pat. No. 5,945,335 to Colosi).

Herpesvirus may also be used as a helper virus in AAV packaging methods. Hybrid herpesviruses encoding the AAV Rep protein(s) may advantageously facilitate for more scalable AAV vector production schemes. A hybrid herpes simplex virus type I (HSV-1) vector expressing the AAV-2 rep and cap genes has been described (Conway et al., (1999) Gene Therapy 6:986 and WO 00/17377).

In summary, the gene cassette to be replicated and packaged, parvovirus cap genes, appropriate parvovirus rep genes, and (preferably) helper functions are provided to a cell (e.g., a permissive or packaging cell) to produce rAAV particles carrying the vector genome. The combined expression of the rep and cap genes encoded by the gene cassette and/or the packaging vector(s) and/or the stably transformed packaging cell results in the production of a viral vector particle in which a viral vector capsid packages a viral vector genome according to the invention. The single stranded or self-complementary viral vectors are allowed to assemble within the cell, and may then be recovered by any method known by those of skill in the art and described in the examples. For example, viral vectors may be purified by standard CsCI centrifugation methods (Grieger JC et al2006) or by various methods of column chromatography known to the skilled artisan (see: Lock M et al (2010), Smith RH et al (2009) and Vadenberghe LH et al (2010)).

The reagents and methods disclosed herein may be employed to produce high-titer stocks of the inventive viral vectors, preferably at essentially wild-type titers. It is also preferred that the parvovirus stock has a titer of at least about 10⁵ transducing units (tu)/ml, more preferably at least about 10⁶ tu/ml, more preferably at least about 10⁷ tu/ml, yet more preferably at least about 10⁸ tu/ml, yet more preferably at least about 10⁹ tu/ml, still yet more preferably at least about 10¹⁰ tu/ml, still more preferably at least about 10¹¹ tu/ml, or more.

Further, the RLBP1 viral vectors of the invention, may have an improved transducing unit/particle ratio over conventional AAV vectors. Preferably, the tu/particle ratio is less than about 1:50, less than about 1:20, less than about 1:15, less than about 1:10, less than about 1:8, less than about 1:7, less than about 1:6, less than about 1:5, less than about 1:4, or lower. Typically, the tu/particle ratio will be greater than about 1:1, 1:2, 1:3 or 1:4.

2. Nucleic Acids for Use in Generating the Viral Vector

The invention also relates to nucleic acids useful for the generation of viral vectors. In certain aspects of the invention, the nucleic acids useful for the generation of viral vectors may be in the form of plasmids. Plasmids useful for the generation of viral vectors, also referred to as a viral vector plasmid, may contain a gene cassette. At a minimum, a gene cassette of a viral vector plasmid contains: a heterologous gene and its regulatory elements (e.g.: promoter, enhancer, and/or introns, etc.), and 5′ and 3′ AAV inverted terminal repeats (ITRs).

The composition of the heterologous gene and its regulatory elements will depend upon the use to which the resulting vector will be put. For example, one type of heterologous gene sequence includes a reporter sequence, which upon expression produces a detectable signal. Such reporter sequences include, without limitation, DNA sequences encoding β-lactamase, β-galactosidase (LacZ), alkaline phosphatase, thymidine kinase, green fluorescent protein (GFP), chloramphenicol acetyltransferase (CAT), luciferase, membrane bound proteins including, for example, CD2, CD4, CD8, the influenza hemagglutinin protein, and others well known in the art, to which high affinity antibodies directed thereto exist or can be produced by conventional means, and fusion proteins comprising a membrane bound protein appropriately fused to an antigen tag domain from, among others, hemagglutinin or Myc. For example, where the reporter sequence is the LacZ gene, the presence of the vector carrying the signal is detected by assays for beta-galactosidase activity. Where the reporter sequence is green fluorescent protein or luciferase, the vector carrying the signal may be measured visually by color or light production in a luminometer.

The heterologous gene sequences, when associated with regulatory elements which drive their expression, provide signals detectable by conventional means, including enzymatic, radiographic, colorimetric, fluorescence or other spectrographic assays, fluorescent activating cell sorting assays and immunological assays, including enzyme linked immunosorbent assay (ELISA), radioimmunoassay (RIA) and immunohistochemistry.

The heterologous gene may also be a non-marker sequence encoding a product which is useful in biology and medicine, such as proteins, peptides, RNA, enzymes, dominant negative mutants, or catalytic RNAs. Desirable RNA molecules include tRNA, dsRNA, ribosomal RNA, catalytic RNAs, siRNA, small hairpin RNA, trans-splicing RNA, and antisense RNAs. One example of a useful RNA sequence is a sequence which inhibits or extinguishes expression of a targeted nucleic acid sequence in the treated animal.

The heterologous gene may also be used to correct or ameliorate gene deficiencies, which may include deficiencies in which normal genes are expressed at less than normal levels or deficiencies in which the functional gene product is not expressed. It is contemplated in the present invention that the heterologous gene sequence may be an RLBP1 coding sequence . Examples of RLBP1 coding sequences are provided in Table 1: SEQ ID NOs: 6, 37, 39, 41, 43, 45 or 47.

In addition to the heterologous gene, the gene cassette may include regulatory elements operably linked to the heterologous gene. These regulatory elements may include appropriate transcription initiation, termination, promoter and enhancer sequences, efficient RNA processing signals such as splicing and polyadenylation (polyA) signals; sequences that stabilize cytoplasmic mRNA; sequences that enhance translation efficiency; sequences that enhance protein stability; and when desired, sequences that enhance secretion of the encoded product. A great number of regulatory sequences, including promoters which are native, constitutive, inducible and/or tissue-specific, are known in the art and may be utilized. Regulatory element sequences of the invention include those described in Table 1, for example SEQ ID NO: 3, 4, 5, 8, 10, 11, 12 and 22.

The gene cassette may include an RLBP1 promoter with a nucleic acid sequence of SEQ ID NO: 3 or 10 operably linked to a heterologous gene. In particular, the RLBP1 short promoter (SEQ ID NO: 3) is operably linked to an RLBP1 coding sequence (SEQ ID NO: 6, 37, 39, 41, 43, 45 or 47). Alternatively, the RLBP1 long promoter (SEQ ID NO: 10) is operably linked to an RLBP1 coding sequence (SEQ ID NO: 6, 37, 39, 41, 43, 45 or 47).

It is contemplated that the ITRs of AAV serotype 2 may be used (e.g.: SEQ ID NO: 2, 9, 16, 17, 36). However, ITRs from other suitable serotypes may be selected from among any AAV serotype known in the art, as described herein. These ITRs or other AAV components may be readily isolated using techniques available to those of skill in the art from any AAV serotype known, or yet to be identified serotypes, for example, the AAV sequences may be obtained through synthetic or other suitable means by reference to published sequences such as are available in the literature or in databases such as, e.g., GenBank, PubMed, or the like. Alternatively, such AAV components may also be isolated or obtained from academic, commercial, or public sources (e.g., the American Type Culture Collection, Manassas, VA).

It is contemplated that in certain aspects of the invention, one ITR of the gene cassette may be a modified ITR, or non-resolvable ITR, sequence without the terminal resolution site (TRS). During replication of a gene cassette comprising a non-resolvable ITR, the inability of Rep protein to resolve the non-resolvable ITRs will result in a dimeric inverted repeat sequence (i.e.: self-complementary) with a non-resolvable ITR (e.g.: ΔITR) in the middle and a wild-type ITR at each end. The resulting sequence is a self-complementary viral genome sequence such that the genome is capable of forming a hairpin structure upon release from the capsid (see also: US7465583 and McCarty (2008)) A non-resolvable ITR may be produced by any method known in the art. For example, insertion into the ITR will displace the TRS and result in a non-resolvable ITR. Preferably, the insertion is in the region of the TRS site. Alternatively, the ITR may be rendered non-resolvable by deletion of the TRS site, a specific example includes ΔITR (SEQ ID NO: 1).

The invention relates to nucleic acids that comprise a gene cassette comprising in the 5′ to 3′ direction nucleic acid sequences selected from the following: a) SEQ ID NOs: 2, 10, 5, 6, 8, and 9; b) SEQ ID NOs: 2, 11, 5, 6, 8, 14 and 9; c) SEQ ID NOs: 2, 22, 5, 6, 8, 23 and 9; d) SEQ ID NOs: 2, 3, 4, 5, 6, 8, 23 and 9; e) SEQ ID NOs: 2, 10, 5, 24, 8, and 9; f) SEQ ID NOs: 2, 11, 24, 8, 14, and 9; and g) SEQ ID NOs: 2, 12, 24, 8, 14, and 9. In certain aspects the nucleic acid comprising the gene cassette may be a plasmid. In particular, the sequence of the plasmid may have a sequence selected from SEQ ID NOs: 27, 28, 29, 30, 32, 33, 34 and 35.

The invention also relates to nucleic acids that comprise a gene cassette comprising in the 5′ to 3′ direction nucleic acid sequences selected from the following: a) SEQ ID NOs: 1, 3, 4, 5, 6, 8, and 9; and b) SEQ ID NOs: 1, 3, 4, 5, 24, 8 and 9. In certain aspects the nucleic acid comprising the gene cassette may be a plasmid. In particular, the sequence of the plasmid may have a sequence selected from SEQ ID NOs: 26, 31 and 50.

Methods for incorporating the elements in Table 2 are well known in the art and would allow for the skilled artisan to generate the nucleic acids and plasmids of the invention using the methods outlined in Table 3 and the Examples.

3 Pharmaceutical Compositions

The invention provides pharmaceutical compositions comprising the viral vectors of the invention formulated together with a pharmaceutically acceptable carrier. The compositions can additionally contain one or more other therapeutic agents that are suitable for treating or preventing, for example, RLBP1-asscoated retinal dystrophy, and/or retinal pigmentosa (RP). Pharmaceutically acceptable carriers enhance or stabilize the composition, or can be used to facilitate preparation of the composition. Pharmaceutically acceptable carriers include solvents, surfactants, dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents, and the like that are physiologically compatible.

A pharmaceutical composition of the present invention can be administered by a variety of methods known in the art. The route and/or mode of administration vary depending upon the desired results. It is preferred that administration be subretinal. The pharmaceutically acceptable carrier should be suitable for subretinal, intravitreal, intravenous, sub-cutaneous or topical administration.

The composition should be sterile and fluid. Proper fluidity can be maintained, for example, by use of coating such as lecithin, by maintenance of required particle size in the case of dispersion and by use of surfactants. In many cases, it is preferable to include isotonic agents, for example, sugars, polyalcohols such as mannitol or sorbitol, and sodium chloride in the composition.

Pharmaceutical compositions of the invention can be prepared in accordance with methods well known and routinely practiced in the art. See, e.g., Remington: The Science and Practice of Pharmacy, Mack Publishing Co., 20th ed., 2000; and Sustained and Controlled Release Drug Delivery Systems, J.R. Robinson, ed., Marcel Dekker, Inc., New York, 1978. Pharmaceutical compositions are preferably manufactured under GMP conditions. Typically, a therapeutically effective dose or efficacious dose of the viral vector is employed in the pharmaceutical compositions of the invention. The viral vectors may be formulated into pharmaceutically acceptable dosage forms by conventional methods known to those of skill in the art. Dosage regimens are adjusted to provide the optimum desired response (e.g., a therapeutic response). For example, a single bolus may be administered, several divided doses may be administered over time or the dose may be proportionally reduced or increased as indicated by the exigencies of the therapeutic situation. It is especially advantageous to formulate parenteral compositions in dosage unit form for ease of administration and uniformity of dosage. Dosage unit form as used herein refers to physically discrete units suited as unitary dosages for the subjects to be treated; each unit contains a predetermined quantity of active compound calculated to produce the desired therapeutic effect in association with the required pharmaceutical carrier.

Actual dosage levels of the active ingredients in the pharmaceutical compositions of the present invention can be varied so as to obtain an amount of the active ingredient which is effective to achieve the desired therapeutic response for a particular patient, composition, and mode of administration, without being toxic to the patient. The selected dosage level depends upon a variety of pharmacokinetic factors including the activity of the particular compositions of the present invention employed, the route of administration, the time of administration, the rate of excretion of the particular compound being employed, the duration of the treatment, other drugs, compounds and/or materials used in combination with the particular compositions employed, the age, sex, weight, condition, general health and prior medical history of the patient being treated, and like factors.

A physician or veterinarian can start doses of the viral vectors of the invention employed in the pharmaceutical composition at levels lower than that required to achieve the desired therapeutic effect and gradually increase the dosage until the desired effect is achieved. In general, effective doses of the compositions of the present invention, for the treatment of RLBP1-associated retinal dystrophy as described herein vary depending upon many different factors, including means of administration, target site, physiological state of the patient, whether the patient is human or an animal, other medications administered, and whether treatment is prophylactic or therapeutic. Treatment dosages need to be titrated to optimize safety and efficacy. For subretinal administration with a viral vector, the dosage may range from 1×10⁸ vector genomes (vg)/eye to 1×10¹² vg/eye. For example the dosage may be, 1×10⁸ vg/eye, 2.5×10⁸ vg/eye, 5×10⁸ vg/eye, 7.5×10⁸ vg/eye, 1×10⁹ vg/eye, 2.5×10⁹ vg/eye, 5×10⁹ vg/eye, 7.5×10⁹ vg/eye, 1×10¹⁰ vg/eye, 2.5×10¹⁰ vg/eye, 5×10¹⁰ vg/eye, 7.5×10¹⁰ vg/eye, 1×10¹¹ vg/eye, 2.5×10¹¹ vg/eye, 5×10¹¹ vg/eye, 7.5×10¹¹ vg/eye, 1×10¹² vg/eye.

The viral vectors described herein are mainly used as one time doses per eye, with the possibility of repeat dosing to treat regions of the retina that are not covered in the previous dosing. The dosage of administration may vary depending on whether the treatment is prophylactic or therapeutic.

The various features and embodiments of the present invention, referred to in individual sections and embodiments above apply, as appropriate, to other sections and embodiments, mutatis mutandis. Consequently features specified in one section or embodiment may be combined with features specified in other sections or embodiments, as appropriate.

4. Therapeutic Uses

Viral vectors as described herein, can be used at a therapeutically useful concentration for the treatment of eye related diseases, by administering to a subject in need thereof, an effective amount of the viral vectors of the invention. More specifically, the present invention provides a method of treating RLBP1-associated retinal dystrophy, by administering to a subject in need thereof an effective amount of a viral vector comprising an RLBP1 coding sequence.

The present invention provides a viral vector comprising an RLBP1 coding sequence for use in treating RLBP1-associated retinal dystrophy in a subject.

Table A: RLBP1 mutations and associated phenotypes of RLBP1-associated retinal dystrophy. Disease phenotypes of RLBP1-associated retinal dystrophy include: Autosomal recessive retinitis pigmentosa (AARP), Bothnia dystrophy (BD), Newfoundland rod-cone dystrophy (NFRCD), Retinitis punctata albescens (RPA) and Fundus albipunctatus (FA).

TABLE A # pts Mutation Region Disease Night Blind Yellow Dots Pigment Deposits Atrophy Reference Missense Mutations 67 R234W Sweden BD Yes Perifoveal, midperiphery In advanced Advanced Burstedt et al 2001; Golovleva et al 2010; Golovleva et al 2012 10 R234W/M226K Sweden BD Yes Perifoveal, midperiphery In advanced Advanced Köhn et al 2008; Golovleva et al 2010; Golovleva et al 2012 2 M226K Sweden BD Yes Perifoveal, midperiphery In advanced Advanced Golovleva et al 2010; Golovleva et al 2012 4 G116R Pakistan FA Yes Midperiphery No No Naz et al 2011 4 R151Q Saudi Arabia FA Yes Whole fundus No No Katsaris et al 2001 4 R151Q India ARRP Yes Whole fundus Yes Yes Maw et al 1997 1 R234W Japan BD Yes Perifoveal, midperiphery In advanced Advanced Nojima et al 2011 1 R103W R234W Japan RPA Yes Perifoveal, midperiphery In advanced Yes Nakamura et al 2011 1 G146D I201T USA RPA No Midperiphery No No Demirci et al 2004 1 R103W USA RPA Yes Midperiphery No Yes Demirci et al 2004 Truncating Mutations 26 324G_A IVS3_2T 3 C Canada NFRCD Yes Perifoveal, midperiphery No Yes Eichers et al 2002 6 R156X Pakistan FA Yes Midperiphery No No Naz et al 2011 4 R151WGIy31 (2-bp del) USA RPA Yes Midperiphery Few, peripheral No Fishman et al 2004 6 Exons 7_9 del Morocco RPA Yes Perifoveal, midperiphery No No Humbert et al 2006 Littink et al 2012 1 IVS3_2T 3 C M226K USA RPA Yes Perifoveal, midperiphery No No Morimura et al 1999 1 Q278(1-bp del) USA RPA Yes Perifoveal Few, peripheral Yes Morimura et al 1999

Use of recombinant AAV has been shown to be feasible and safe for the treatment of retinal disease (See, e.g., Bainbridge et al. 2008, Houswirth et al 2008, Maguire et al 2008). The viral vectors of the invention can be used, inter alia, to treat and prevent progression of RLBP1-associated retinal dystrophy and improve vision loss. Viral vectors of the invention can also be used in patients where other retinal dystrophy is caused by other loss of function mutations in the RLBP1 gene, for example, Autosomal recessive retinitis pigmentosa, Retinitis punctata albescens and Fundus albipunctatus.

The present invention is also relates to a method of expressing an RLBP1 coding sequence in RPE and Muller cells of the retina, by administering viral vectors of the invention to a subject in need thereof. The present invention also relates to viral vectors of the invention for use in expressing an RLBP1 coding sequence in RPE and/or Müller cells of the retina of the subject in need thereof. The invention also contemplates a method of delivering an RLBP1 coding sequence to the retina, specifically to RPE and/or Müller cells in the retina, of a subject having RLBP1-associated retinal dystrophy. It is contemplated that the an RLBP1 coding sequence is delivered to the subject in need thereof by contacting the retina, RPE and/or Muller cells of the subject with a viral vector as described herein. Alternatively, an RLBP1 coding sequence is delivered to a subject by administering to the subject a viral vector as described herein.

The present invention further includes methods of expressing an RLBP1 coding sequence in RPE and/or Muller cells in the retina of a subject having RLBP1-associated retinal dystrophy, by contacting the retina of the subject with viral vectors of the invention. In certain aspects RPE and/or Müller cells of the retina of the subject are contacted with viral vectors of the invention.

It is further contemplated that the viral vectors used in the methods described herein comprise an AAV2 or AAV8 capsid, and the vector genome comprises an RLBP1 coding sequence operably linked to an RLBP1 promoter with a nucleotide sequence selected from SEQ ID NO: 3 or 10. It is further contemplated that the vector genome can be self-complementary.

In one aspect the viral vectors described herein can be administered subretinally or intravitreally using methods known to those of skill in the art.

Treatment and/or prevention of ocular disease such as RLBP1-associated retinal dystrophy can be determined by an ophthalmologist or health care professional using clinically relevant measurements of visual function and/or retinal anatomy. Treatment of RLBP1-associated retinal dystrophy means any action (e.g., administration of a viral vector described herein) contemplated to improve or preserve visual function and/or retinal anatomy. In addition, prevention as it relates to RLBP1-associated retinal dystrophy means any action (e.g., administration of a viral vector described herein) that prevents or slows a worsening in visual function, retinal anatomy, and/or RLBP1-associated retinal dystrophy disease phenotype, as defined herein, in a patient at risk for said worsening.

Visual function may include, for example, visual acuity, visual acuity with low illumination, visual field, central visual field, peripheral vision, contrast sensitivity, dark adaptation, photostress recovery, color discrimination, reading speed, dependence on assistive devices (e.g., large typeface, magnifying devices, telescopes), facial recognition, proficiency at operating a motor vehicle, ability to perform one or more activities of daily living, and/or patient-reported satisfaction related to visual function. Thus, treatment of retinitis pigmentosa (RP), specifically RLBP1-associated retinal dystrophy, can be said to occur where a subject has an at least 10% decrease or lack of a 10% or more increase in time to a pre-specified degree of dark adaptation. In addition, treatment of RLBP1-associated retinal dystrophy can be said to occur where a subject exhibits early severe night blindness and slow dark adaptation in young age, followed by progressive loss of visual acuity, visual fields and color vision, leading to legal blindness, determined by a qualified health care professional (i.e., ophthalmologist) (Burstedt and Mönestam, 2010).

Exemplary measures of visual function include Snellen visual acuity, ETDRS visual acuity, low-luminance visual acuity, Amsler grid, Goldmann visual field, standard automated perimetry, microperimetry, Pelli-Robson charts, SKILL card, Ishihara color plates, Farnsworth D15 or D100 color test, standard electroretinography, multifocal electroretinography, validated tests for reading speed, facial recognition, driving simulations, and patient reported satisfaction. Thus, treatment of RLBP1-associated retinal dystrophy can be said to be achieved upon a gain of or failure to lose 2 or more lines (or 10 letters) of vision on an ETDRS scale. In addition, treatment of RLBP1-associated retinal dystrophy can be said to occur where a subject exhibits at least a 10% increase or lack of 10% decrease in reading speed (words per minute). In addition, treatment of RLBP1-associated retinal dystrophy can be said to occur where a subject exhibits at least a 20% increase or lack of a 20% decrease in the proportion of correctly identified plates on an Ishihara test or correctly sequenced disks on a Farnsworth test. Thus, treatment of, for example, RLBP1-associated retinal dystrophy can be determined by, for example, improvement of rate of dark adaptation, or an improvement in, or slowing of the rate of, visual acuity loss.

Undesirable aspects of retinal anatomy that may be treated or prevented include, for example, retinal atrophy, retinal pigment epithelium atrophy, narrowing of retinal vessels, pigmentary clumping, retinal yellow/white spots, subretinal fluid.

Exemplary means of assessing retinal anatomy include fundoscopy, fundus photography, fluorescein angiography, indocyanine green angiography, optical coherence tomography (OCT), spectral domain optical coherence tomography, scanning laser ophthalmoscopy, confocal microscopy, adaptive optics, fundus autofluorescence, biopsy, necropsy, and immunohistochemistry. Thus, RLBP1-associated retinal dystrophy can be said to be treated in a subject as determined by, for example, a reduction in the rate of development of retinal atrophy.

Subjects to be treated with therapeutic agents of the present invention can also be administered other therapeutic agents or devices with known efficacy for treating retinal dystrophy such as vitamin and mineral preparations, low-vision aids, guide dogs, or other devices known to assist patients with low vision.

Currently there are no other approved therapeutic agents for the treatment of RLBP1-associated retinal dystrophy. As other new therapies emerge, the two can be administered sequentially in either order or simultaneously as clinically indicated.

EXAMPLES

The following examples are provided to further illustrate the invention but not to limit its scope. Other variants of the invention will be readily apparent to one of ordinary skill in the art and are encompassed by the appended claims.

Example 1 Construction of AAV-ITR Plasmids 1.1 Cloning of AAVITR Plasmids:

The nucleic acid sequences of the individual plasmid elements are described in Table 1. The sequences were either synthesized or purchased commercially. Table 2 describes the elements that exist in each plasmid that was constructed. Standard molecular biology cloning techniques were used in generating the plasmids as described in Table 3.The plasmid backbone pAAV-MCS (Stratagene®) with Ampicillin resistance or pUC57 with Kanamycin resistance was used as the backbone and starting material. The individual sequence elements were cloned in at restriction enzyme sites or using blunt end cloning.

Because the antibiotic resistance gene cassette contained in the plasmid backbone does not play a role in the production of the AAV vectors, one of skill in the art could use alternate plasmid backbones and/or antibiotic resistance gene cassettes and yield the same viral vectors. We have demonstrated that functionally equivalent NVS2 vectors can be generated using plasmids with different backbones. For example, plasmid sequences SEQ ID NO: 26 and SEQ ID NO: 50 produce functionally equivalent NVS2 vectors.

1.2. Triple Plasmid Transfection to Produce rAAVvectors:

Recombinant AAV (rAAV) viral vectors were generated by triple transfection methods. Methods for triple transfection are known in the art (Ferrari FK et al 1997). Briefly, AAV-ITR-containing plasmids (described in Table 2), AAV-RepCap containing plasmid (carrying Rep2 and Cap2 or Cap8) and Adeno-helper plasmid (carrying genes that assist in completing AAV replication cycle) were co-transfected into 293 cells. Cells were cultured for 4 days. At the end of the culture period the cells were lysed and the vectors in the culture supernatant and in the cell lysate were purified by a standard CsCI gradient centrifugation method (method modified based on Grieger JC et al 2006). The purified viral vectors are described in Table 4.

Alternatively, GMP-like rAAV vectors were generated by the cell transfection and culture methods described above. The harvested cell culture material was then processed by column chromatography based on methods described by Lock M et al (2010), Smith RH et al (2009) and Vadenberghe LH et al (2010).

1.3. Variation of 5′ ITR Sequences:

As described previously (Samulski et al, 1983; Muzyczka et al, 1984), mutations within the terminal repeat sequences of AAV plasmids are well tolerated in generating functional AAV vectors. Even plasmids with one of the two ITRs deleted, the AAV sequences could be rescued, replicated, and infectious virions be produced, as long as the existing ITR in the construct contains the full AAV ITR sequence (Samulski et al, 1983; Muzyczka et al, 1984). Therefore, even though SEQ.ID.NO.2 is used as the 5′ ITR sequence of all single-stranded AAV vectors described in this document, it is expected that any 5′ITR sequence that carries the terminal resolution site (i.e.: SEQ.ID.NOS. 2, 16 and 17) would produce vectors with the same functionality.

TABLE 1 Sequence of viral vector and plasmid elements AMINO ACID SEQUENCE OR POLYNUCLEOTIDE (PN) SEQUENCE ELEMENTS SEQUENCE IDENTIFIER (SEQ.ID.NO:)AND SEQUENCE ΔITR 1 cgcgctcgctcgctcactgaggccgcccgggcaaagcccgggcgtcgggcgacctttggtcgcccggcctcagtgagcgagcgagcgcgcagagagggagtgg 5′ ITR 2 ctgcgcgctcgctcgctcactgaggccgcccgggcgtcgggcgacctttggtcgcccggcctcagtgagcgagcgagcgcgcagagagggagtggccaactccatcactaggggttcct Human RLBP1 Promoter(short) (NT_010274.17) 3 ttgtcctctccctgcttggccttaaccagccacatttctcaactgaccccactcactgcagaggtgaaaactaccatgccaggtcctgctggctgggggaggggtgggcaataggcctggatttgccagagctgccactgtagatgtagtcatatttacgatttcccttcacctcttattaccctggtggtggtggtgggggggggggggtgctctctcagcaaccccaccccgggatcttgaggagaaagagggcagagaaaagagggaatgggactggcccagatcccagccccacagccgggcttccacatggccgagcaggaactccagagcaggagcacacaaaggagggctttgatgcgcctccagccaggcccaggcctctcccctctcccctttctctctgggtcttcctttgccccactgagggcctcctgtgagcccgatttaacggaaactgtgggcggtgagaagttccttatgacacactaatcccaacctgctgaccggaccacgcctccagcggagggaacctctagagctccaggacattcaggtaccaggtagccccaaggaggagctgccga MODIFIED SV40INTRON (MODIFIED EF579804) 4 aactgaaaaaccagaaagttaactggtaagtttagtctttttgtcttttatttcaggtcccggatccggtggtggtgcaaatcaaagaactgctcctcagtggatgttgcctttacttctaggcctgtacggaagtgttacttctgctctaaaagctgcggaattgtacccgccccgggatcc ADDED-KOZAK 5 gccacc HUMAN RLBP1 GENE CDS NM_000326.4 6 atgtcagaaggggtgggcacgttccgcatggtacctgaagaggaacaggagctccgtgcccaactggagcagctcacaaccaaggaccatggacctgtctttggcccgtgcagccagctgccccgccacaccttgcagaaggccaaggatgagctgaacgagagagaggagacccgggaggaggcagtgcgagagctgcaggagatggtgcaggcgcaggcggcctcgggggaggagctggcggtggccgtggcggagagggtgcaagagaaggacagcggcttcttcctgcgcttcatccgcgcacggaagttcaacgtgggccgtgcctatgagctgctcagaggctatgtgaatttccggctgcagtaccctgagctctttgacagcctgtccccagaggctgtccgctgcaccattgaagctggctaccctggtgtcctctctagtcgggacaagtatggccgagtggtcatgctcttcaacattgagaactggcaaagtcaagaaatcacctttgatgagatcttgcaggcatattgcttcatcctggagaagctgctggagaatgaggaaactcaaatcaatggcttctgcatcattgagaacttcaagggctttaccatgcagcaggctgctagtctccggacttcagatctcaggaagatggtggacatgctccaggattccttcccagcccggttcaaagccatccacttcatccaccagccatggtacttcaccacgacctacaatgtggtcaagcccttcttgaagagcaagctgcttgagagggtctttgtccacggggatgacctttctggtttctaccaggagatcgatgagaacatcctgccctctgacttcgggggcacgctgcccaagtatgatggcaaggccgttgctgagcagctctttggcccccaggcccaagctgagaacacagccttctga HUMAN RLBP1 GENE PRODUCT (CELLULAR RETINALDEHYDE BINDING PROTEIN - CRALBP) 7 MSEGVGTFRMVPEEEQELRAQLEQLTTKDHGPVFGPCSQLPRHTLQKAKDELNEREETREEAVRELQEMVQAQAASGEELAVAVAERVQEKDSGFFLRFIRARKFNVGRAYELLRGYVNFRLQYPELFDSLSPEAVRCTIEAGYPGVLSSRDKYGRVVMLFNIENWQSQEITFDEILQAYCFILEKLLENEETQINGFCIIENFKGFTMQQAASLRTSDL RKMVDMLQDSFPARFKAIHFIHQPWYFTTTYNWKPFLKSKLLERVFVHGDDLSGFYQEIDENILPSDFGGTLPKYDGKAVAEQLFGPQAQAENTAF SV40 POLYA (EF579804) 8 gatcataatcagccataccacatttgtagaggttttacttgctttaaaaaacctcccacacctccccctgaacctgaaacataaaatgaatgcaattgttgttgttaacttgtttattgcagcttataatggttacaaataaagcaatagcatcacaaatttcacaaataaagcatttttttcactgcattctagttgtggtttgtccaaactcatcaatgtatcttatcatgtct 3′ ITR (AF043303) 9 aggaacccctagtgatggagttggccactccctctctgcgcgctcgctcgctcactgaggccgggcgaccaaaggtcgcccgacgcccgggctttgcccgggcggcctcagtgagcgagcgagcgcgcag Human RLBP1 Promoter(long) (NT_010274.17) 10 ttgtcctctccctgcttggccttaaccagccacatttctcaactgaccccactcactgcagaggtgaaaactaccatgccaggtcctgctggctgggggaggggtgggcaataggcctggatttgccagagctgccactgtagatgtagtcatatttacgatttcccttcacctcttattaccctggtggtggtggtgggggggggggggtgctctctcagcaaccccaccccgggatcttgaggagaaagagggcagagaaaagagggaatgggactggcccagatcccagccccacagccgggcttccacatggccgagcaggaactccagagcaggagcacacaaaggagggctttgatgcgcctccagccaggcccaggcctctcccctctcccctttctctctgggtcttcctttgccccactgagggcctcctgtgagcccgatttaacggaaactgtgggcggtgagaagttccttatgacacactaatcccaacctgctgaccggaccacgcctccagcggagggaacctctagagctccaggacattcaggtaccaggtagccccaaggaggagctgccgacctggcaggtaagtcaatacctggggcttgcctgggccagggagcccaggactggggtgaggactcaggggagcagggagaccacgtcccaagatgcctgtaaaactgaaaccacctggccattctccaggttgagccagaccaatttgatggcagatttagcaaataaaaatacaggacacccagttaaatgtgaatttcagatgaacagcaaatacttttttagtattaaaaaagttcacatttaggctcacgcctgtaatcccagcactttgggaggccgaggcaggcagatcacctgaggtcaggagttcgagaccagcctggccaacatggtgaaaccccatctccactaaaaataccaaaaattagccaggcgtgctggtgggcacctgtagttccagctactcaggaggctaaggcaggagaattgcttgaacctgggaggcagaggttgcagtgagctgagatcgcaccattgcactctagcctgggcgacaagaacaaaactccatctcaaaaaaaaaaaaaaaaaaaaagttcacatttaactgggcattctgtatttaattggtaatctgagatggcagggaacagcatcagcatggtgtgagggataggcattttttcattgtgtacagcttgtaaatcagtatttttaaaactcaaagttaatggcttgggcatatttagaaaagagttgccgcacggacttgaaccctgtattcctaaaatctaggatcttgttctgatggtctgcacaactggctgggggtgtccagccactgtccctcttgcctgggctccccagggcagttctgtcagcctctccatttccattcctgttccagcaaaacccaactgatagcacagcagcatttcagcctgtctacctctgtgcccacatacctggatgtctaccagccagaaaggtggcttagatttggttcctgtgggtggattatggcccccagaacttccctgtgcttgctgggggtgtggagtggaaagagcaggaaatgggggaccctccgatactctatgggggtcctccaagtctctttgtgcaagttagggtaataatcaatatggagctaagaaagagaaggggaactatgctttagaacaggacactgtgccaggagcattgcagaaattatatggttttcacgacagttctttttggtaggtactgttattatcctcagtttgcagatgaggaaactgagacccagaaaggttaaataacttgctagggtcacacaagtcataactgacaaagcctgattcaaacccaggtctccctaacctttaaggtttctatgacgccagctctcctagggagtttgtcttcagatgtcttggctctaggtgtcaaaaaaagacttggtgtcaggcaggcataggttcaagtcccaactctgtcacttaccaactgtgactaggtgattgaactgaccatggaacctggtcacatgcaggagcaggatggtgaagggttcttgaaggcacttaggcaggacatttaggcaggagagaaaacctggaaacagaagagctgtctccaaaaatacccactggggaagcaggttgtcatgtgggccatgaatgggacctgttctggtaaccaagcattgcttatgtgtccattacatttcataacacttccatcctactttacagggaacaaccaagactggggttaaatctcacagcctgcaagtggaagagaagaacttgaa cccaggtccaacttttgcgccacagcaggctgcctcttggtcctgacaggaagtcacaacttgggtctgagtactgatccctggctattttttggctgtgttaccttggacaagtcacttattcctcctcccgtttcctcctatgtaaaatggaaataataatgttgaccctgggtctgagagagtggatttgaaagtacttagtgcatcacaaagcacagaacacacttccagtctcgtgattatgtacttatgtaactggtcatcacccatcttgagaatgaatgcattggggaaagggccatccactaggctgcgaagtttctgagggactccttcgggctggagaaggatggccacaggagggaggagagattgccttatcctgcagtgatcatgtcattgagaacagagccagattctttttttcctggcagggccaacttgttttaacatctaaggactgagctatttgtgtctgtgccctttgtccaagcagtgtttcccaaagtgtagcccaagaaccatctccctcagagccaccaggaagtgctttaaattgcaggttccta ggccacagcctgcacctgcagagtcagaatcatggaggttgggacccaggcacctgcgtttctaacaaatgcctcgggtgattctgatgcaattgaaagtttgagatccacagttctgagacaataacagaatggtttttctaacccctgcagccctgacttcctatcctagggaaggggccggctggagaggccaggacagagaaagcagatcccttctttttccaaggactctgtgtcttccataggcaac HUMAN RPE65 PROMOTER 11 tacgtaatatttattgaagtttaatattgtgtttgtgatacagaagtatttgctttaattctaaataaaaattttatgcttttattgctggtttaagaagatttggattatccttgtactttgaggagaagtttcttatttgaaatattttggaaacaggtcttttaatgtggaaagatagatattaatctcctcttctattactctccaagatccaacaaaagtgattataccccccaaaatatgatggtagtatcttatactaccatcattttataggcatagggctcttagctgcaaataatggaactaactctaataaagcagaacgcaaatattgtaaatattagagagctaacaatctctgggatggctaaaggatggagcttggaggctacccagccagtaacaatattccgggctccactgttgaatggagacactacaactgccttggatgggcagagatattatggatgctaagccccaggtgctaccattaggacttctaccactgtccctaacgggtggagcccatcacatgcctatgccctcactgtaaggaaatgaagctactgttgtatatcttgggaagcacttggattaattgttatac agttttgttgaagaagacccctagggtaagtagccataactgcacactaaatttaaaattgttaatgagtttctcaaaaaaaatgttaaggttgttagctggtatagtatatatcttgcctgttttccaaggacttctttgggcagtaccttgtctgtgctggcaagcaactgagacttaatgaaagagtattggagatatgaatgaattgatgctgtatactctcagagtgccaaacatataccaatggacaagaaggtgaggcagagagcagacaggcattagtgacaagcaaagatatgcagaatttcattctcagcaaatcaaaagtcctcaacctggttggaagaatattggcactgaatggtatcaataaggttgctagagagggttagaggtgcacaatgtgcttccataacattttatacttctccaatcttagcactaatcaaacatggttgaatactttgtttactataactcttacagagttataagatctgtgaagacagggacagggacaatacccatctctgtctggttcataggtggtatgtaatagatatttttaaaaataagtgagttaatgaatgagggtgagaatgaaggcacagaggtattagggggaggtgggccccagagaatggtgccaaggtccagtggggtgactgggatcagctcaggcctgacgctggccactcccacctagctcctttctttctaatctgttctcattctccttgggaaggattgaggtctctggaaaacagccaaacaactgttatgggaacagcaagcccaaataaagccaagcatcagggggatctgagagctgaaagcaacttctgttccccctccctcagctgaaggggtggggaagggctcccaaagccataactccttttaagggatttagaaggcataaaaaggcccctggctgagaacttccttcttcattctgcagttggt HUMAN VMD2 PROMOTER 12 tacgtaattctgtcattttactagggtgatgaaattcccaagcaacaccatccttttcagataagggcactgaggctgagagaggagctgaaacctacccggcgtcaccacacacaggtggcaaggctgggaccagaaaccaggactgttgactgcagcccggtattcattctttccatagcccacagggctgtcaaagaccccagggcctagtcagaggctcctccttcctggagagttcctggcacagaagttgaagctcagcacagccccctaacccccaactctctctgcaaggcctcaggggtcagaacactggtggagcagatcctttagcctctggattttagggccatggtagagggggtgttgccctaaattccagccctggtctcagcccaacaccctccaagaagaaattagaggggccatggccaggc tgtgctagccgttgcttctgagcagattacaagaagggactaagacaaggactcctttgtggaggtcctggcttagggagtcaagtgacggcggctcagcactcacgtgggcagtgccagcctctaagagtgggcaggggcactggccacagagtcccagggagtcccaccagcctagtcgccagacc SYNUCLEIN INTRONIC SEQUENCE AS STUFFER SEQUENCE 13 gggccccggtgttatctcattcttttttctcctctgtaagttgacatgtgatgtgggaacaaaggggataaagtcattattttgtgctaaaatcgtaattggagaggacctcctgttagctgggctttcttctatttattgtggtggttactggagttccttcttctagttttaggatatatatatatattttttttttttctttccctgaagatataataatatatatacttctgaagattgagatttttaaattagttgtattgaaaactagctaatcagcaatttaaggctagcttgagacttatgtcttgaatttgtttttgtaggctccaaaaccaaggagggagtggtgcatggtgtggcaacaggtaagctccattgtgcttatatccaaagatgatatttaaagtatctagtgattagtgtggcccagtattcaagattcctatgaaattgtaaaacaatcactgagcattctaagaacatatcagtcttattgaaactgaattctttataaagtatttttaaaaaggtaaatattgattataaataaaaaatatacttgccaagaataatgagggctttgaattgataagctatgtttaatttatagtaagtgggcatttaaatattctgaccaaaaatgtattgacaaactgctgacaaaaataaaatgtgaatattgccataattttaaaaaaagagtaaaatttctgttgattacagtaaaatattttgaccttaaattatgttgattacaatattcctttgataattcagagtgcatttcaggaaacacccttggacagtcagtaaattgtttattgtatttatctttgtattgttatggtatagctatttgtacaaatattattgtgcaattattacatttctgattatattattcatttggcctaaatttaccaagaatttgaacaagtcaattaggtttacaatcaagaaatatcaaaaatgatgaaaaggatgataatcatcatcagatgttgaggaagatgacgatgagagtgccagaaatagagaaatcaaaggagaaccaaaatttaacaaattaaaagcccacagacttgctgtaattaagttttctgttgtaagtactccacgtttcctggcagatgtggtgaagcaaaagatataatcagaaatataatttatatgatcggaaagcattaaacacaatagtgcctatacaaataaaatgttcctatcac tgacttctaaaatggaaatgaggacaatgatatgggaatcttaatacagtgttgtggataggactaaaaacacaggagtcagatcttcttggttcaacttcctgcttactccttaccagctgtgtgttttttgcaaggttcttcacctctatgtgatttagcttcctcatctataaaataattcagtgaattaatgtacacaaaacatctggaaaacaaaagcaaacaatatgtattttataagtgttacttatagttttatagtgaactttcttgtgcaacatttttacaactagtggagaaaaatatttctttaaatgaatacttttgatttaaaaatcagagtgtaaaaataaaacagactcctttgaaactagttctgttagaagttaattgtgcacctttaatgggctctgttgcaatccaacagagaagtagttaagtaagtggactatgatggcttctagggacctcctataaatatgatattgtgaagcatgattataataagaactagataacagacaggtggagactccactatctgaagagggtcaacctagatgaatggtgttccatttagtagttgaggaagaacccatgaggtttagaaagcagacaagcatgtggcaagttctggagtcagtggtaaaaattaaagaacccaactattactgtcacctaatgatctaatggagactgtggagatgggctgcatttttttaatcttctccagaatgccaaaatgtaaacacatatctgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgagagagagagagagagagagagagactgaagtttgtacaattagacattttataaaatgttttctgaaggacagtggctcacaatcttaagtttctaacattgtacaatgttgggagactttgtatactttattttctctttagcatattaaggaatctgagatgtcctacagtaaagaaatttgcattacatagttaaaatcagggttattcaaactttttgattattgaaacctttcttcattagttactagggttgaatgaaactagtgttccacagaaaactatgggaaatgttgctaggcagtaaggacatggtgatttcagcatgtgcaatatttacagcgattgcacccatggaccaccctggcagtagtgaaataaccaaaaatgctgtcataactagtatggctatgagaaacacattggg RLBP1 INTRONIC SEQUENCE AS STUFFER SEQUENCE (NT 010274.17) 14 ATTCTCCAGGTTGAGCCAGACCAATTTGATGGTAGATTTAGCAAATAAAAATACAGGACACCCAGTTAAATGTGAATTTCCGATGAACAGCAAATACTTTTTTAGTATTAAAAAAGTTCACATTTAGGCTCACGCCTGTAATCCCAGCACTTTGGGAGGCCGAGGCAGGCAGATCACCTGAGGTCAGGAGTTCGAGACCAGCCTGGCCAACATGGTGAAA CCCCATCTCCACTAAAAATACCAAAAATTAGCCAGGCGTGCTGGTGGGCACCTGTAGTTCCAGCTACTCAGGAGGCTAAGGCAGGAGAATTGCTTGAACCTGGGAGGCAGAGGTTGCAGTGAGCTGAGATCGCACCATTGCACTCTAGCCTGGGCGACAAGAACAAAACTCCATCTCAAAAAAAAAAAAAAAAAAAAAGTTCACATTTAACTGGGCATTCTGTATTTAATTGGTAATCTGAGATGGCAGGGAACAGCATCAGCATGGTGTGAGGGATAGGCATTTTTTCATTGTGTACAGCTTGTAAATCAGTATTTTTAAAACTCAAAGTTAATGGCTTGGGCATATTTAGAAAAGAGTTGCCGCACGGACTTGAACCCTGTATTCCTAAAATCTAGGATCTTGTTCTGATGGTCTGCACAACTGGCTGGGGGTGTCCAGCCACTGTCCCTCTTGCCTGGGCTCCCCAGGGCAGTTCTGTCAGCCTCTCCATTTCCATTCCTGTTCCAGCAAAACCCAACTGATAGCACAGCAGCATTTCAGCCTGTCTACCTCTGTGCCCACATACCTGGATGTCTACCAGCCAGAAAGGTGGCTTAGATTTGGTTCCTGTGGGTGGATTATGGCCCCCAGAACTTCCCTGTGCTTGCTGGGGGTGTGGAGTGGAAAGAGCAGGAAATGGGGGACCCTCCGATACTCTATGGGGGTCCTCCAAGTCTCTTTGTGCAAGTTAGGGTAATAATCAATATGGAGCTAAGAAAGAGAAGGGGAACTATGCTTTAGAACAGGACACTGTGCCAGGAGCATTGCAGAAATTATATGGTTTTCACGACAGTTCTTTTTGGTAGGTACTGTTATTATCCTCAGTTTGCAGATGAGGAAACTGAGACCCAGAAAGGTTAAATAACTTGCTAGGGTCACACAAGTCATAACTGACAAAGCCTGATTCAAACCCAGGTCTCCCTAACCTTTAAGGTTTCTATGACGCCAGCTCTCCTAGGGAGTTTGTCTTCAGATGTCTTGGCTCTAGGTGTCAAAAAAAGACTTGGTGTCAGGCAGGCATAGGTTCAAGTCCCAACTCTGTCACTTACCAACTGTGACTAGGTGATTGAACTGACCATGGAACCTGGTCACATGCAGGAGCAGGATGGTGAAGGGTTCTTGAAGGCACTTAGGCAGGACATTTAGGCAGGAGAGAAAACCTGGAAACAGAAGAGCTGTCTCCAAAAATACCCACTGGGGAAGCAGGTTGTCATGTGGGCCATGAATGGGACCTGTTCTGG AMP BACTERIAL BACKBONE 15 ctgcctgcaggggcgcctgatgcggtattttctccttacgcatctgtgcggtatttcacaccgcatacgtcaaagcaaccatagtacgcgccctgtagcggcgcattaagcgcggcgggtgtggtggttacg cgcagcgtgaccgctacacttgccagcgccttagcgcccgctcctttcgctttcttcccttcctttctcgccacgttcgccggctttccccgtcaagctctaaatcgggggctccctttagggttccgatttagtgctttacggcacctcgaccccaaaaaacttgatttgggtgatggttcacgtagtgggccatcgccctgatagacggtttttcgccctttgacgttggagtccacgttctttaatagtggactcttgttccaaactggaacaacactcaactctatctcgggctattcttttgatttataagggattttgccgatttcggtctattggttaaaaaatgagctgatttaacaaaaatttaacgcgaattttaacaaaatattaacgtttacaattttatggtgcactctcagtacaatctgctctgatgccgcatagttaagccagccccgacacccgccaacacccgctgacgcgccctgacgggcttgtctgctcccggcatccgcttacagacaagctgtgaccgtctccgggagctgcatgtgtcagaggttttcaccgtcatcaccgaaacgcgcgagacgaaagggcctcgtgatacgcctatttttataggttaatgtcatgataataatggtttcttagacgtcaggtggcacttttcggggaaatgtgcgcggaacccctatttgtttatttttctaaatacattcaaatatgtatccgctcatgagacaataaccctgataaatgcttcaataatattgaaaaaggaagagtatgagtattcaacatttccgtgtcgcccttattcccttttttgcggcattttgccttcctgtttttgctcacccagaaacgctggtgaaagtaaaagatgctgaagatcagttgggtgcacgagtgggttacatcgaactggatctcaacagcggtaagatccttgagagttttcgccccgaagaacgttttccaatgatgagcacttttaaagttctgctatgtggcgcggtattatcccgtattgacgccgggcaagagcaactcggtcgccgcatacactattctcagaatgacttggttgagtactcaccagtcacagaaaagcatcttacggatggcatgacagtaagagaattatgcagtgctgccataaccatgagtgataacactgcggccaacttacttctgacaacgatcggaggaccgaaggagctaaccgcttttttgcacaacatgggggatcatgtaactcgccttgatcgttgggaaccggagctgaatgaagccataccaaacgacgagcgtgacaccacgatgcctgtagcaatggcaacaacgttgcgcaaactattaactggcgaactacttactctagcttcccggcaacaattaatagactggatggaggcggataaagttgcaggaccacttctgcgctcggcccttccggctggctggtttattgctgataaatctgg agccggtgagcgtgggtctcgcggtatcattgcagcactggggccagatggtaagccctcccgtatcgtagttatctacacgacggggagtcaggcaactatggatgaacgaaatagacagatcgctgagataggtgcctcactgattaagcattggtaactgtcagaccaagtttactcatatatactttagattgatttaaaacttcatttttaatttaaaaggatctaggtgaagatcctttttgataatctcatgaccaaaatcccttaacgtgagttttcgttccactgagcgtcagaccccgtagaaaagatcaaaggatcttcttgaaatcctttttttctgcgcgtaatctgctgcttgcaaacaaaaaaaccaccgctaccagcggtggtttgtttgccggatcaagagctaccaactctttttccgaaggtaactggcttcagcagagcgcagataccaaatactgttcttctagtgtagccgtagttaggccaccacttcaagaactctgtagcaccgcctacatacctcgctctgctaatcctgttaccagtggctgctgccagtggcgataagtcgtgtcttaccgggttggactcaagacgatagttaccggataaggcgcagcggtcgggctgaacggggggttcgtgcacacagcccagcttggagcgaacgacctacaccgaactgagatacctacagcgtgagctatgagaaagcgccacgcttcccgaagggagaaaggcggacaggtatccggtaagcggcagggtcggaacaggagagcgcacgagggagcttccagggggaaacgcctggtatctttatagtcctgtcgggtttcgccacctctgacttgagcgtcgatttttgtgatgctcgtcaggggggcggagcctatggaaaaacgccagcaacgcggcctttttacggttcctggccttttgctggccttttgctcacatgtcctgcaggcag 5′ ITR -STRATAGENE 16 Ctgcgcgctcgctcgctcactgaggccgcccgggcaaagcccgggcgtcgggcgacctttggtcgcccggcctcagtgagcgagcgagcgcgcagagagggagtggccaactccatcactaggggttcct 5′ ITR - NCBI (AF043303) 17 Ttggccactccctctctgcgcgctcgctcgctcactgaggccgggcgaccaaaggtcgcccgacgcccgggctttgcccgggcggcctcagtgagcgagcgagcgcgcagagagggagtggccaactccatcactaggggttcct AAV2 CAPSID CODING SEQUENCE 18 atggctgccgatggttatcttccagattggctcgaggacactctctctgaaggaataagacagtggtggaagctcaaacctggcccaccaccaccaaagcccgcagagcggcataaggacgacagcaggggtcttgtgcttcctgggtacaagtacctcggacccttcaacggactcgacaagggagagccggtcaacgaggcagacgccgcggccctcgagcacgacaaagcctacgaccggcagctcgacagcggagacaacccgtacctcaagtacaaccacgccgacgcggagtttcaggagcgccttaaagaagatacgtcttttgggggcaacctcggacgagcagtcttccaggcgaaaaagagggttcttgaacctctgggcctggttgaggaacctgttaagacggctccgggaaaaaagaggccggtagagcactctcctgtggagccagactcctcctcgggaaccggaaaggcgggccagcagcctgcaagaaaaagattgaattttggtcagactggagacgcagactcagtacctgacccccagcctctcggacagccaccagcagccccctctggtctgggaactaatacgatggctacaggcagtggcgcaccaatggcagacaataacgagggcgccgacggagtgggtaattcctcgggaaattggcattgcgattccacatggatgggcgacagagtcatcaccaccagcacccgaacctgggccctgcccacctacaacaaccacctctacaaacaaatttccagccaatcaggagcctcgaacgacaatcactactttggctacagcaccccttgggggtattttgacttcaacagattccactgccacttttcaccacgtgactggcaaagactcatcaacaacaactggggattccgacccaagagactcaacttcaagctctttaacattcaagtcaaagaggtcacgcagaatgacggtacgacgacgattgccaataaccttaccagcacggttcaggtgtttactgactcggagtaccagctcccgtacgtcctcggctcggcgcatcaaggatgcctcccgccgttcccagcagacgtcttcatggtgccacagtatggatacctcaccctgaacaacgggagtcaggcagtaggacgctcttcattttactgcctggagtactttccttctcagatgctgcgtaccggaaacaactttaccttcagctacacttttgaggacgttcctttccacagcagctacgctcacagccagagtctggaccgtctcatgaatcctctcatcgaccagtacctgtattacttgagcagaacaaacactccaagtggaaccaccacgcagtcaaggcttcagttttctcaggccggagcgagtgacattcgggaccagtctaggaactggcttcctggaccctgttaccgccagcagcgagtatcaaagacatctgcggataacaacaacagtga atactcgtggactggagctaccaagtaccacctcaatggcagagactctctggtgaatccgggcccggccatggcaagccacaaggacgatgaagaaaagttttttcctcagagcggggttctcatctttgggaagcaaggctcagagaaaacaaatgtggacattgaaaaggtcatgattacagacgaagaggaaatcaggacaaccaatcccgtggctacggagcagtatggttctgtatctaccaacctccagagaggcaacagacaagcagctaccgcagatgtcaacacacaaggcgttcttccaggcatggtctggcaggacagagatgtgtaccttcaggggcccatctgggcaaagattccacacacggacggacattttcacccctctcccctcatgggtggattcggacttaaacaccctcctccacagattctcatcaagaacaccccggtacctgcgaatccttcgaccaccttcagtgcggcaaagtttgcttccttcatcacacagtactccacgggacaggtcagcgtggagatcgagtgggagctgcagaaggaaaacagcaaacgctggaatcccgaaattcagtacacttccaactacaacaagtctgttaatgtggactttactgtggacactaatggcgtgtattcagagcctcgccccattggcaccagatacctgactcgtaatctgtaa AAV2 CAPSID SEQUENCE (VP1) 19 maadgylpdwledtlsegirqwwklkpgppppkpaerhkddsrglvlpgykylgpfngldkgepvneadaaalehdkaydrqldsgdnpylkynhadaefqerlkedtsfggnlgravfqakkrvleplglveepvktapgkkrpvehspvepdsssgtgkagqqparkrlnfgqtgdadsvpdpqplgqppaapsglgtntmatgsgapmadnnegadgvgnssgnwhcdstwmgdrvittstrtwalptynnhlykqissqsgasndnhyfgystpwgyfdfnrfhchfsprdwqrlinnnwgfrpkrlnfklfniqvkevtqndgtttiannltstvqvftdseyqlpyvlgsahqgclppfpadvfmvpqygyltlnngsqavgrssfycleyfpsqmlrtgnnftfsytfedvpfhssyahsqsldrlmnplidqylyylsrtntpsgtttqsrlqfsqagasdirdqsrnwlpgpcyrqqrvsktsadnnnseyswtgatkyhlngrdslvnpgpamashkddeekffpqsgvlifgkqgsektnvdiekvmitdeeeirttnpvateqygsvstnlqrgnrqaatadvntqgvlpgmvwqdrdvylqgpiwakiphtdghfhpsplmggfglkhpppqilikntpvpanpstt fsaakfasfitqystgqvsveiewelqkenskrwnpeiqytsnynksvnvdftvdtngvyseprpigtryltrnl AAV2 CAPSID SEQUENCE (VP2) 68 mapgkkrpvehspvepdsssgtgkagqqparkrlnfgqtgdadsvpdpqplgqppaapsglgtntmatgsgapmadnnegadgvgnssgnwhcdstwmgdrvittstrtwalptynnhlykqissqsgasndnhyfgystpwgyfdfnrfhchfsprdwqrlinnnwgfrpkrlnfklfniqvkevtqndgtttiannltstvqvftdseyqlpyvlgsahqgclppfpadvfmvpqygyltlnngsqavgrssfycleyfpsqmlrtgnnftfsytfedvpfhssyahsqsldrlmnplidqylyylsrtntpsgtttqsrlqfsqagasdirdqsrnwlpgpcyrqqrvsktsadnnnseyswtgatkyhlngrdslvnpgpamashkddeekffpqsgvlifgkqgsektnvdiekvmitdeeeirttnpvateqygsvstnlqrgnrqaatadvntqgvlpgmvwqdrdvylqgpiwakiphtdghfhpsplmggfglkhpppqilikntpvpanpsttfsaakfasfitqystgqvsveiewelqkenskrwnpeiqytsnynksvnvdftvdtngvyseprpigtryltrnl AAV2 CAPSID SEQUENCE (VP3) 69 matgsgapmadnnegadgvgnssgnwhcdstwmgdrvittstrtwalptynnhlykqissqsgasndnhyfgystpwgyfdfnrfhchfsprdwqrlinnnwgfrpkrlnfklfniqvkevtqndgtttiannltstvqvftdseyqlpyvlgsahqgclppfpadvfmvpqygyltlnngsqavgrssfycleyfpsqmlrtgnnftfsytfedvpfhssyahsqsldrlmnplidqylyylsrtntpsgtttqsrlqfsqagasdirdqsrnwlpgpcyrqqrvsktsadnnnseyswtgatkyhlngrdslvnpgpamashkddeekffpqsgvlifgkqgsektnvdiekvmitdeeeirttnpvateqygsvstnlqrgnrqaatadvntqgvlpgmvwqdrdvylqgpiwakiphtdghfhpsplmggfglkhpppqilikntpvpanpsttfsaakfasfitqystgqvsveiewelqkenskrwnpeiqytsnynksvnvdftvdtngvyseprpigtryltrnl AAV8 CAPSID CODING SEQUENCE 20 atggctgccgatggttatcttccagattggctcgaggacaacctctctgagggcattcgcgagtggtgggcgctgaaacctggagccc cgaagcccaaagccaaccagcaaaagcaggacgacggccggggtctggtgcttcctggctacaagtacctcggacccttcaacggactcgacaagggggagcccgtcaacgcggcggacgcagcggccctcgagcacgacaaggcctacgaccagcagctgcaggcgggtgacaatccgtacctgcggtataaccacgccgacgccgagtttcaggagcgtctgcaagaagatacgtcttttgggggcaacctcgggcgagcagtcttccaggccaagaagcgggttctcgaacctctcggtctggttgaggaaggcgctaagacggctcctggaaagaagagaccggtagagccatcaccccagcgttctccagactcctctacgggcatcggcaagaaaggccaacagcccgccagaaaaagactcaattttggtcagactggcgactcagagtcagttccagaccctcaacctctcggagaacctccagcagcgccctctggtgtgggacctaatacaatggctgcaggcggtggcgcaccaatggcagacaataacgaaggcgccgacggagtgggtagttcctcgggaaattggcattgcgattccacatggctgggcgacagagtcatcaccaccagcacccgaacctgggccctgcccacctacaacaaccacctctacaagcaaatctccaacgggacatcgggaggagccaccaacgacaacacctacttcggctacagcaccccctgggggtattttgactttaacagattccactgccacttttcaccacgtgactggcagcgactcatcaacaacaactggggattccggcccaagagactcagcttcaagctcttcaacatccaggtcaaggaggtcacgcagaatgaaggcaccaagaccatcgccaataacctcaccagcaccatccaggtgtttacggactcggagtaccagctgccgtacgttctcggctctgcccaccagggctgcctgcctccgttcccggcggacgtgttcatgattccccagtacggctacctaacactcaacaacggtagtcaggccgtgggacgctcctccttctactgcctggaatactttccttcgcagatgctgagaaccggcaacaacttccagtttacttacaccttcgaggacgtgcctttccacagcagctacgcccacagccagagcttggaccggctgatgaatcctctgattgaccagtacctgtactacttgtctcggactcaaacaacaggaggcacggcaaatacgcagactctgggcttcagccaaggtgggcctaatacaatggccaatcaggcaaagaactggctgccaggaccctgttaccgccaacaacgcgtctcaacgacaaccgggcaaaacaacaatagcaactttgcctggactgctgggaccaaataccatctgaatggaagaaattcattggctaatcctggcatcgctatggcaaca cacaaagacgacgaggagcgtttttttcccagtaacgggatcctgatttttggcaaacaaaatgctgccagagacaatgcggattacagcgatgtcatgctcaccagcgaggaagaaatcaaaaccactaaccctgtggctacagaggaatacggtatcgtggcagataacttgcagcagcaaaacacggctcctcaaattggaactgtcaacagccagggggccttacccggtatggtctggcagaaccgggacgtgtacctgcagggtcccatctgggccaagattcctcacacggacggcaacttccacccgtctccgctgatgggcggctttggcctgaaacatcctccgcctcagatcctgatcaagaacacgcctgtacctgcggatcctccgaccaccttcaaccagtcaaagctgaactctttcatcacgcaatacagcaccggacaggtcagcgtggaaattgaatgggagctgcagaaggaaaacagcaagcgctggaaccccgagatccagtacacctccaactactacaaatctacaagtgtggactttgctgttaatacagaaggcgtgtactctgaaccccgccccattggcacccgttacctcacccgtaatctgtaa AAV8 CAPSID SEQUENCE (VP1) 21 maadgylpdwlednlsegirewwalkpgapkpkanqqkqddgrglvlpgykylgpfngldkgepvnaadaaalehdkaydqqlqagdnpylrynhadaefqerlqedtsfggnlgravfqakkrvleplglveegaktapgkkrpvepspqrspdsstgigkkgqqparkrlnfgqtgdsesvpdpqplgeppaapsgvgpntmaagggapmadnnegadgvgsssgnwhcdstwlgdrvittstrtwalptynnhlykqisngtsggatndntyfgystpwgyfdfnrfhchfsprdwqrlinnnwgfrpkrlsfklfniqvkevtqnegtktiannltstiqvftdseyqIpyvlgsahqgclppfpadvfmipqygyltlnngsqavgrssfycleyfpsqmlrtgnnfqftytfedvpfhssyahsqsldrlmnplidqylyylsrtqttggtantqtlgfsqggpntmanqaknwlpgpcyrqqrvstttgqnnnsnfawtagtkyhlngrnslanpgiamathkddeerffpsngilifgkqnaardnadysdvmltseeeikttnpvateeygivadnlqqqntapqigtvnsqgalpgmvwqnrdvylqgpiwakiphtdgnfhpsplmggfglkhpppqilikntpvpadppttfnqskinsfitqystgqvsveiewelqkenskrwnpeiqytsnyykstsvdfavntegvyseprpigtryltrnl AAV8 CAPSID SEQUENCE (VP2) 70 mapgkkrpvepspqrspdsstgigkkgqqparkrlnfgqtgdsesvpdpqplgeppaapsgvgpntmaagggapmadnnegadgvgsssgnwhcdstwlgdrvittstrtwalptynnhlykqisngtsggatndntyfgystpwgyfdfnrfhchfsprdwqrlinnnwgfrpkrlsfklfniqvkevtqnegtktiannltstiqvftdseyqlpyvlgsahqgclppfpadvfmipqygyltlnngsqavgrssfycleyfpsqmlrtgnnfqftytfedvpfhssyahsqsldrlmnplidqylyylsrtqttggtantqtlgfsqggpntmanqaknwlpgpcyrqqrvstttgqnnnsnfawtagtkyhlngrnslanpgiamathkddeerffpsngilifgkqnaardnadysdvmltseeeikttnpvateeygivadnlqqqntapqigtvnsqgalpgmvwqnrdvylqgpiwakiphtdgnfhpsplmggfglkhpppqilikntpvpadppttfnqsklnsfitqystgqvsveiewelqkenskrwnpeiqytsnyykstsvdfavntegvyseprpigtryltrnl AAV8 CAPSID SEQUENCE (VP3) 71 maagggapmadnnegadgvgsssgnwhcdstwlgdrvittstrtwalptynnhlykqisngtsggatndntyfgystpwgyfdfnrfhchfsprdwqrlinnnwgfrpkrlsfklfniqvkevtqnegtktiannltstiqvftdseyqlpyvlgsahqgclppfpadvfmipqygyltlnngsqavgrssfycleyfpsqmlrtgnnfqftytfedvpfhssyahsqsldrlmnplidqylyylsrtqttggtantqtlgfsqggpntmanqaknwlpgpcyrqqrvstttgqnnnsnfawtagtkyhlngrnslanpgiamathkddeerffpsngilifgkqnaardnadysdvmltseeeikttnpvateeygivadnlqqqntapqigtvnsqgalpgmvwqnrdvylqgpiwakiphtdgnfhpsplmggfglkhpppqilikntpvpadppttfnqskinsfitqystgqvsveiewelqkenskrwnpeiqytsnyykstsvdfavntegvyseprpigtryltrnl CVM ENHANCER AND CBA PROMOTER ( GENBANK ACCESSION DD215332 FROM BP 1-BP 1616) 22 ACTAGTTATTAATAGTAATCAATTACGGGGTCATTAGTTCATAGCCCATATATGGAGTTCCGCGTTACATAACTTACGGTAAATGGCCCGCCTGGCTGACCGCCCAACGACCCCCGCCCATTGACGTCAATAATGACGTATGTTCCCATAGTAACGCCAATAGGGACTTTCCATTG ACGTCAATGGGTGGAGTATTTACGGTAAACTGCCCACTTGGCAGTACATCAAGTGTATCATATGCCAAGTACGCCCCCTATTGACGTCAATGACGGTAAATGGCCCGCCTGGCATTATGCCCAGTACATGACCTTATGGGACTTTCCTACTTGGCAGTACATCTACGTATTAGTCATCGCTATTACCATGGTCGAGGTGAGCCCCACGTTCTGCTTCACTCTCCCCATCTCCCCCCCCTCCCCACCCCCAATTTTGTATTTATTTATTTTTTAATTATTTTGTGCAGCGATGGGGGCGGGGGGGGGGGGGGGGCGCGCGCCAGGCGGGGCGGGGCGGGGCGAGGGGCGGGGCGGGGCGAGGCGGAGAGGTGCGGCGGCAGCCAATCAGAGCGGCGCGCTCCGAAAGTTTCCTTTTATGGCGAGGCGGCGGCGGCGGCGGCCCTATAAAAAGCGAAGCGCGCGGCGGGCGGGGAGTCGCTGCGACGCTGCCTTCGCCCCGTGCCCCGCTCCGCCGCCGCCTCGCGCCGCCCGCCCCGGCTCTGACTGACCGCGTTACTCCCACAGGTGAGCGGGCGGGACGGCCCTTCTCCTCCGGGCTGTAATTAGCGCTTGGTTTAATGACGGCTTGTTTCTTTTCTGTGGCTGCGTGAAAGCCTTGAGGGGCTCCGGGAGGGCCCTTTGTGCGGGGGGAGCGGCTCGGGGGGTGCGTGCGTGTGTGTGTGCGTGGGGAGCGCCGCGTGCGGCTCCGCGCTGCCCGGCGGCTGTGAGCGCTGCGGGCGCGGCGCGGGGCTTTGTGCGCTCCGCAGTGTGCGCGAGGGGAGCGCGGCCGGGGGCGGTGCCCCGCGGTGCGGGGGGGGCTGCGAGGGGAACAAAGGCTGCGTGCGGGGTGTGTGCGTGGGGGGGTGAGCAGGGGGTGTGGGCGCGTCGGTCGGGCTGCAACCCCCCCTGCACCCCCCTCCCCGAGTTGCTGAGCACGGCCCGGCTTCGGGTGCGGGGCTCCGTACGGGGCGTGGCGCGGGGCTCGCCGTGCCGGGCGGGGGGTGGCGGCAGGTGGGGGTGCCGGGCGGGGCGGGGCCGCCTCGGGCCGGGGAGGGCTCGGGGGAGGGGCGCGGCGGCCCCCGGAGCGCCGGCGGCTGTCGAGGCGCGGCGAGCCGCAGCCATTGCCTTTTATGGTAATCGTGCGAGAGGGCGCAGGGACTTCCTTTGTCCCAAATCTGTGCGGAGCCGAAATCTGGGAGGCGCCGCCGCACCCCCTCTAGCGGGCGCGGGGCGAAGCGGTGCGGCGCCGGCAGGAAGGAAATGGGCGGGGAGGGCCTTCGTGCGTCGCCGCGCCGCCGTCCCCTTCTCCCTCTCCAGCCTCGGGGCTGTCCGCGGGGGGACGGCTGCCTTCGGGGGGGACGGGGCAGGGCGGGGTTCGGCTTCTGGCGTGTGACCGGCGGC REVERSE COMPLEMENT OF RLBP1 INTRONIC SEQUENCE AS STUFFER SEQUENCE (NT 010274.17) 23 CCAGAACAGGTCCCATTCATGGCCCACATGACAACCTGCTTCCCCAGTGGGTATTTTTGGAGACAGCTCTTCTGTTTCCAGGTTTTCTCTCCTGCCTAAATGTCCTGCCTAAGTGCCTTCAAGAACCCTTCACCATCCTGCTCCTGCATGTGACCAGGTTCCATGGTCAGTTCAATCACCTAGTCACAGTTGGTAAGTGACAGAGTTGGGACTTGAACCTATGCCTGCCTGACACCAAGTCTTTTTTTGACACCTAGAGCCAAGACATCTGAAGACAAACTCCCTAGGAGAGCTGGCGTCATAGAAACCTTAAAGGTTAGGGAGACCTGGGTTTGAATCAGGCTTTGTCAGTTATGACTTGTGTGACCCTAGCAAGTTATTTAACCTTTCTGGGTCTCAGTTTCCTCATCTGCAAACTGAGGATAATAACAGTACCTACCAAAAAGAACTGTCGTGAAAACCATATAATTTCTGCAATGCTCCTGGCACAGTGTCCTGTTCTAAAGCATAGTTCCCCTTCTCTTTCTTAGCTCCATATTGATTATTACCCTAACTTGCACAAAGAGACTTGGAGGACCCCCATAGAGTATCGGAGGGTCCCCCATTTCCTGCTCTTTCCACTCCACACCCCCAGCAAGCACAGGGAAGTTCTGGGGGCCATAATCCACCCACAGGAACCAAATCTAAGCCACCTTTCTGGCTGGTAGACATCCAGGTATGTGGGCACAGAGGTAGACAGGCTGAAATGCTGCTGTGCTATCAGTTGGGTTTTGCTGGAACAGGAATGGAAATGGAGAGGCTGACAGAACTGCCCTGGGGAGCCCAGGCAAGAGGGACAGTGGCTGGACACCCCCAGCCAGTTGTGCAGACCATCAGAACAAGATCCTAGATTTTAGGAATACAGGGTTCAAGTCCGTGCGGCAACTCTTTTCTAAATATGCCCAAGCCATTAACTTTGAGTTTTAAAAATACTGATTTACAAGCTGTACACAATGAAAAAATGCCTATCCCTCACACCATGCTGATGCTGTTCCCTGCCATCTCAGATTACCAATTAAATACAGAATGCCCAGTTAAATGTGAACTTTTTTTTTTTTTTTTTTTTTGAGATGGAGTTTTGTTCTTGTCGCCCAGGCTAGAGTGCAATGGTGCGATCTCAGCTCACTGCAACCTCTGCCTCCCAGGTTCAAGCAATTCTCCTGCCTTAGCCTCCTGAGTAGCTGGAACTACAGGTGCCCACCAGCACGCCTGGCTAATTTTTGGTATTTTTAGTGGAGATGGGGTTTCACCATGTTGGCCAGGCTGGTCTCGAACTCCTGACCTCAGGTGATCTGCCTGCCTCGGCCTCCCAAAGTGCTGGGATTACAGGCGTGAGCCTAAATGTGAACTTTTTTAATACTAAAAAAGTATTTGCTGTTCATCGGAAATTCACATTTAACTGGGTGTCCTGTA TTTTTATTTGCTAAATCTACCATCAAATTGGTCTGGCTCAACCTGGAGAAT EGFP SEQUENCE 24 ATGGTGAGCAAGGGCGAGGAGCTGTTCACCGGGGTGGTGCCCATCCTGGTCGAGCTGGACGGCGACGTAAACGGCCACAAGTTCAGCGTGTCCGGCGAGGGCGAGGGCGATGCCACCTACGGCAAGCTGACCCTGAAGTTCATCTGCACCACCGGCAAGCTGCCCGTGCCCTGGCCCACCCTCGTGACCACCCTGACCTACGGCGTGCAGTGCTTCAGCCGCTACCCCGACCACATGAAGCAGCACGACTTCTTCAAGTCCGCCATGCCCGAAGGCTACGTCCAGGAGCGCACCATCTTCTTCAAGGACGACGGCAACTACAAGACCCGCGCCGAGGTGAAGTTCGAGGGCGACACCCTGGTGAACCGCATCGAGCTGAAGGGCATCGACTTCAAGGAGGACGGCAACATCCTGGGGCACAAGCTGGAGTACAACTACAACAGCCACAACGTCTATATCATGGCCGACAAGCAGAAGAACGGCATCAAGGTGAACTTCAAGATCCGCCACAACATCGAGGACGGCAGCGTGCAGCTCGCCGACCACTACCAGCAGAACACCCCCATCGGCGACGGCCCCGTGCTGCTGCCCGACAACCACTACCTGAGCACCCAGTCCGCCCTGAGCAAAGACCCCAACGAGAAGCGCGATCACATGGTCCTGCTGGAGTTCGTGACCGCCGCCGGGATCACTCTCGGCATGGACGAGCTGTACAAGTAA GFP AMINO ACID SEQUENCE 25 MVSKGEELFTGWPILVELDGDVNGHKFSVSGEGEGDATYGKLTLKFICTTGKLPVPWPTLVTTLTYGVQCFSRYPDHMKQHDFFKSAMPEGYVQERTIFFKDDGNYKTRAEVKFEGDTLVNRIELKGIDFKEDGNILGHKLEYNYNSHNVYIMADKQKNGIKVNFKIRHNIEDGSVQLADHYQQNTPIGDGPVLLPDNHYLSTQSALSKDPNEKRDHMVLLEFVTAAGITLGMDELYK SC5′ITR 36 CTGCGCGCTCGCTCGCTCACTGAGGCCGCCCGGGCAAAGCCCGGGCGTCGGGCGACCTTTGGTCGCCCGGCCTCAGTGAGCGAGCGAGCGCGCAGAGAGGGAGTGGCCAACTCCATCACTAGGGGTTCCT MACACA MULATTA (RHESUS MONKEY) RLBP1 CDS XM_001091538 37 ATGTCAGAAGGGGTGGGCACGTTCCGCATGGTACCTGAAGAGGAACAGGAGCTCCGTGCCCAACTGGAGCAGCTCACAACCAAGGACCATGGACCTGTCTTTGGCCCGTGCAGCCAGCTGCCCCGCCACACCTTGCAGAAGGCCAAAGATGAGCTGAATGAGAGAGAGGAGACCCGGGAGGAGGCAGTGCGAGAGCTGCAGGAGATGGTGCAGGCGCAGGCGGCCTCGGGGGAGGAGCTGGCCGTGGCCGTGGCGGAGAGGGTGCAAGAGAAGGACAGCGGCTTCTTCCTGCGCTTCATCCGCGCGCGAAAGTTCAACGTGGGCCGTGCCTATGAGCTGCTCAGAGGCTATGTGAATTTCCGGCTGCAGTACCCTGAGCTCTTTGACAGCCTGTCCCCAGAGGCTGTCCGCTGTACCATTGAAGCTGGCTACCCTGGTGTCCTCTCTAGTCGGGACAAGTATGGCCGAGTGGTCATGCTCTTCAACATTGAGAACTGGCAAAGTCAAGAAATCACCTTCGATGAGATCTTGCAGGCATATTGCTTCATCCTGGAGAAGCTGCTGGAGAATGAGGAAACTCAAATTAATGGATTCTGCATCATTGAGAACTTCAAGGGCTTTACCATGCAGCAGGCTGCTAGTCTCCGCACTTCAGATCTCAGGAAGATGGTGGACATGCTCCAGGATTCCTTCCCAGCCCGGTTCAAAGCCATCCACTTCATCCACCAGCCATGGTACTTCACCACGACCTACAATGTGGTCAAGCCCTTCTTGAAGAGCAAGCTGCTTGAGAGGGTCTTTGTCCACGGGGAGGACCTCTCTGGTTTCTACCAGGAGATTGATGAGAACATCCTGCCCTCTGACTTTGGGGGCACGCTGCCCAAGTATGATGGCAAAGCTGTTGCTGAGCAGCTCTTTGGCCCCCGGGCCCAAGCTGAGAACACAGCCTTCTGA MACACA MULATTA (RHESUS MONKEY) RLBP1 GENE PRODUCT (CELLULAR RETINALDEHYDE BINDING PROTEIN - CRALBP) 38 MSEGVGTFRMVPEEEQELRAQLEQLTTKDHGPVFGPCSQLPRHTLQKAKDELNEREETREEAVRELQEMVQAQAASGEELAVAVAERVQEKDSGFFLRFIRARKFNVGRAYELLRGYVNFRLQYPELFDSLSPEAVRCTIEAGYPGVLSSRDKYGRVVMLFNIENWQSQEITFDEILQAYCFILEKLLENEETQINGFCIIENFKGFTMQQAASLRTSDLRKMVDMLQDSFPARFKAIHFIHQPWYFTTTYNWKPFLKSKLLERVFVHGEDLSGFYQEIDENILPSDFGGTLPKYDGKAVAEQLFGPRAQAENTAF BOS TAURUS RLBP1 CDS NM_174451 39 ATGTCAGAGGGGGCGGGCACGTTCCGCATGGTCCCTGAAGAGGAACAGGAGCTCCGTGCCCAACTGGAGAGGCTTACGACCAAAGACCATGGACCTGTCTTTGGCCCGTGCAGCCAGCTGCCCCGCCACACCTTGCAGAAGGCCAAGGACGAGCTGAATGAAAAGGAAGAGACCCGGGAAGAGGCAGTGCGGGAGCTACAGGAGCTGGTGCAGGCGGAGGCCGCCTCGGGGCAGGAGCTGGCCGTGGCCGTGGCGGAGAGGGTGCAGGGAAAAGACAGTGCCTTCTTCCTGCGCTTCATCCGCGCGCGCAAGTTCCACGTGGGGCGCGCCTACGAGCTGCTCAGAGGCTACGTGAACTTCCGGCTGCAGTACCCAGAGCTCTTCGACAGCCTGTCCCCAGAGGCTGTCCGCTGCACCGTTGAGGCTGGCTACCCTGGTGTCCTCTCCACGCGGGACAAGTATGGCCGAGTGGTCATGCTCTTCAATATTGAGAACTGGGACTCTGAAGAAATCACCTTTGATGAGATCTTGCAGGCATACTGCGTCATCCTGGAGAAGCTACTGGAGAATGAGGAGACTCAAATTAATGGCTTTTGCATCATTGAGAACTTCAAGGGCTTCACCATGCAGCAGGCTGCCGGACTTCGGCCTTCCGATCTCAGAAAGATGGTGGACATGCTCCAGGATTCCTTCCCAGCTCGGTTCAAAGCCATCCACTTCATCTACCAGCCCTGGTACTTCACCACCACCTACAACGTGGTCAAGCCCTTCTTGAAGAGCAAATTGCTCCAGAGGGTATTTGTCCATGGAGAAGACCTCTCCAGCTTCTACCAGGAGTTTGACGAGGACATCCTGCCCTCCGACTTTGGGGGTACACTGCCCAAGTATGATGGCAAGGCCGTTGCTGAGCAGCTCTTTGGTCCTCGGGACCAAACTGAGAACACAGCCTTCTGA BOS TAURUS RLBP1 GENE PRODUCT (CELLULAR RETINALDEHYDE BINDING PROTEIN - CRALBP) 40 MSEGAGTFRMVPEEEQELRAQLERLTTKDHGPVFGPCSQLPRHTLQKAKDELNEKEETREEAVRELQELVQAEAASGQELAVAVAERVQGKDSAFFLRFIRARKFHVGRAYELLRGYVNFRLQYPELFDSLSPEAVRCTVEAGYPGVLSTRDKYGRVVMLFNIENWDSEEITFDEILQAYCVILEKLLENEETQINGFCIIENFKGFTMQQAAGLRPSDLRKMVDMLQDSFPARFKAIHFIYQPWYFTTTYNWKPFLKSKLLQRVFVHGEDLSSFYQEFDEDILPSDFGGTLPKYDGKAVAEQLFGPRDQTENTAF CANIS LUPUS FAMILIARIS RLBP1 CDS XM_549634 41 ATGTCAGAAGGCGTGGGCACATTCCGTGTGGTCCCTGAAGAGGAACAGGAGCTCCGTGCCCAGCTGGAGCGGCTTACAACCAAGGACCATGGGCCTGTCTTTGGCCCTTGCAGCCAGCTCCCTCGTCATACCTTACAGAAGGCCAAGGACGAGCTGAACGAGAGGGAGGAGACCCGGGAGGAGGTGGTGCGAGAGCTGCAGGAGCTGGTGCAGGCACAGGCTGCCACCGGGCAGGAGCTGGCCAGGGCGGTGGCTGAGAGGGTGCAGGGAAGGGACAGTGCCTTCTTCCTGCGCTTCATCCGCGCGCGGAAGTTCCATGTGGGGCGTGCCTACGAGCTGCTTCGAGGCTACGTGAACTTCCGGCTGCAGTACCCAGAGCTCTTCGACAGCCTGTCCCTGGAGGCTGTCCGTTGCACCGTCGAGGCCGGCTATCCTGGGGTCCTCCCCAGTCGGGACAAGTATGGCCGAGTGGTCATGCTCTTCAACATCGAGAACTGGGACTCCGAAGAAATCACCTTCGATGAGATCTTGCAGGCATATTGTTTCATCCTGGAGAAGCTACTAGAGAATGAGGAAACTCAAATTAATGGCTTCTGCATTATTGAGAACTTTAAGGGCTTTACCATGCAGCAGGCTGCTGGACTTCGGGCTTCCGATCTCAGGAAGATGGTGGACATGCTCCAGGATTCCTTCCCAGCGCGGTTCAAAGCCATCCACTTCATTCACCAACCATGGTACTTCACCACCACCTACAACATGGTCAAGCCCCTCCTGAAGAACAAGCTGCTCCAAAGAGTCTTTGTCCATGGAGATGACCTCTCTGGCTTCTTCCAGGAGATTGATGAAGACATACTGCCCGCTGACTTTGGGGGCACACTGCCCAAGTATGATGGCAAGGTGGTTGCTGAGCAGCTCTTTGGCCCCCGGGCCCAAGCTGAGAACACAGCCTTCTGA CANIS LUPUS FAMILIARIS RLBP1 GENE PRODUCT (CELLULAR RETINALDEHYDE BINDING PROTEIN - CRALBP) 42 MSEGVGTFRWPEEEQELRAQLERLTTKDHGPVFGPCSQLPRHTLQKAKDELNEREETREEVVRELQELVQAQAATGQELARAVAERVQGRDSAFFLRFIRARKFHVGRAYELLRGYVNFRLQYPELFDSLSLEAVRCTVEAGYPGVLPSRDKYGRVVMLFNIENWDSEEITFDEILQAYCFILEKLLENEETQINGFCIIENFKGFTMQQAAGLRASDLRKMVDMLQDSFPARFKAIHFIHQPWYFTTTYNMVKPLLKNKLLQRVFVHGDDLSGFFQEIDEDILPADFGGTLPKYDGKWAEQLFGPRAQAENTAF RATTUS NORVEGICUS RLBP1 CDS NM_001106274.1 43 ATGTCAGAGGGGGTGGGCACATTCCGAATGGTCCCTGAAGAGGAGCAGGAGCTCCGGGCACAGCTAGAACAGCTCACAACCAAGGATC ATGGTCCTGTCTTTGGCCCATGCAGCCAGCTGCCCCGCCACACTTTGCAGAAGGCTAAGGATGAGCTGAATGAAAGGGAGGAAACCCGGGATGAGGCGGTGAGGGAGCTACAGGAGCTGGTCCAGGCACAGGCAGCTTCTGGGGAAGAGTTGGCCGTGGCAGTGGCTGAGAGGGTGCAGGCAAGAGACAGCGCCTTCCTCCTGCGCTTCATCCGTGCCCGAAAGTTTGATGTGGGCCGGGCTTATGAGCTGCTCAAAGGCTATGTGAACTTCCGGCTCCAGTACCCTGAACTCTTCGATAGCCTATCTATGGAGGCTCTCCGCTGCACTATCGAGGCCGGTTACCCTGGTGTCCTTTCCAGTCGGGACAAGTATGGTCGAGTGGTTATGCTCTTCAACATTGAAAACTGGCACTGTGAAGAAGTCACCTTTGATGAGATCTTACAGGCATATTGTTTCATTCTGGAGAAACTGCTGGAGAACGAGGAAACCCAAATCAACGGCTTCTGTATTGTGGAGAACTTCAAGGGCTTCACCATGCAGCAGGCCGCGGGACTCCGCCCCTCCGATCTCAAGAAGATGGTGGACATGCTCCAGGATTCATTCCCAGCCAGGTTCAAAGCTATCCACTTCATCCACCAACCATGGTACTTCACCACCACTTACAATGTGGTCAAGCCCTTCTTGAAGAACAAGTTGCTACAGAGGGTCTTCGTTCATGGAGATGACCTGGACGGCTTCTTCCAGGAGATTGATGAGAATATCTTGCCTGCTGACTTTGGGGGTACACTGCCCAAGTATGACGGCAAAGTTGTCGCTGAGCAGCTCTTCGGTCCCCGGGTTGAGGTTGAGAACACAGCCTTGTGA RATTUS NORVEGICUS RLBP1 GENE PRODUCT (CELLULAR RETINALDEHYDE BINDING PROTEIN - CRALBP) 44 MSEGVGTFRMVPEEEQELRAQLEQLTTKDHGPVFGPCSQLPRHTLQKAKDELNEREETRDEAVRELQELVQAQAASGEELAVAVAERVQARDSAFLLRFIRARKFDVGRAYELLKGYVNFRLQYPELFDSLSMEALRCTIEAGYPGVLSSRDKYGRVVMLFNIENWHCEEVTFDEILQAYCFILEKLLENEETQINGFCIVENFKGFTMQQAAGLRPSDLKKMVDMLQDSFPARFKAIHFIHQPWYFTTTYNWKPFLKNKLLQRVFVHGDDLDGFFQEIDENILPADFGGTLPKYDGKWAEQLFGPRVEVENTAL MUS MUSCULUS RLBP1 CDS NM_020599.2 45 ATGTCAGACGGGGTGGGCACTTTCCGCATGGTTCCTGAAGAGGAGCAGGAGCTCCGAGCACAACTGGAGCAGCTCACAACCAAGGATCATGGTCCTGTCTTTGGCCCATGCAGCCAGCTGCCCCGCCACACTTTGCAGAAGGCCAAGGATGAGCTGAATGAAAAGGAGGAGACCCG GGAGGAAGCGGTGAGGGAGCTACAGGAGCTGGTACAGGCACAGGCAGCTTCTGGCGAGGAATTGGCCCTGGCAGTGGCTGAGAGGGTGCAGGCAAGAGACAGCGCCTTCCTCCTGCGCTTCATCCGTGCCCGCAAGTTCGATGTGGGTCGTGCTTATGAGCTGCTCAAAGGCTATGTGAACTTCCGCCTCCAGTACCCTGAACTCTTCGATAGTCTCTCCATGGAGGCTCTCCGCTGCACTATCGAGGCCGGATACCCTGGTGTCCTTTCCAGTCGGGACAAGTATGGTCGAGTGGTTATGCTCTTCAACATCGAAAACTGGCACTGTGAAGAAGTGACCTTTGATGAGATCTTACAGGCATATTGTTTCATTTTGGAGAAACTGCTGGAAAATGAGGAAACCCAAATCAACGGCTTCTGTATTGTTGAGAACTTCAAGGGCTTCACCATGCAGCAGGCAGCAGGGCTCCGCCCCTCGGATCTCAAGAAGATGGTGGACATGCTCCAGGATTCATTCCCAGCCAGGTTCAAAGCTATCCACTTCATCCACCAGCCATGGTACTTCACCACCACCTATAATGTGGTCAAGCCCTTCTTGAAGAACAAGCTGCTACAGAGGGTCTTTGTTCACGGAGATGACCTGGATGGCTTCTTCCAGGAGATTGATGAGAACATCCTGCCTGCTGACTTTGGGGGTACACTGCCCAAGTACGACGGCAAAGTTGTTGCTGAGCAGCTCTTTGGTCCCCGGGCTGAAGTTGAGAACACAGCCTTATGA MUS MUSCULUS RLBP1 GENE PRODUCT (CELLULAR RETINALDEHYDE BINDING PROTEIN - CRALBP) 46 MSDGVGTFRMVPEEEQELRAQLEQLTTKDHGPVFGPCSQLPRHTLQKAKDELNEKEETREEAVRELQELVQAQAASGEELALAVAERVQARDSAFLLRFIRARKFDVGRAYELLKGYVNFRLQYPELFDSLSMEALRCTIEAGYPGVLSSRDKYGRVVMLFNIENWHCEEVTFDEILQAYCFILEKLLENEETQINGFCIVENFKGFTMQQAAGLRPSDLKKMVDMLQDSFPARFKAIHFIHQPWYFTTTYNVVKPFLKNKLLQRVFVHGDDLDGFFQEIDENILPADFGGTLPKYDGKVVAEQLFGPRAEVENTAL GALLUS GALLUS RLBP1 CDS NM _001024694.1 47 ATGTCTGCTGTTACGGGCACCTTCCGCATTGTCTCGGAAGAGGAGCAGGCGCTGCGCACCAAACTGGAGCGCCTCACCACCAAGGACCACGGCCCTGTTTTTGGGAGGTGCCAGCAGATCCCCCCTCACACCCTGCAGAAGGCAAAAGATGAGCTGAATGAGACGGAGGAGCAGAGGGAGGCAGCGGTCAAAGCGCTGCGGGAGCTGGTGCAGGAGCGGGCCGGCAGCGAGGATGTCTGCAAGGCAGTGGCAGAGAAGATGCAG GGGAAGGACGATTCCTTCTTCCTCCGCTTCATCCGTGCCCGCAAGTTTGACGTGCACAGGGCCTACGACCTGCTGAAAGGCTATGTGAACTTTCGCCAGCAATACCCTGAACTCTTTGACAACCTGACCCCCGAGGCCGTGCGCAGCACCATCGAGGCGGGCTACCCCGGCATCCTGGCCAGCAGGGACAAATACGGGCGGGTAGTGATGCTCTTCAACATCGAGAACTGGGACTACGAGGAGATCACCTTTGATGAGATCCTTCGTGCCTACTGCGTTATCTTGGAGAAGCTGCTGGAAAACGAAGAGACCCAGATCAATGGGTTCTGCATCATTGAGAACTTCAAGGGCTTCACCATGCAGCAGGCATCAGGGATCAAACCCTCCGAGCTCAAGAAGATGGTGGACATGCTACAGGACTCCTTCCCAGCGCGGTTCAAAGCTGTCCACTTCATCCACCAGCCCTGGTACTTCACCACTACCTACAACGTGGTCAAACCGTTCCTGAAGAGCAAGCTGCTGGAGAGGGTGTTTGTGCACGGCGAGGAGCTGGAGTCCTTCTACCAGGAGATCGATGCTGACATACTGCCAGCAGACTTCGGTGGCAACCTGCCCAAGTACGACGGCAAAGCAACTGCAGAGCAGCTCTTTGGGCCCCGCATTGAGGCTGAAGACACGGCACTTTAA GALLUS GALLUS RLBP1 GENE PRODUCT (CELLULAR RETINALDEHYDE BINDING PROTEIN - CRALBP) NP_001019865.1 48 MSAVTGTFRIVSEEEQALRTKLERLTTKDHGPVFGRCQQIPPHTLQKAKDELNETEEQREAAVKALRELVQERAGSEDVCKAVAEKMQGKDDSFFLRFIRARKFDVHRAYDLLKGYVNFRQQYPELFDNLTPEAVRSTIEAGYPGILASRDKYGRVVMLFNIENWDYEEITFDEILRAYCVILEKLLENEETQINGFCIIENFKGFTMQQASGIKPSELKKMVDMLQDSFPARFKAVHFIHQPWYFTTTYNVVKPFLKSKLLERVFVHGEELESFYQEIDADILPADFGGNLPKYDGKATAEQLFGPRIEAEDTAL KAN-R BACTERIAL BACKBONE 49 CTGCCTGCAGGGTTCCATCCCAATGGCGCGTCAATTCACTGGCCGTCGTTTTACAACGTCGTGACTGGGAAAACCCTGGCGTTACCCAACTTAATCGCCTTGCAGCACATCCCCCTTTCGCCAGCTGGCGTAATAGCGAAGAGGCCCGCACCGATCGCCCTTCCCAACAGTTGCGCAGCCTGAATGGCGAATGGCGCCTGATGCGGTATTTTCTCCTTACGCATCTGTGCGGTATTTCACACCGCATATGGTGCACTCTCAGTACAATCTGCTCTGATGCCGCATAGTTAAGCCAGCCCCGACACCCGCCAACACCCGCTGACGCGCCCTGACGGGCTTGTCTGCTCCCGGC ATCCGCTTACAGACAAGCTGTGACCGTCTCCGGGAGCTGCATGTGTCAGAGGTTTTCACCGTCATCACCGAAACGCGCGAGACGAAAGGGCCTCGTGATACGCCTATTTTTATAGGTTAATGTCATGATAATAATGGTTTCTTAGACGTCAGGTGGCACTTTTCGGGGAAATGTGCGCGGAACCCCTATTTGTTTATTTTTCTAAATACATTCAAATATGTATCCGCTCATGAGACAATAACCCTGATAAATGCTTCAATAATATTGAAAAAGGAAGAGTATGAGCCATATTCAACGGGAAACGTCTTGCTCTAGGCCGCGATTAAATTCCAACATGGATGCTGATTTATATGGGTATAAATGGGCTCGCGATAATGTCGGGCAATCAGGTGCGACAATCTATCGATTGTATGGGAAGCCCGATGCGCCAGAGTTGTTTCTGAAACATGGCAAAGGTAGCGTTGCCAATGATGTTACAGATGAGATGGTCAGACTAAACTGGCTGACGGAATTTATGCCTCTTCCGACCATCAAGCATTTTATCCGTACTCCTGATGATGCATGGTTACTCACCACTGCGATCCCTGGGAAAACAGCATTCCAGGTATTAGAAGAATATCCTGATTCAGGTGAAAATATTGTTGATGCGCTGGCAGTGTTCCTGCGCCGGTTGCATTCGATTCCTGTTTGTAATTGTCCTTTTAACAGCGATCGCGTATTTCGTCTCGCTCAGGCGCAATCACGAATGAATAACGGTTTGGTTGATGCGAGTGATTTTGATGACGAGCGTAATGGCTGGCCTGTTGAACAAGTCTGGAAAGAAATGCATAAACTTTTGCCATTCTCACCGGATTCAGTCGTCACTCATGGTGATTTCTCACTTGATAACCTTATTTTTGACGAGGGGAAATTAATAGGTTGTATTGATGTTGGACGAGTCGGAATCGCAGACCGATACCAGGATCTTGCCATCCTATGGAACTGCCTCGGTGAGTTTTCTCCTTCATTACAGAAACGGCTTTTTCAAAAATATGGTATTGATAATCCTGATATGAATAAATTGCAGTTTCATTTGATGCTCGATGAGTTTTTCTAACTGTCAGACCAAGTTTACTCATATATACTTTAGATTGATTTAAAACTTCATTTTTAATTTAAAAGGATCTAGGTGAAGATCCTTTTTGATAATCTCATGACCAAAATCCCTTAACGTGAGTTTTCGTTCCACTGAGCGTCAGACCCCGTAGAAAAGATCAAAGGATCTTCTTGAGATCCTTTTTTTCTGCGCGTAATCTGCTGCTTGCAAACAAAAAAACCACCGCTACCAGCGGTGGTTTGTTTGCCGGATCAAGAGCTACCAACTCTTTTTCCGAAGGTAACTGGCTTCAGCAGAGCGCAGATACCAAATACTGTTCTTCTAGTGTAGCCGTAGTTAGGCCACCACTTCAAGAACTCTGTAGCACCGCCTACATACCTCGCTCTGCTAATCCTGTTAC CAGTGGCTGCTGCCAGTGGCGATAAGTCGTGTCTTACCGGGTTGGACTCAAGACGATAGTTACCGGATAAGGCGCAGCGGTCGGGCTGAACGGGGGGTTCGTGCACACAGCCCAGCTTGGAGCGAACGACCTACACCGAACTGAGATACCTACAGCGTGAGCTATGAGAAAGCGCCACGCTTCCCGAAGGGAGAAAGGCGGACAGGTATCCGGTAAGCGGCAGGGTCGGAACAGGAGAGCGCACGAGGGAGCTTCCAGGGGGAAACGCCTGGTATCTTTATAGTCCTGTCGGGTTTCGCCACCTCTGACTTGAGCGTCGATTTTTGTGATGCTCGTCAGGGGGGCGGAGCCTATGGAAAAACGCCAGCAACGCGGCCTTTTTACGGTTCCTGGCCTTTTGCTGGCCTTTTGCTCACATGTTCTTTCCTGCGTTATCCCCTGATTCTGTGGATAACCGTATTACCGCCTTTGAGTGAGCTGATACCGCTCGCCGCAGCCGAACGACCGAGCGCAGCGAGTCAGTGAGCGAGGAAGCGGAAGAGCGCCCAATACGCAAACCGCCTCTCCCCGCGCGTTGGCCGATTCATTAATGCAGCTGGCACGACAGGTTTCCCGACTGGAAAGCGGGCAGTGAGCGCAACGCAATTAATGTGAGTTAGCTCACTCATTAGGCACCCCAGGCTTTACACTTTATGCTTCCGGCTCGTATGTTGTGTGGAATTGTGAGCGGATAACAATTTCACACAGGAAACAGCTATGACCATGATTACGCCAAGCTCGGCGCGCCATTGGGATGGAACCCTGCAGGCAG Reverse Complementary sequence of SV40polyA (SEQ ID NO: 8) 62 AGACATGATAAGATACATTGATGAGTTTGGACAAACCACAACTAGAATGCAGTGAAAAAAATGCTTTATTTGTGAAATTTGTGATGCTATTGCTTTATTTGTAACCATTATAAGCTGCAATAAACAAGTTAACAACAACAATTGCATTCATTTTATGTTTCAGGTTCAGGGGGAGGTGTGGGAGGTTTTTTAAAGCAAGTAAAACCTCTACAAATGTGGTATGGCTGATTATGATC Reverse Complementary sequence of HUMAN RLBP1 GENE CDS (SEQ ID NO: 7) 63 TCAGAAGGCTGTGTTCTCAGCTTGGGCCTGGGGGCCAAAGAGCTGCTCAGCAACGGCCTTGCCATCATACTTGGGCAGCGTGCCCCCGAAGTCAGAGGGCAGGATGTTCTCATCGATCTCCTGGTAGAAACCAGAAAGGTCATCCCCGTGGACAAAGACCCTCTCAAGCAGCTTGCTCTTCAAGAAGGGCTTGACCACATTGTAGGTCGTGGTGAAGTACCATGGCTGGTGGATGAAGTGGATGGCTTTGAACCGGGCTGGGAAGGAATCCTGGAGCATGTCCACCATCTTCCTGAGATCTGAAGTCC GGAGACTAGCAGCCTGCTGCATGGTAAAGCCCTTGAAGTTCTCAATGATGCAGAAGCCATTGATTTGAGTTTCCTCATTCTCCAGCAGCTTCTCCAGGATGAAGCAATATGCCTGCAAGATCTCATCAAAGGTGATTTCTTGACTTTGCCAGTTCTCAATGTTGAAGAGCATGACCACTCGGCCATACTTGTCCCGACTAGAGAGGACACCAGGGTAGCCAGCTTCAATGGTGCAGCGGACAGCCTCTGGGGACAGGCTGTCAAAGAGCTCAGGGTACTGCAGCCGGAAATTCACATAGCCTCTGAGCAGCTCATAGGCACGGCCCACGTTGAACTTCCGTGCGCGGATGAAGCGCAGGAAGAAGCCGCTGTCCTTCTCTTGCACCCTCTCCGCCACGGCCACCGCCAGCTCCTCCCCCGAGGCCGCCTGCGCCTGCACCATCTCCTGCAGCTCTCGCACTGCCTCCTCCCGGGTCTCCTCTCTCTCGTTCAGCTCATCCTTGGCCTTCTGCAAGGTGTGGCGGGGCAGCTGGCTGCACGGGCCAAAGACAGGTCCATGGTCCTTGGTTGTGAGCTGCTCCAGTTGGGCACGGAGCTCCTGTTCCTCTTCAGGTACCATGCGGAACGTGCCCACCCCTTCTGACAT Reverse Complementary sequence of Added KOZAK (SEQ ID NO:5) 64 GGTGGC Reverse Complementary sequence of Modified SV40INTRON (SEQ ID NO:4) 65 GGATCCCGGGGCGGGTACAATTCCGCAGCTTTTAGAGCAGAAGTAACACTTCCGTACAGGCCTAGAAGTAAAGGCAACATCCACTGAGGAGCAGTTCTTTGATTTGCACCACCACCGGATCCGGGACCTGAAATAAAAGACAAAAAGACTAAACTTACCAGTTAACTTTCTGGTTTTTCAGTT Reverse Complementary sequence of Human RLBP1 PROMOTER (short) (SEQ ID NO: 3) 66 TCGGCAGCTCCTCCTTGGGGCTACCTGGTACCTGAATGTCCTGGAGCTCTAGAGGTTCCCTCCGCTGGAGGCGTGGTCCGGTCAGCAGGTTGGGATTAGTGTGTCATAAGGAACTTCTCACCGCCCACAGTTTCCGTTAAATCGGGCTCACAGGAGGCCCTCAGTGGGGCAAAGGAAGACCCAGAGAGAAAGGGGAGAGGGGAGAGGCCTGGGCCTGGCTGGAGGCGCATCAAAGCCCTCCTTTGTGTGCTCCTGCTCTGGAGTTCCTGCTCGGCCATGTGGAAGCCCGGCTGTGGGGCTGGGATCTG GGCCAGTCCCATTCCCTCTTTTCTCTGCCCTCTTTCTCCTCAAGATCCCGGGGTGGGGTTGCTGAGAGAGCACCCCCCCCCCCCCACCACCACCACCAGGGTAATAAGAGGTGAAGGGAAATCGTAAATATGACTACATCTACAGTGGCAGCTCTGGCAAATCCAGGCCTATTGCCCACCCCTCCCCCAGCCAGCAGGACCTGGCATGGTAGTTTTCACCTCTGCAGTGAGTGGGGTCAGTTGAGAAATGTGGCTGGTTAAGGCCAAGCAGGGAGAGGACAA Reverse Complementary sequence of eGFP (SEQ ID NO: 24) 67 TTACTTGTACAGCTCGTCCATGCCGAGAGTGATCCCGGCGGCGGTCACGAACTCCAGCAGGACCATGTGATCGCGCTTCTCGTTGGGGTCTTTGCTCAGGGCGGACTGGGTGCTCAGGTAGTGGTTGTCGGGCAGCAGCACGGGGCCGTCGCCGATGGGGGTGTTCTGCTGGTAGTGGTCGGCGAGCTGCACGCTGCCGTCCTCGATGTTGTGGCGGATCTTGAAGTTCACCTTGATGCCGTTCTTCTGCTTGTCGGCCATGATATAGACGTTGTGGCTGTTGTAGTTGTACTCCAGCTTGTGCCCCAGGATGTTGCCGTCCTCCTTGAAGTCGATGCCCTTCAGCTCGATGCGGTTCACCAGGGTGTCGCCCTCGAACTTCACCTCGGCGCGGGTCTTGTAGTTGCCGTCGTCCTTGAAGAAGATGGTGCGCTCCTGGACGTAGCCTTCGGGCATGGCGGACTTGAAGAAGTCGTGCTGCTTCATGTGGTCGGGGTAGCGGCTGAAGCACTGCACGCCGTAGGTCAGGGTGGTCACGAGGGTGGGCCAGGGCACGGGCAGCTTGCCGGTGGTGCAGATGAACTTCAGGGTCAGCTTGCCGTAGGTGGCATCGCCCTCGCCCTCGCCGGACACGCTGAACTTGTGGCCGTTTACGTCGCCGTCCAGCTCGACCAGGATGGGCACCACCCCGGTGAACAGCTCCTCGCCCTTGCTCACCAT

TABLE 2 Plasmid Composition Elements SEQUENCE IDENTIFIER (SEQ.ID.NO:)AND SEQUENCE INFORMATION Plasmid TM017 Composition ΔITR 1 occurs at bp 4 through bp 106 of SEQ ID NO: 26 Human RLBP1 Promoter(short) 3 Occurs at bp 119 through bp 708 of SEQ ID NO: 26 MODIFIED SV40INTRON 4 occurs at bp 723 through bp 905 of SEQ ID NO: 26 Added Kozak 5 occurs at bp 919 through bp 924 of SEQ ID NO: 26 HUMAN RLBP1 GENE CDS 6 occurs at bp 925 through bp 1878 of SEQ ID NO: 26 SV40 POLYA 8 occurs at bp 1937 through bp 2172 of SEQ ID NO: 26 3′ ITR 9 occurs at bp 2201 through bp 2330 of SEQ ID NO: 26 AMP BACTERIAL BACKBONE 15 occurs at bp 2331 through bp 4949 of SEQ ID NO: 26 TM017 PLASMID SEQUENCE 26 ctgcgcgctcgctcgctcactgaggccgcccgggcaaagcccgggcgtcgggcgacctttggtcgcccggcctcagtgagcgagcgagcgcgcagagagggagtggggtaccacgcgtttgtcctctccctgcttggccttaaccagccacatttctcaactgaccccactcactgcagaggtgaaaactaccatgccaggtcctgctggctgggggaggggtgggcaataggcctggatttgccagagctgccactgtagatgtagtcatatttacgatttcccttcacctcttattaccctggtggtggtggtgggggggggggggtgctctctcagcaaccccaccccgggatcttgaggagaaagagggcagagaaaagagggaatgggactggcccagatcccagccccacagccgggcttccacatggccgagcaggaactccagagcaggagcacacaaaggagggctttgatgcgcctccagccaggcccaggcct ctcccctctcccctttctctctgggtcttcctttgccccactgagggcctcctgtgagcccgatttaacggaaactgtgggcggtgagaagttccttatgacacactaatcccaacctgctgaccggaccacgcctccagcggagggaacctctagagctccaggacattcaggtaccaggtagccccaaggaggagctgccgaatcgatggatcgggaactgaaaaaccagaaagttaactggtaagtttagtctttttgtcttttatttcaggtcccggatccggtggtggtgcaaatcaaagaactgctcctcagtggatgttgcctttacttctaggcctgtacggaagtgttacttctgctctaaaagctgcggaattgtacccgccccgggatccatcgattgaattcgccaccatgtcagaaggggtgggcacgttccgcatggtacctgaagaggaacaggagctccgtgcccaactggagcagctcacaaccaaggaccatggacctgtctttggcccgtgcagccagctgccccgccacaccttgcagaaggccaaggatgagctgaacgagagagaggagacccgggaggaggcagtgcgagagctgcaggagatggtgcaggcgcaggcggcctcgggggaggagctggcggtggccgtggcggagagggtgcaagagaaggacagcggcttcttcctgcgcttcatccgcgcacggaagttcaacgtgggccgtgcctatgagctgctcagaggctatgtgaatttccggctgcagtaccctgagctctttgacagcctgtccccagaggctgtccgctgcaccattgaagctggctaccctggtgtcctctctagtcgggacaagtatggccgagtggtcatgctcttcaacattgagaactggcaaagtcaagaaatcacctttgatgagatcttgcaggcatattgcttcatcctggagaagctgctggagaatgaggaaactcaaatcaatggcttctgcatcattgagaacttcaagggctttaccatgcagcaggctgctagtctccggacttcagatctcaggaagatggtggacatgctccaggattccttcccagcccggttcaaagccatccacttcatccaccagccatggtacttcaccacgacctacaatgtggtcaagcccttcttgaagagcaagctgcttgagagggtctttgtccacggggatgacctttctggtttctaccaggagatcgatgagaacatcctgccctctgacttcgggggcacgctgcccaagtatgatggcaaggccgttgctgagcagctctttggcccccaggcccaagctgagaacacagccttctgaggatcgtaccggtcgacctgcagaagcttgcctcgagcagcgctgctcgagagatctggatcataatcagccataccacatttgtagaggttttacttgctttaaaaaacctcccacacctccccctgaacctgaaacataaaatgaatgcaattgttgttgttaacttgtttattgcagcttataatggttacaaataaagcaatagcatcacaaatttcacaaataaagcatttttttcactgcattctagttgtggtttgtccaaactcatcaatgtatcttatcatgtctggtaaccacgtgcggaccgagcggccgcaggaacccctagtgatggagttggccactccctctctgcgcgctcgctcgctcactgaggccgggcgaccaaaggtcgcccgacgcccgggctttgcccgggcggcctcagtgagcgagcgagcgcgcagctgcctgcaggggcgcctgatgcggtattttctccttacgcatctgtgcggtatttcacaccgcatacgtcaaagcaaccatagtacgcgccctgtagcggcgcattaagcgcggcgggtgtggtggttacgcgcagcgtgaccgctacacttgccagcgccttagcgcccgctcctttcgctttcttcccttcctttctcgccacgttcgccggctttccccgtcaagctctaaatcgggggctccctttagggttccgatttagtgctttacggcacctcgaccccaaaaaacttgatttgggtgatggttcacgtagtgggccatcgccctgatagacggtttttcgccctttgacgttggagtccacgttctttaatagtggactcttgttccaaactggaacaacactcaactctatctcgggctattcttttgatttataagggattttgccgatttcggtctattggttaaaaaatgagctgatttaacaaaaatttaacgcgaattttaacaaaatattaacgtttacaattttatggtgcactctcagtacaatctgctctgatgccgcatagttaagccagccccgacacccgccaacacccgctgacgcgccctgacgggcttgtctgctcccggcatccgcttacagacaagctgtgaccgtctccgggagctgcatgtgtcagaggttttcaccgtcatcaccgaaacgcgcgagacgaaagggcctcgtgatacgcctatttttataggttaatgtcatgataataatggtttcttagacgtcaggtggcacttttcggggaaatgtgcgcggaacccctatttgtttatttttctaaatacattcaaatatgtatccgctcatgagacaataaccctgataaatgcttcaataatattgaaaaaggaagagtatgagtattcaacatttccgtgtcgcccttattcccttttttgcggcattttgccttcctgtttttgctcacccagaaacgctggtgaaagaagatcagttgggtgcacgagtgggttacatcgaactggatctcaacagcggtaagatccttgagagttttcgccccgaagaacgttttccaatgatgagcacttttaaagttctgctatgtggcgcggtattatcccgtattgacgccgggcaagagcaactcggtcgccgcatacactattctcagaatgacttggttgagtactcaccagtcacagaaaagcatcttacggatggcatgacagtaagagaattatgcagtgctgccataaccatgagtgataacactgcggccaacttacttctgacaacgatcggaggaccgaaggagctaaccgcttttttgcacaacatgggggatcatgtaactcgccttgatcgttgggaaccggagctgaatgaagccataccaaacgacgagcgtgacaccacgatgcctgtagcaatggcaacaacgttgcgcaaactattaactggcgaactacttactctagcttcccggcaacaattaatagactggatggaggcggataaagttgcaggaccacttctgcgctcggcccttccggctggctggtttattgctgataaatctggagccggtgagcgtgggtctcgcggtatcattgcagcactggggccagatggtaagccctcccgtatcgtagttatctacacgacggggagtcaggcaactatggatgaacgaaatagacagatcgctgagataggtgcctcactgattaagcattggtaactgtcagaccaagtttactcatatatactttagattgatttaaaacttcatttttaatttaaaaggatctaggtgaagatcctttttgataatctcatgaccaaaatcccttaacgtgagttttcgttccactgagcgtcagaccccgtagaaaagatcaaaggatcttcttgaaatcctttttttctgcgcgtaatctgctgcttgcaaacaaaaaaaccaccgctaccagcggtggtttgtttgccggatcaagagctaccaactctttttccgaaggtaactggcttcagcagagcgcagataccaaatactgttcttctagtgtagccgtagttaggccaccacttcaagaactctgtagcaccgcctacatacctcgctctgctaatcctgttaccagtggctgctgccagtggcgataagtcgtgtcttaccgggttggactcaagacgatagttaccggataaggcgcagcggtcgggctgaacggggggttcgtgcacacagcccagcttggagcgaacgacctacaccgaactgagatacctacagcgtgagctatgagaaagcgccacgcttcccgaagggagaaaggcggacaggtatccggtaagcggcagggtcggaacaggagagcgcacgagggagcttccagggggaaacgcctggtatctttatagtcctgtcgggtttcgccacctctgacttgagcgtcgatttttgtgatgctcgtcaggggggcggagcctatggaaaaacgccagcaacgcggcctttttacggttcctggccttttgctggccttttgctcacatgtcctgcaggcag GENE CASSETTE OF PLASMID TM017 OCCURS AT BP 4 THROUGH 2330 OF SEQ ID NO: 26 51 cgcgctcgctcgctcactgaggccgcccgggcaaagcccgggcgtcgggcgacctttggtcgcccggcctcagtgagcgagcgagcgcgcagagagggagtggggtaccacgcgtttgtcctctccctgcttggccttaaccagccacatttctcaactgaccccactcactgcagaggtgaaaactaccatgccaggtcctgctggctgggggaggggtgggcaataggcctggatttgccagagctgccactgtagatgtagtcatatttacgatttcccttcacctcttattaccctggtggtggtggtgggggggggggggtgctctctcagcaaccccaccccgggatcttgaggagaaagagggcagagaaaagagggaatgggactggcccagatcccagccccacagccgggcttccacatggccgagcaggaactccagagcaggagcacacaaaggagggctttgatgcgcctccagccaggcccaggcctctcccctctcccctttctctctgggtcttcctttgccccactgagggcctcctgtgagcccgatttaacggaaactgtgggcggtgagaagttccttatgacacactaatcccaacctgctgaccggaccacgcctccagcggagggaacctctagagctccaggacattcaggtaccaggtagccccaaggaggagctgccgaatcgatggatcgggaactgaaaaaccagaaagttaactggtaagtttagtctttttgtcttttatttcaggtcccggatccggtggtggtgcaaatcaaagaactgctcctcagtggatgttgcctttacttctaggcctgtacggaagtgttacttctgctctaaaagctgcggaattgtacccgccccgggatccatcgattgaattcgccaccatgtcagaaggggtgggcacgttccgcatggtacctgaagaggaacaggagctccgtgcccaactggagcagctcacaaccaaggaccatggacctgtctttggcccgtgcagccagctgccccgccacaccttgcagaaggccaaggatgagctgaacgagagagaggagacccgggaggaggcagtgcgagagctgcaggagatggtgcaggcgcaggcggcctcgggggaggagctggcggtggccgtggcggagagggtgcaagagaaggacagcggcttcttcctgcgcttcatccgcgcacggaagttcaacgtgggccgtgcctatgagctgctcagaggctatgtgaatttccggctgcagtaccctgagctctttgacagcctgtccccagaggctgtccgctgcaccattgaagctggctaccctggtgtcctctctagtcgggacaagtatggccgagtggtcatgctcttcaacattgagaactggcaaagtcaagaaatcacctttgatgagatcttgcaggcatattgcttcatcctggagaagctgctggagaatgaggaaactcaaatcaatggcttctgcatcattgagaacttcaagggctttaccatgcagcaggctgctagtctccggacttcagatctcaggaagatggtggacatgctccaggattccttcccagcccggttcaaagccatccacttcatccaccagccatggtacttcaccacgacctacaatgtggtcaagcccttcttgaagagcaagctgcttgagagggtctttgtccacggggatgacctttctggtttctaccaggagatcgatgagaacatcctgccctctgacttcgggggcacgctgcccaagtatgatggcaaggccgttgctgagcagctctttggcccccaggcccaagctgagaacacagccttctgaggatcgtaccggtcgacctgcagaagcttgcctcgagcagcgctgctcgagagatctggatcataatcagccataccacatttgtagaggttttacttgctttaaaaaacctcccacacctccccctgaacctgaaacataaaatgaatgcaattgttgttgttaacttgtttattgcagcttataatggttacaaataaagcaatagcatcacaaatttcacaaataaagcatttttttcactgcattctagttgtggtttgtccaaactcatcaatgtatcttatcatgtctggtaaccacgtgcggaccgagcggccgcaggaacccctagtgatggagttggccactccctctctgcgcgctcgctcgctcactgaggccgggcgaccaaaggtcgcccgacgcccgggctttgcccgggcggcctcagtgagcgagcgagcgcgcag Plasmid TM037 Composition 5′ ITR 2 occurs @ bp 1 through bp 119 of SEQ ID NO: 27 Human RLBP1 Promoter(long) 10 occurs @ bp 137 through bp 3293 of SEQ ID NO: 27 Added Kozak 5 occurs at bp 3300 through bp 3305 of SEQ ID NO: 27 HUMAN RLBP1 GENE CDS 6 occurs at bp 3306 through bp 4259 of SEQ ID NO: 27 SV40 POLYA 8 occurs at bp 4318 through bp 4553 of SEQ ID NO: 27 3′ ITR 9 occurs at bp 4582 through bp 4711 of SEQ ID NO: 27 AMP BACTERIAL BACKBONE 15 occurs at bp 4712 through bp 7330 of SEQ ID NO: 27 Plasmid TM037 sequence 27 CTGCGCGCTCGCTCGCTCACTGAGGCCGCCCGGGCGTCGGGCGACCTTTGGTCGCCCGGCCTCAGTGAGCGAGCGAGCGCGCAGAGAGGGAGTGGCCAACTCCATCACTAGGGGTTCCTGCGGCCGCACGCAGCTTTTGTCCTCTCCCTGCTTGGCCTTAACCAGCCACATTTCTCAACTGACCCCACTCACTGCAGAGGTGAAAACTACCATGCCAGGTCCTGCTGGCTGGGGGAGGGGTGGGCAATAGGCCTGGATTTGCCAGAGCTGCCACTGTAGATGTAGTCATATTTACGATTTCCCTTCACCTCTTATTACCCTGGTGGTGGTGGTGGGGGGGGGGGGGTGCTCTCTCAGCAACCCCACCCCGGGATCTTGAGGAGAAAGAGGGCAGAGAAAAGAGGGAATGGGACTGGCCCAGATCCCAGCCCCACAGCCGGGCTTCCACATGGCCGAGCAGGAACTCCAGAGCAGGAGCACACAAAGGAGGGCTTTGATGCGCCTCCAGCCAGGCCCAGGCCTCTCCCCTCTCCCCTTTCTCTCTGGGTCTTCCTTTGCCCCACTGAGGGCCTCCTGTGAGCCCGATTTAACGGAAACTGTGGGCGGTGAGAAGTTCCTTATGACACACTAATCCCAACCTGCTGACCGGACCACGCCTCCAGCGGAGGGAACCTCTAGAGCTCCAGGACATTCAGGTACCAGGTAGCCCCAAGGAGGAGCTGCCGACCTGGCAGGTAAGTCAATACCTGGGGCTTGCCTGGGCCAGGGAGCCCAGGACTGGGGTGAGGACTCAGGGGAGCAGGGAGACCACGTCCCAAGATGCCTGTAAAACTGAAACCACCTGGCCATTCTCCAGGTTGAGCCAGACCAATTTGATGGCAGATTTAGCAAATAAAAATACAGGACACCCAGTTAAATGTGAATTTCAGATGAACAGCAAATACTTTTTTAGTATTAAAAAAGTTCACATTTAGGCTCACGCCTGTAATCCCAGCACTTTGGGAGGCCGAGGCAGGCAGATCACCTGAGGTCAGGAGTTCGAGACCAGCCTGGCCAACATGGTGAAACCCCATCTCCACTAAAAATACCAAAAATTAGCCAGGCGTGCTGGTGGGCACCTGTAGTTCCAGCTACTCAGGAGGCTAAGGCAGGAGAATTGCTTGAACCTGGGAGGCAGAGGTTGCAGTGAGCTGAGATCGCACCATTGCACTCTAGCCTGGGCGACAAGAACAAAACTCCATCTCAAAAAAAAAAAAAAAAAAAAAGTTCACATTTAACTGGGCATTCTGTATTTAATTGGTAATCTGAGATGGCAGGGAACAGCATCAGCATGGTGTGAGGGATAGGCATTTTTTCATTGTGTACAGCTTGTAAATCAGTATTTTTAAAACTCAAAGTTAATGGCTTGGGCATATTTAGAAAAGAGTTGCCGCACGGACTTGAACCCTGTATTCCTAAAATCTAGGATCTTGTTCTGATGGTCTGCACAACTGGCTGGGGGTGTCCAGCCACTGTCCCTCTTGCCTGGGCTCCCCAGGGCAGTTCTGTCAGCCTCTCCATTTCCATTCCTGTTCCAGCAAAACCCAACTGATAGCACAGCAGCATTTCAGCCTGTCTACCTCTGTGCCCACATACCTGGATGTCTACCAGCCAGAAAGGTGGCTTAGATTTGGTTCCTGTGGGTGGATTATGGCCCCCAGAACTTCCCTGTGCTTGCTGGGGGTGTGGAGTGGAAAGAGCAGGAAATGGGGGACCCTCCGATACTCTATGGGGGTCCTCCAAGTCTCTTTGTGCAAGTTAGGGTAATAATCAATATGGAGCTAAGAAAGAGAAGGGGAACTATGCTTTAGAACAGGACACTGTGCCAGGAGCATTGCAGAAATTATATGGTTTTCACGACAGTTCTTTTTGGTAGGTACTGTTATTATCCTCAGTTTGCAGATGAGGAAACTGAGACCCAGAAAGGTTAAATAACTTGCTAGGGTCACACAAGTCATAACTGACAAAGCCTGATTCAAACCCAGGTCTCCCTAACCTTTAAGGTTTCTATGACGCCAGCTCTCCTAGGGAGTTTGTCTTCAGATGTCTTGGCTCTAGGTGTCAAAAAAAGACTTGGTGTCAGGCAGGCATAGGTTCAAGTCCCAACTCTGTCACTTACCAACTGTGACTAGGTGATTGAACTGACCATGGAACCTGGTCACATGCAGGAGCAGGATGGTGAAGGGTTCTTGAAGGCACTTAGGCAGGACATTTAGGCAGGAGAGAAAACCTGGAAACAGAAGAGCTGTCTCCAAAAATACCCACTGGGGAAGCAGGTTGTCATGTGGGCCATGAATGGGACCTGTTCTGGTAACCAAGCATTGCTTATGTGTCCATTACATTTCATAACACTTCCATCCTACTTTACAGGGAACAACCAAGACTGGGGTTAAATCTCACAGCCTGCAAGTGGAAGAGAAGAACTTGAACCCAGGTCCAACTTTTGCGCCACAGCAGGCTGCCTCTTGGTCCTGACAGGAAGTCACAACTTGGGTCTGAGTACTGATCCCTGGCTATTTTTTGGCTGTGTTACCTTGGACAAGTCACTTATTCCTCCTCCCGTTTCCTCCTATGTAAAATGGAAATAATAATGTTGACCCTGGGTCTGAGAGAGTGGATTTGAAAGTACTTAGTGCATCACAAAGCACAGAACACACTTCCAGTCTCGTGATTATGTACTTATGTAACTGGTCATCACCCATCTTGAGAATGAATGCATTGGGGAAAGGGCCATCCACTAGGCTGCGAAGTTTCTGAGGGACTCCTTCGGGCTGGAGAAGGATGGCCACAGGAGGGAGGAGAGATTGCCTTATCCTGCAGTGATCATGTCATTGAGAACAGAGCCAGATTCTTTTTTTCCTGGCAGGGCCAACTTGTTTTAACATCTAAGGACTGAGCTATTTGTGTCTGTGCCCTTTGTCCAAGCAGTGTTTCCCAAAGTGTAGCCCAAGAACCATCTCCCTCAGAGCCACCAGGAAGTGCTTTAAATTGCAGGTTCCTAGGCCACAGCCTGCACCTGCAGAGTCAGAATCATGGAGGTTGGGACCCAGGCACCTGCGTTTCTAACAAATGCCTCGGGTGATTCTGATGCAATTGAAAGTTTGAGATCCACAGTTCTGAGACAATAACAGAATGGTTTTTCTAACCCCTGCAGCCCTGACTTCCTATCCTAGGGAAGGGGCCGGCTGGAGAGGCCAGGACAGAGAAAGCAGATCCCTTCTTTTTCCAAGGACTCTGTGTCTTCCATAGGCAACGAATTCGCCACCATGTCAGAAGGGGTGGGCACGTTCCGCATGGTACCTGAAGAGGAACAGGAGCTCCGTGCCCAACTGGAGCAGCTCACAACCAAGGACCATGGACCTGTCTTTGGCCCGTGCAGCCAGCTGCCCCGCCACACCTTGCAGAAGGCCAAGGATGAGCTGAACGAGAGAGAGGAGACCCGGGAGGAGGCAGTGCGAGAGCTGCAGGAGATGGTGCAGGCGCAGGCGGCCTCGGGGGAGGAGCTGGCGGTGGCCGTGGCGGAGAGGGTGCAAGAGAAGGACAGCGGCTTCTTCCTGCGCTTCATCCGCGCACGGAAGTTCAACGTGGGCCGTGCCTATGAGCTGCTCAGAGGCTATGTGAATTTCCGGCTGCAGTACCCTGAGCTCTTTGACAGCCTGTCCCCAGAGGCTGTCCGCTGCACCATTGAAGCTGGCTACCCTGGTGTCCTCTCTAGTCGGGACAAGTATGGCCGAGTGGTCATGCTCTTCAACATTGAGAACTGGCAAAGTCAAGAAATCACCTTTGATGAGATCTTGCAGGCATATTGCTTCATCCTGGAGAAGCTGCTGGAGAATGAGGAAACTCAAATCAATGGCTTCTGCATCATTGAGAACTTCAAGGGCTTTACCATGCAGCAGGCTGCTAGTCTCCGGACTTCAGATCTCAGGAAGATGGTGGACATGCTCCAGGATTCCTTCCCAGCCCGGTTCAAAGCCATCCACTTCATCCACCAGCCATGGTACTTCACCACGACCTACAATGTGGTCAAGCCCTTCTTGAAGAGCAAGCTGCTTGAGAGGGTCTTTGTCCACGGGGATGACCTTTCTGGTTTCTACCAGGAGATCGATGAGAACATCCTGCCCTCTGACTTCGGGGGCACGCTGCCCAAGTATGATGGCAAGGCCGTTGCTGAGCAGCTCTTTGGCCCCCAGGCCCAAGCTGAGAACACAGCCTTCTGAGGATCGTACCGGTCGACCTGCAGAAGCTTGCCTCGAGCAGCGCTGCTCGAGAGATCTGGATCATAATCAGCCATACCACATTTGTAGAGGTTTTACTTGCTTTAAAAAACCTCCCACACCTCCCCCTGAACCTGAAACATAAAATGAATGCAATTGTTGTTGTTAACTTGTTTATTGCAGCTTATAATGGTTACAAATAAAGCAATAGCATCACAAATTTCACAAATAAAGCATTTTTTTCACTGCATTCTAGTTGTGGTTTGTCCAAACTCATCAATGTATCTTATCATGTCTGGTAACCACGTGCGGACCGAGCGGCCGCAGGAACCCCTAGTGATGGAGTTGGCCACTCCCTCTCTGCGCGCTCGCTCGCTCACTGAGGCCGGGCGACCAAAGGTCGCCCGACGCCCGGGCTTTGCCCGGGCGGCCTCAGTGAGCGAGCGAGCGCGCAGCTGCCTGCAGGGGCGCCTGATGCGGTATTTTCTCCTTACGCATCTGTGCGGTATTTCACACCGCATACGTCAAAGCAACCATAGTACGCGCCCTGTAGCGGCGCATTAAGCGCGGCGGGTGTGGTGGTTACGCGCAGCGTGACCGCTACACTTGCCAGCGCCTTAGCGCCCGCTCCTTTCGCTTTCTTCCCTTCCTTTCTCGCCACGTTCGCCGGCTTTCCCCGTCAAGCTCTAAATCGGGGGCTCCCTTTAGGGTTCCGATTTAGTGCTTTACGGCACCTCGACCCCAAAAAACTTGATTTGGGTGATGGTTCACGTAGTGGGCCATCGCCCTGATAGACGGTTTTTCGCCCTTTGACGTTGGAGTCCACGTTCTTTAATAGTGGACTCTTGTTCCAAACTGGAACAACACTCAACTCTATCTCGGGCTATTCTTTTGATTTATAAGGGATTTTGCCGATTTCGGTCTATTGGTTAAAAAATGAGCTGATTTAACAAAAATTTAACGCGAATTTTAACAAAATATTAACGTTTACAATTTTATGGTGCACTCTCAGTACAATCTGCTCTGATGCCGCATAGTTAAGCCAGCCCCGACACCCGCCAACACCCGCTGACGCGCCCTGACGGGCTTGTCTGCTCCCGGCATCCGCTTACAGACAAGCTGTGACCGTCTCCGGGAGCTGCATGTGTCAGAGGTTTTCACCGTCATCACCGAAACGCGCGAGACGAAAGGGCCTCGTGATACGCCTATTTTTATAGGTTAATGTCATGATAATAATGGTTTCTTAGACGTCAGGTGGCACTTTTCGGGGAAATGTGCGCGGAACCCCTATTTGTTTATTTTTCTAAATACATTCAAATATGTATCCGCTCATGAGACAATAACCCTGATAAATGCTTCAATAATATTGAAAAAGGAAGAGTATGAGTATTCAACATTTCCGTGTCGCCCTTATTCCCTTTTTTGCGGCATTTTGCCTTCCTGTTTTTGCTCACCCAGAAACGCTGGTGAAAGTAAAAGATGCTGAAGATCAGTTGGGTGCACGAGTGGGTTACATCGAACTGGATCTCAACAGCGGTAAGATCCTTGAGAGTTTTCGCCCCGAAGAACGTTTTCCAATGATGAGCACTTTTAAAGTTCTGCTATGTGGCGCGGTATTATCCCGTATTGACGCCGGGCAAGAGCAACTCGGTCGCCGCATACACTATTCTCAGAATGACTTGGTTGAGTACTCACCAGTCACAGAAAAGCATCTTACGGATGGCATGACAGTAAGAGAATTATGCAGTGCTGCCATAACCATGAGTGATAACACTGCGGCCAACTTACTTCTGACAACGATCGGAGGACCGAAGGAGCTAACCGCTTTTTTGCACAACATGGGGGATCATGTAACTCGCCTTGATCGTTGGGAACCGGAGCTGAATGAAGCCATACCAAACGACGAGCGTGACACCACGATGCCTGTAGCAATGGCAACAACGTTGCGCAAACTATTAACTGGCGAACTACTTACTCTAGCTTCCCGGCAACAATTAATAGACTGGATGGAGGCGGATAAAGTTGCAGGACCACTTCTGCGCTCGGCCCTTCCGGCTGGCTGGTTTATTGCTGATAAATCTGGAGCCGGTGAGCGTGGGTCTCGCGGTATCATTGCAGCACTGGGGCCAGATGGTAAGCCCTCCCGTATCGTAGTTATCTACACGACGGGGAGTCAGGCAACTATGGATGAACGAAATAGACAGATCGCTGAGATAGGTGCCTCACTGATTAAGCATTGGTAACTGTCAGACCAAGTTTACTCATATATACTTTAGATTGATTTAAAACTTCATTTTTAATTTAAAAGGATCTAGGTGAAGATCCTTTTTGATAATCTCATGACCAAAATCCCTTAACGTGAGTTTTCGTTCCACTGAGCGTCAGACCCCGTAGAAAAGATCAAAGGATCTTCTTGAAATCCTTTTTTTCTGCGCGTAATCTGCTGCTTGCAAACAAAAAAACCACCGCTACCAGCGGTGGTTTGTTTGCCGGATCAAGAGCTACCAACTCTTTTTCCGAAGGTAACTGGCTTCAGCAGAGCGCAGATACCAAATACTGTTCTTCTAGTGTAGCCGTAGTTAGGCCACCACTTCAAGAACTCTGTAGCACCGCCTACATACCTCGCTCTGCTAATCCTGTTACCAGTGGCTGCTGCCAGTGGCGATAAGTCGTGTCTTACCGGGTTGGACTCAAGACGATAGTTACCGGATAAGGCGCAGCGGTCGGGCTGAACGGGGGGTTCGTGCACACAGCCCAGCTTGGAGCGAACGACCTACACCGAACTGAGATACCTACAGCGTGAGCTATGAGAAAGCGCCACGCTTCCCGAAGGGAGAAAGGCGGACAGGTATCCGGTAAGCGGCAGGGTCGGAACAGGAGAGCGCACGAGGGAGCTTCCAGGGGGAAACGCCTGGTATCTTTATAGTCCTGTCGGGTTTCGCCACCTCTGACTTGAGCGTCGATTTTTGTGATGCTCGTCAGGGGGGCGGAGCCTATGGAAAAACGCCAGCAACGCGGCCTTTTTACGGTTCCTGGCCTTTTGCTGGCCTTTTGCTCACATGTCCTGCAGGCAG GENE CASSETTE OF PLASMID TM037 OCCURS AT BP 1 THROUGH 4711 OF SEQ ID NO: 27 52 ctgcgcgctcgctcgctcactgaggccgcccgggcgtcgggcgacctttggtcgcccggcctcagtgagcgagcgagcgcgcagagagggagtggccaactccatcactaggggttcctgcggccgcacgcagcttttgtcctctccctgcttggccttaaccagccacatttctcaactgaccccactcactgcagaggtgaaaactaccatgccaggtcctgctggctgggggaggggtgggcaataggcctggatttgccagagctgccactgtagatgtagtcatatttacgatttcccttcacctcttattaccctggtggtggtggtgggggggggggggtgctctctcagcaaccccaccccgggatcttgaggagaaagagggcagagaaaagagggaatgggactggcccagatcccagccccacagccgggcttccacatggccgagcaggaactccagagcaggagcacacaaaggagggctttgatgcgcctccagccaggcccaggcctctcccctctcccctttctctctgggtcttcctttgccccactgagggcctcctgtgagcccgatttaacggaaactgtgggcggtgagaagttccttatgacacactaatcccaacctgctgaccggaccacgcctccagcggagggaacctctagagctccaggacattcaggtaccaggtagccccaaggaggagctgccgacctggcaggtaagtcaatacctggggcttgcctgggccagggagcccaggactggggtgaggactcaggggagcagggagaccacgtcccaagatgcctgtaaaactgaaaccacctggccattctccaggttgagccagaccaatttgatggcagatttagcaaataaaaatacaggacacccagttaaatgtgaatttcagatgaacagcaaatacttttttagtattaaaaaagttcacatttaggctcacgcctgtaatcccagcactttgggaggccgaggcaggcagatcacctgaggtcaggagttcgagaccagcctggccaacatggtgaaaccccatctccactaaaaataccaaaaattagccaggcgtgctggtgggcacctgtagttccagctactcaggaggctaaggcaggagaattgcttgaacctgggaggcagaggttgcagtgagctgagatcgcaccattgcactctagcctgggcgacaagaacaaaactccatctcaaaaaaaaaaaaaaaaaaaaagttcacatttaactgggcattctgtatttaattggtaatctgagatggcagggaacagcatcagcatggtgtgagggataggcattttttcattgtgtacagcttgtaaatcagtatttttaaaactcaaagttaatggcttgggcatatttagaaaagagttgccgcacggacttgaaccctgtattcctaaaatctaggatcttgttctgatggtctgcacaactggctgggggtgtccagccactgtccctcttgcctgggctccccagggcagttctgtcagcctctccatttccattcctgttccagcaaaacccaactgatagcacagcagcatttcagcctgtctacctctgtgcccacatacctggatgtctaccagccagaaaggtggcttagatttggttcctgtgggtggattatggcccccagaacttccctgtgcttgctgggggtgtggagtggaaagagcaggaaatgggggaccctccgatactctatgggggtcctccaagtctctttgtgcaagttagggtaataatcaatatggagctaagaaagagaaggggaactatgctttagaacaggacactgtgccaggagcattgcagaaattatatggttttcacgacagttctttttggtaggtactgttattatcctcagtttgcagatgaggaaactgagacccagaaaggttaaataacttgctagggtcacacaagtcataactgacaaagcctgattcaaacccaggtctccctaacctttaaggtttctatgacgccagctctcctagggagtttgtcttcagatgtcttggctctaggtgtcaaaaaaagacttggtgtcaggcaggcataggttcaagtcccaactctgtcacttaccaactgtgactaggtgattgaactgaccatggaacctggtcacatgcaggagcaggatggtgaagggttcttgaaggcacttaggcaggacatttaggcaggagagaaaacctggaaacagaagagctgtctccaaaaatacccactggggaagcaggttgtcatgtgggccatgaatgggacctgttctggtaaccaagcattgcttatgtgtccattacatttcataacacttccatcctactttacagggaacaaccaagactggggttaaatctcacagcctgcaagtggaagagaagaacttgaacccaggtccaacttttgcgccacagcaggctgcctcttggtcctgacaggaagtcacaacttgggtctgagtactgatccctggctattttttggctgtgttaccttggacaagtcacttattcctcctcccgtttcctcctatgtaaaatggaaataataatgttgaccctgggtctgagagagtggatttgaaagtacttagtgcatcacaaagcacagaacacacttccagtctcgtgattatgtacttatgtaactggtcatcacccatcttgagaatgaatgcattggggaaagggccatccactaggctgcgaagtttctgagggactccttcgggctggagaaggatggccacaggagggaggagagattgccttatcctgcagtgatcatgtcattgagaacagagccagattctttttttcctggcagggccaacttgttttaacatctaaggactgagctatttgtgtctgtgccctttgtccaagcagtgtttcccaaagtgtagcccaagaaccatctccctcagagccaccaggaagtgctttaaattgcaggttcctaggccacagcctgcacctgcagagtcagaatcatggaggttgggacccaggcacctgcgtttctaacaaatgcctcgggtgattctgatgcaattgaaagtttgagatccacagttctgagacaataacagaatggtttttctaacccctgcagccctgacttcctatcctagggaaggggccggctggagaggccaggacagagaaagcagatcccttctttttccaaggactctgtgtcttccataggcaacgaattcgccaccatgtcagaaggggtgggcacgttccgcatggtacctgaagaggaacaggagctccgtgcccaactggagcagctcacaaccaaggaccatggacctgtctttggcccgtgcagccagctgccccgccacaccttgcagaaggccaaggatgagctgaacgagagagaggagacccgggaggaggcagtgcgagagctgcaggagatggtgcaggcgcaggcggcctcgggggaggagctggcggtggccgtggcggagagggtgcaagagaaggacagcggcttcttcctgcgcttcatccgcgcacggaagttcaacgtgggccgtgcctatgagctgctcagaggctatgtgaatttccggctgcagtaccctgagctctttgacagcctgtccccagaggctgtccgctgcaccattgaagctggctaccctggtgtcctctctagtcgggacaagtatggccgagtggtcatgctcttcaacattgagaactggcaaagtcaagaaatcacctttgatgagatcttgcaggcatattgcttcatcctggagaagctgctggagaatgaggaaactcaaatcaatggcttctgcatcattgagaacttcaagggctttaccatgcagcaggctgctagtctccggacttcagatctcaggaagatggtggacatgctccaggattccttcccagcccggttcaaagccatccacttcatccaccagccatggtacttcaccacgacctacaatgtggtcaagcccttcttgaagagcaagctgcttgagagggtctttgtccacggggatgacctttctggtttctaccaggagatcgatgagaacatcctgccctctgacttcgggggcacgctgcccaagtatgatggcaaggccgttgctgagcagctctttggcccccaggcccaagctgagaacacagccttctgaggatcgtaccggtcgacctgcagaagcttgcctcgagcagcgctgctcgagagatctggatcataatcagccataccacatttgtagaggttttacttgctttaaaaaacctcccacacctccccctgaacctgaaacataaaatgaatgcaattgttgttgttaacttgtttattgcagcttataatggttacaaataaagcaatagcatcacaaatttcacaaataaagcatttttttcactgcattctagttgtggtttgtccaaactcatcaatgtatcttatcatgtctggtaaccacgtgcggaccgagcggccgcaggaacccctagtgatggagttggccactccctctctgcgcgctcgctcgctcactgaggccgggcgaccaaaggtcgcccgacgcccgggctttgcccgggcggcctcagtgagcgagcgagcgcgcag Plasmid AG007 Composition Elements SEQUENCE IDENTIFIER (SEQ.ID.NO:)AND SEQUENCE INFORMATION 5′ ITR 2 occurs @ bp 1 through bp 119 of SEQ ID NO: 28 Human RPE65 Promoter 11 occurs @ bp 134 through bp 1718 of SEQ ID NO: 28 ADDED-KOZAK 5 occurs @ bp 1725 through bp 1730 of SEQ ID NO: 28 HUMAN RLBP1 GENE CDS 6 occurs at bp 1731 through bp 2684 of SEQ ID NO: 28 SV40 POLYA 8 occurs at bp 2742 through bp 2977 of SEQ ID NO: 28 RLBP1 INTRONIC SEQUENCE AS STUFFER SEQUENCE 14 occurs at bp 2985 through bp 4487 of SEQ ID NO: 28 3′ ITR 9 occurs at bp 4516 through bp 4645 of SEQ ID NO: 28 AMP BACTERIAL BACKBONE 15 occurs at bp 4646 through bp 7264 of SEQ ID NO: 28 AG007 Plasmid Sequence 28 ctgcgcgctcgctcgctcactgaggccgcccgggcgtcgggcgacctttggtcgcccggcctcagtgagcgagcgagcgcgcagagagggagtggccaactccatcactaggggttcctgcggccgcacgcgttacgtaatatttattgaagtttaatattgtgtttgtgatacagaagtatttgctttaattctaaataaaaattttatgcttttattgctggtttaagaagatttggattatccttgtactttgaggagaagtttcttatttgaaatattttggaaacaggtcttttaatgtggaaagatagatattaatctcctcttctattactctccaagatccaacaaaagtgattataccccccaaaatatgatggtagtatcttatactaccatcattttataggcatagggctcttagctgcaaataatggaactaactctaataaagcagaacgcaaatattgtaaatattagagagctaacaatctctgggatggctaaaggatggagcttggaggctacccagccagtaacaatattccgggctccactgttgaatggagacactacaactgccttggatgggcagagatattatggatgctaagccccaggtgctaccattaggacttctaccactgtccctaacgggtggagcccatcacatgcctatgccctcactgtaaggaaatgaagctactgttgtatatcttgggaagcacttggattaattgttatacagttttgttgaagaagacccctagggtaagtagccataactgcacactaaatttaaaattgttaatgagtttctcaaaaaaaatgttaaggttgttagctggtatagtatatatcttgcctgttttccaaggacttctttgggcagtaccttgtctgtgctggcaagcaactgagacttaatgaaagagtattggagatatgaatgaattgatgctgtatactctcagagtgccaaacatataccaatggacaagaaggtgaggcagagagcagacaggcattagtgacaagcaaagatatgcagaatttcattctcagcaaatcaaaagtcctcaacctggttggaagaatattggcactgaatggtatcaataaggttgctagagagggttagaggtgcacaatgtgcttccataacattttatacttctccaatcttagcactaatcaaacatggttgaatactttgtttactataactcttacagagttataagatctgtgaagacagggacagggacaatacccatctctgtctggttcataggtggtatgtaatagatatttttaaaaataagtgagttaatgaatgagggtgagaatgaaggcacagaggtattagggggaggtgggccccagagaatggtgccaaggtccagtggggtgactgggatcagctcaggcctgacgctggccactcccacctagctcctttctttctaatctgttctcattctccttgggaaggattgaggtctctggaaaacagccaaacaactgttatgggaacagcaagcccaaataaagccaagcatcagggggatctgagagctgaaagcaacttctgttccccctccctcagctgaaggggtggggaagggctcccaaagccataactccttttaagggatttagaaggcataaaaaggcccctggctgagaacttccttcttcattctgcagttggtgaattcgccaccatgtcagaaggggtgggcacgttccgcatggtacctgaagaggaacaggagctccgtgcccaactggagcagctcacaaccaaggaccatggacctgtctttggcccgtgcagccagctgccccgccacaccttgcagaaggccaaggatgagctgaacgagagagaggagacccgggaggaggcagtgcgagagctgcaggagatggtgcaggcgcaggcggcctcgggggaggagctggcggtggccgtggcggagagggtgcaagagaaggacagcggcttcttcctgcgcttcatccgcgcacggaagttcaacgtgggccgtgcctatgagctgctcagaggctatgtgaatttccggctgcagtaccctgagctctttgacagcctgtccccagaggctgtccgctgcaccattgaagctggctaccctggtgtcctctctagtcgggacaagtatggccgagtggtcatgctcttcaacattgagaactggcaaagtcaagaaatcacctttgatgagatcttgcaggcatattgcttcatcctggagaagctgctggagaatgaggaaactcaaatcaatggcttctgcatcattgagaacttcaagggctttaccatgcagcaggctgctagtctccggacttcagatctcaggaagatggtggacatgctccaggattccttcccagcccggttcaaagccatccacttcatccaccagccatggtacttcaccacgacctacaatgtggtcaagcccttcttgaagagcaagctgcttgagagggtctttgtccacggggatgacctttctggtttctaccaggagatcgatgagaacatcctgccctctgacttcgggggcacgctgcccaagtatgatggcaaggccgttgctgagcagctctttggcccccaggcccaagctgagaacacagccttctgaggatctaccggtcgacctgcagaagcttgcctcgagcagcgctgctcgagagatctggatcataatcagccataccacatttgtagaggttttacttgctttaaaaaacctcccacacctccccctgaacctgaaacataaaatgaatgcaattgttgttgttaacttgtttattgcagcttataatggttacaaataaagcaatagcatcacaaatttcacaaataaagcatttttttcactgcattctagttgtggtttgtccaaactcatcaatgtatcttatcatgtctggtaaccattctccaggttgagccagaccaatttgatggtagatttagcaaataaaaatacaggacacccagttaaatgtgaatttccgatgaacagcaaatacttttttagtattaaaaaagttcacatttaggctcacgcctgtaatcccagcactttgggaggccgaggcaggcagatcacctgaggtcaggagttcgagaccagcctggccaacatggtgaaaccccatctccactaaaaataccaaaaattagccaggcgtgctggtgggcacctgtagttccagctactcaggaggctaaggcaggagaattgcttgaacctgggaggcagaggttgcagtgagctgagatcgcaccattgcactctagcctgggcgacaagaacaaaactccatctcaaaaaaaaaaaaaaaaaaaaagttcacatttaactgggcattctgtatttaattggtaatctgagatggcagggaacagcatcagcatggtgtgagggataggcattttttcattgtgtacagcttgtaaatcagtatttttaaaactcaaagttaatggcttgggcatatttagaaaagagttgccgcacggacttgaaccctgtattcctaaaatctaggatcttgttctgatggtctgcacaactggctgggggtgtccagccactgtccctcttgcctgggctccccagggcagttctgtcagcctctccatttccattcctgttccagcaaaacccaactgatagcacagcagcatttcagcctgtctacctctgtgcccacatacctggatgtctaccagccagaaaggtggcttagatttggttcctgtgggtggattatggcccccagaacttccctgtgcttgctgggggtgtggagtggaaagagcaggaaatgggggaccctccgatactctatgggggtcctccaagtctctttgtgcaagttagggtaataatcaatatggagctaagaaagagaaggggaactatgctttagaacaggacactgtgccaggagcattgcagaaattatatggttttcacgacagttctttttggtaggtactgttattatcctcagtttgcagatgaggaaactgagacccagaaaggttaaataacttgctagggtcacacaagtcataactgacaaagcctgattcaaacccaggtctccctaacctttaaggtttctatgacgccagctctcctagggagtttgtcttcagatgtcttggctctaggtgtcaaaaaaagacttggtgtcaggcaggcataggttcaagtcccaactctgtcacttaccaactgtgactaggtgattgaactgaccatggaacctggtcacatgcaggagcaggatggtgaagggttcttgaaggcacttaggcaggacatttaggcaggagagaaaacctggaaacagaagagctgtctccaaaaatacccactggggaagcaggttgtcatgtgggccatgaatgggacctgttctggggtaaccacgtgcggaccgagcggccgcaggaacccctagtgatggagttggccactccctctctgcgcgctcgctcgctcactgaggccgggcgaccaaaggtcgcccgacgcccgggctttgcccgggcggcctcagtgagcgagcgagcgcgcagctgcctgcaggggcgcctgatgcggtattttctccttacgcatctgtgcggtatttcacaccgcatacgtcaaagcaaccatagtacgcgccctgtagcggcgcattaagcgcggcgggtgtggtggttacgcgcagcgtgaccgctacacttgccagcgccttagcgcccgctcctttcgctttcttcccttcctttctcgccacgttcgccggctttccccgtcaagctctaaatcgggggctccctttagggttccgatttagtgctttacggcacctcgaccccaaaaaacttgatttgggtgatggttcacgtagtgggccatcgccctgatagacggtttttcgccctttgacgttggagtccacgttctttaatagtggactcttgttccaaactggaacaacactcaactctatctcgggctattcttttgatttataagggattttgccgatttcggtctattggttaaaaaatgagctgatttaacaaaaatttaacgcgaattttaacaaaatattaacgtttacaattttatggtgcactctcagtacaatctgctctgatgccgcatagttaagccagccccgacacccgccaacacccgctgacgcgccctgacgggcttgtctgctcccggcatccgcttacagacaagctgtgaccgtctccgggagctgcatgtgtcagaggttttcaccgtcatcaccgaaacgcgcgagacgaaagggcctcgtgatacgcctatttttataggttaatgtcatgataataatggtttcttagacgtcaggtggcacttttcggggaaatgtgcgcggaacccctatttgtttatttttctaaatacattcaaatatgtatccgctcatgagacaataaccctgataaatgcttcaataatattgaaaaaggaagagtatgagtattcaacatttccgtgtcgcccttattcccttttttgcggcattttgccttcctgtttttgctcacccagaaacgctggtgaaagtaaaagatgctgaagatcagttgggtgcacgagtgggttacatcgaactggatctcaacagcggtaagatccttgagagttttcgccccgaagaacgttttccaatgatgagcacttttaaagttctgctatgtggcgcggtattatcccgtattgacgccgggcaagagcaactcggtcgccgcatacactattctcagaatgacttggttgagtactcaccagtcacagaaaagcatcttacggatggcatgacagtaagagaattatgcagtgctgccataaccatgagtgataacactgcggccaacttacttctgacaacgatcggaggaccgaaggagctaaccgcttttttgcacaacatgggggatcatgtaactcgccttgatcgttgggaaccggagctgaatgaagccataccaaacgacgagcgtgacaccacgatgcctgtagcaatggcaacaacgttgcgcaaactattaactggcgaactacttactctagcttcccggcaacaattaatagactggatggaggcggataaagttgcaggaccacttctgcgctcggcccttccggctggctggtttattgctgataaatctggagccggtgagcgtgggtctcgcggtatcattgcagcactggggccagatggtaagccctcccgtatcgtagttatctacacgacggggagtcaggcaactatggatgaacgaaatagacagatcgctgagataggtgcctcactgattaagcattggtaactgtcagaccaagtttactcatatatactttagattgatttaaaacttcatttttaatttaaaaggatctaggtgaagatcctttttgataatctcatgaccaaaatcccttaacgtgagttttcgttccactgagcgtcagaccccgtagaaaagatcaaaggatcttcttgaaatcctttttttctgcgcgtaatctgctgcttgcaaacaaaaaaaccaccgctaccagcggtggtttgtttgccggatcaagagctaccaactctttttccgaaggtaactggcttcagcagagcgcagataccaaatactgttcttctagtgtagccgtagttaggccaccacttcaagaactctgtagcaccgcctacatacctcgctctgctaatcctgttaccagtggctgctgccagtggcgataagtcgtgtcttaccgggttggactcaagacgatagttaccggataaggcgcagcggtcgggctgaacggggggttcgtgcacacagcccagcttggagcgaacgacctacaccgaactgagatacctacagcgtgagctatgagaaagcgccacgcttcccgaagggagaaaggcggacaggtatccggtaagcggcagggtcggaacaggagagcgcacgagggagcttccagggggaaacgcctggtatctttatagtcctgtcgggtttcgccacctctgacttgagcgtcgatttttgtgatgctcgtcaggggggcggagcctatggaaaaacgccagcaacgcggcctttttacggttcctggccttttgctggccttttgctcacatgtcctgcaggcag GENE CASSETTE OF PLASMID AG007 OCCURS AT BP 1 THROUGH 4645 OF SEQ ID NO: 28 53 ctgcgcgctcgctcgctcactgaggccgcccgggcgtcgggcgacctttggtcgcccggcctcagtgagcgagcgagcgcgcag agagggagtggccaactccatcactaggggttcctgcggccgcacgcgttacgtaatatttattgaagtttaatattgtgtttgtgatacagaagtatttgctttaattctaaataaaaattttatgcttttattgctggtttaagaagatttggattatccttgtactttgaggagaagtttcttatttgaaatattttggaaacaggtcttttaatgtggaaagatagatattaatctcctcttctattactctccaagatccaacaaaagtgattataccccccaaaatatgatggtagtatcttatactaccatcattttataggcatagggctcttagctgcaaataatggaactaactctaataaagcagaacgcaaatattgtaaatattagagagctaacaatctctgggatggctaaaggatggagcttggaggctacccagccagtaacaatattccgggctccactgttgaatggagacactacaactgccttggatgggcagagatattatggatgctaagccccaggtgctaccattaggacttctaccactgtccctaacgggtggagcccatcacatgcctatgccctcactgtaaggaaatgaagctactgttgtatatcttgggaagcacttggattaattgttatacagttttgttgaagaagacccctagggtaagtagccataactgcacactaaatttaaaattgttaatgagtttctcaaaaaaaatgttaaggttgttagctggtatagtatatatcttgcctgttttccaaggacttctttgggcagtaccttgtctgtgctggcaagcaactgagacttaatgaaagagtattggagatatgaatgaattgatgctgtatactctcagagtgccaaacatataccaatggacaagaaggtgaggcagagagcagacaggcattagtgacaagcaaagatatgcagaatttcattctcagcaaatcaaaagtcctcaacctggttggaagaatattggcactgaatggtatcaataaggttgctagagagggttagaggtgcacaatgtgcttccataacattttatacttctccaatcttagcactaatcaaacatggttgaatactttgtttactataactcttacagagttataagatctgtgaagacagggacagggacaatacccatctctgtctggttcataggtggtatgtaatagatatttttaaaaataagtgagttaatgaatgagggtgagaatgaaggcacagaggtattagggggaggtgggccccagagaatggtgccaaggtccagtggggtgactgggatcagctcaggcctgacgctggccactcccacctagctcctttctttctaatctgttctcattctccttgggaaggattgaggtctctgg aaaacagccaaacaactgttatgggaacagcaagcccaaataaagccaagcatcagggggatctgagagctgaaagcaacttctgttccccctccctcagctgaaggggtggggaagggctcccaaagccataactccttttaagggatttagaaggcataaaaaggcccctggctgagaacttccttcttcattctgcagttggtgaattcgccaccatgtcagaaggggtgggcacgttccgcatggtacctgaagaggaacaggagctccgtgcccaactggagcagctcacaaccaaggaccatggacctgtctttggcccgtgcagccagctgccccgccacaccttgcagaaggccaaggatgagctgaacgagagagaggagacccgggaggaggcagtgcgagagctgcaggagatggtgcaggcgcaggcggcctcgggggaggagctggcggtggccgtggcggagagggtgcaagagaaggacagcggcttcttcctgcgcttcatccgcgcacggaagttcaacgtgggccgtgcctatgagctgctcagaggctatgtgaatttccggctgcagtaccctgagctctttgacagcctgtccccagaggctgtccgctgcaccattgaagctggctaccctggtgtcctctctagtcgggacaagtatggccgagtggtcatgctcttcaacattgagaactggcaaagtcaagaaatcacctttgatgagatcttgcaggcatattgcttcatcctggagaagctgctggagaatgaggaaactcaaatcaatggcttctgcatcattgagaacttcaagggctttaccatgcagcaggctgctagtctccggacttcagatctcaggaagatggtggacatgctccaggattccttcccagcccggttcaaagccatccacttcatccaccagccatggtacttcaccacgacctacaatgtggtcaagcccttcttgaagagcaagctgcttgagagggtctttgtccacggggatgacctttctggtttctaccaggagatcgatgagaacatcctgccctctgacttcgggggcacgctgcccaagtatgatggcaaggccgttgctgagcagctctttggcccccaggcccaagctgagaacacagccttctgaggatctaccggtcgacctgcagaagcttgcctcgagcagcgctgctcgagagatctggatcataatcagccataccacatttgtagaggttttacttgctttaaaaaacctcccacacctccccctgaacctgaaacataaaatgaatgcaattgttgttgttaacttgtttattgcagcttataatggttacaaataaagcaatagcatcacaaatttcacaaataaagcatttttttcactgcattctagttgt ggtttgtccaaactcatcaatgtatcttatcatgtctggtaaccattctccaggttgagccagaccaatttgatggtagatttagcaaataaaaatacaggacacccagttaaatgtgaatttccgatgaacagcaaatacttttttagtattaaaaaagttcacatttaggctcacgcctgtaatcccagcactttgggaggccgaggcaggcagatcacctgaggtcaggagttcgagaccagcctggccaacatggtgaaaccccatctccactaaaaataccaaaaattagccaggcgtgctggtgggcacctgtagttccagctactcaggaggctaaggcaggagaattgcttgaacctgggaggcagaggttgcagtgagctgagatcgcaccattgcactctagcctgggcgacaagaacaaaactccatctcaaaaaaaaaaaaaaaaaaaaagttcacatttaactgggcattctgtatttaattggtaatctgagatggcagggaacagcatcagcatggtgtgagggataggcattttttcattgtgtacagcttgtaaatcagtatttttaaaactcaaagttaatggcttgggcatatttagaaaagagttgccgcacggacttgaaccctgtattcctaaaatctaggatcttgttctgatggtctgcacaactggctgggggtgtccagccactgtccctcttgcctgggctccccagggcagttctgtcagcctctccatttccattcctgttccagcaaaacccaactgatagcacagcagcatttcagcctgtctacctctgtgcccacatacctggatgtctaccagccagaaaggtggcttagatttggttcctgtgggtggattatggcccccagaacttccctgtgcttgctgggggtgtggagtggaaagagcaggaaatgggggaccctccgatactctatgggggtcctccaagtctctttgtgcaagttagggtaataatcaatatggagctaagaaagagaaggggaactatgctttagaacaggacactgtgccaggagcattgcagaaattatatggttttcacgacagttctttttggtaggtactgttattatcctcagtttgcagatgaggaaactgagacccagaaaggttaaataacttgctagggtcacacaagtcataactgacaaagcctgattcaaacccaggtctccctaacctttaaggtttctatgacgccagctctcctagggagtttgtcttcagatgtcttggctctaggtgtcaaaaaaagacttggtgtcaggcaggcataggttcaagtcccaactctgtcacttaccaactgtgactaggtgattgaactgaccatggaacctggtcacatgcaggagcaggatggtgaagggttcttg aaggcacttaggcaggacatttaggcaggagagaaaacctggaaacagaagagctgtctccaaaaatacccactggggaagcaggttgtcatgtgggccatgaatgggacctgttctggggtaaccacgtgcggaccgagcggccgcaggaacccctagtgatggagttggccactccctctctgcgcgctcgctcgctcactgaggccgggcgaccaaaggtcgcccgacgcccgggctttgcccgggcggcctcagtgagcgagcgagcgcgcag Plasmid TM039 Composition Elements SEQUENCE IDENTIFIER (SEQ.ID.NO:)AND SEQUENCE INFORMATION 5′ ITR 2 occurs at bp 1 through bp 119 of SEQ ID NO: 29 CVM ENHANCER AND CBA PROMOTER GENBANK ACCESSION DD215332 FROM BP 1-BP 1616) 22 occurs at bp 134 through bp 1749 of SEQ ID NO: 29 Added Kozak 5 occurs at bp 1763 through bp 1768 of SEQ ID NO: 29 HUMAN RLBP1 GENE CDS 6 occurs at bp 1769 through bp 2722 of SEQ ID NO: 29 SV40 POLYA 8 occurs at bp 2781 through bp 3016 of SEQ ID NO: 29 REVERSE COMPLEMENT OF RLBP1 INTRONIC SEQUENCE AS STUFFER SEQUENCE (NT 010274.17) 23 occurs at bp 3032 through bp 4534 of SEQ ID NO: 29 3′ ITR 9 occurs at bp 4573 through bp 4702 of SEQ ID NO: 29 AMP BACTERIAL BACKBONE 15 occurs at bp 4703 through bp 7321 of SEQ ID NO: 29 PLASMID TM039 SEQUENCE 29 ctgcgcgctcgctcgctcactgaggccgcccgggcgtcgggcgacctttggtcgcccggcctcagtgagcgagcgagcgcgcagagagggagtggccaactccatcactaggggttcctgcggccgcacgcgtactagttattaatagtaatcaattacggggtcattagttcatagcccatatatggagttccgcgttacataacttacggtaaatggcccgcctggctgaccgcccaacgacccccgcccattgacgtcaataatgacgtatgttcccatagtaacgccaatagggactttccattgacgtcaatgggtggagtatttacggtaaactgcccacttggcagtacatcaagtgtatcatatgccaagtacgccccctattgacgtcaatgacggtaaatggcccgcctggcattatgcccagtacatgaccttatgggactttcctacttggcagtacatctacgtattagtcatcgctattaccatggtcgaggtgagccccacgttctgcttcactctccccatctcccccccctccccacccccaattttgtatttatttattttttaattattttgtgcagcgatgggggcggggggggggggggggcgcgcgccaggcggggcggggcggggcgaggggcggggcggggcgaggcggagaggtgcggcggcagccaatcagagcggcgcgctccgaaagtttccttttatggcgaggcggcggcggcggcggccctataaaaagcgaagcgcgcggcgggcggggagtcgctgcgacgctgccttcgccccgtgccccgctccgccgccgcctcgcgccgcccgccccggctctgactgaccgcgttactcccacaggtgagcgggcgggacggcccttctcctccgggctgtaattagcgcttggtttaatgacggcttgtttcttttctgtggctgcgtgaaagccttgaggggctccgggagggccctttgtgcggggggagcggctcggggggtgcgtgcgtgtgtgtgtgcgtggggagcgccgcgtgcggctccgcgctgcccggcggctgtgagcgctgcgggcgcggcgcggggctttgtgcgctccgcagtgtgcgcgaggggagcgcggccgggggcggtgccccgcggtgcggggggggctgcgaggggaacaaaggctgcgtgcggggtgtgtgcgtgggggggtgagcagggggtgtgggcgcgtcggtcgggctgcaaccccccctgcacccccctccccgagttgctgagcacggcccggcttcgggtgcggggctccgtacggggcgtggcgcggggctcgccgtgccgggcggggggtggcggcaggtgggggtgccgggcggggcggggccgcctcgggccggggagggctcgggggaggggcgcggcggcccccggagcgccggcggctgtcgaggcgcggcgagccgcagccattgccttttatggtaatcgtgcgagagggcgcagggacttcctttgtcccaaatctgtgcggagccgaaatctgggaggcgccgccgcaccccctctagcgggcgcggggcgaagcggtgcggcgccggcaggaaggaaatgggcggggagggccttcgtgcgtcgccgcgccgccgtccccttctccctctccagcctcggggctgtccgcggggggacggctgccttcgggggggacggggcagggcggggttcggcttctggcgtgtgaccggcggcatcgattgaattcgccaccatgtcagaaggggtgggcacgttccgcatggtacctgaagaggaacaggagctccgtgcccaactggagcagctcacaaccaaggaccatggacctgtctttggcccgtgcagccagctgccccgccacaccttgcagaaggccaaggatgagctgaacgagagagaggagacccgggaggaggcagtgcgagagctgcaggagatggtgcaggcgcaggcggcctcgggggaggagctggcggtggccgtggcggagagggtgcaagagaaggacagcggcttcttcctgcgcttcatccgcgcacggaagttcaacgtgggccgtgcctatgagctgctcagaggctatgtgaatttccggctgcagtaccctgagctctttgacagcctgtccccagaggctgtccgctgcaccattgaagctggctaccctggtgtcctctctagtcgggacaagtatggccgagtggtcatgctcttcaacattgagaactggcaaagtcaagaaatcacctttgatgagatcttgcaggcatattgcttcatcctggagaagctgctggagaatgaggaaactcaaatcaatggcttctgcatcattgagaacttcaagggctttaccatgcagcaggctgctagtctccggacttcagatctcaggaagatggtggacatgctccaggattccttcccagcccggttcaaagccatccacttcatccaccagccatggtacttcaccacgacctacaatgtggtcaagcccttcttgaagagcaagctgcttgagagggtctttgtccacggggatgacctttctggtttctaccaggagatcgatgagaacatcctgccctctgacttcgggggcacgctgcccaagtatgatggcaaggccgttgctgagcagctctttggcccccaggcccaagctgagaacacagccttctgaggatcgtaccggtcgacctgcagaagcttgcctcgagcagcgctgctcgagagatctggatcataatcagccataccacatttgtagaggttttacttgctttaaaaaacctcccacacctccccctgaacctgaaacataaaatgaatgcaattgttgttgttaacttgtttattgcagcttataatggttacaaataaagcaatagcatcacaaatttcacaaataaagcatttttttcactgcattctagttgtggtttgtccaaactcatcaatgtatcttatcatgtctggtactagggttaccccagaacaggtcccattcatggcccacatgacaacctgcttccccagtgggtatttttggagacagctcttctgtttccaggttttctctcctgcctaaatgtcctgcctaagtgccttcaagaacccttcaccatcctgctcctgcatgtgaccaggttccatggtcagttcaatcacctagtcacagttggtaagtgacagagttgggacttgaacctatgcctgcctgacaccaagtctttttttgacacctagagccaagacatctgaagacaaactccctaggagagctggcgtcatagaaaccttaaaggttagggagacctgggtttgaatcaggctttgtcagttatgacttgtgtgaccctagcaagttatttaacctttctgggtctcagtttcctcatctgcaaactgaggataataacagtacctaccaaaaagaactgtcgtgaaaaccatataatttctgcaatgctcctggcacagtgtcctgttctaaagcatagttccccttctctttcttagctccatattgattattaccctaacttgcacaaagagacttggaggacccccatagagtatcggagggtcccccatttcctgctctttccactccacacccccagcaagcacagggaagttctgggggccataatccacccacaggaaccaaatctaagccacctttctggctggtagacatccaggtatgtgggcacagaggtagacaggctgaaatgctgctgtgctatcagttgggttttgctggaacaggaatggaaatggagaggctgacagaactgccctggggagcccaggcaagagggacagtggctggacacccccagccagttgtgcagaccatcagaacaagatcctagattttaggaatacagggttcaagtccgtgcggcaactcttttctaaatatgcccaagccattaactttgagttttaaaaatactgatttacaagctgtacacaatgaaaaaatgcctatccctcacaccatgctgatgctgttccctgccatctcagattaccaattaaatacagaatgcccagttaaatgtgaactttttttttttttttttttttgagatggagttttgttcttgtcgcccaggctagagtgcaatggtgcgatctcagctcactgcaacctctgcctcccaggttcaagcaattctcctgccttagcctcctgagtagctggaactacaggtgcccaccagcacgcctggctaatttttggtatttttagtggagatggggtttcaccatgttggccaggctggtctcgaactcctgacctcaggtgatctgcctgcctcggcctcccaaagtgctgggattacaggcgtgagcctaaatgtgaacttttttaatactaaaaaagtatttgctgttcatcggaaattcacatttaactgggtgtcctgtatttttatttgctaaatctaccatcaaattggtctggctcaacctggagaatggttaccctaggtaaccacgtgcggaccgagcggccgcaggaacccctagtgatggagttggccactccctctctgcgcgctcgctcgctcactgaggccgggcgaccaaaggtcgcccgacgcccgggctttgcccgggcggcctcagtgagcgagcgagcgcgcagctgcctgcaggggcgcctgatgcggtattttctccttacgcatctgtgcggtatttcacaccgcatacgtcaaagcaaccatagtacgcgccctgtagcggcgcattaagcgcggcgggtgtggtggttacgcgcagcgtgaccgctacacttgccagcgccttagcgcccgctcctttcgctttcttcccttcctttctcgccacgttcgccggctttccccgtcaagctctaaatcgggggctccctttagggttccgatttagtgctttacggcacctcgaccccaaaaaacttgatttgggtgatggttcacgtagtgggccatcgccctgatagacggtttttcgccctttgacgttggagtccacgttctttaatagtggactcttgttccaaactggaacaacactcaactctatctcgggctattcttttgatttataagggattttgccgatttcggtctattggttaaaaaatgagctgatttaacaaaaatttaacgcgaattttaacaaaatattaacgtttacaattttatggtgcactctcagtacaatctgctctgatgccgcatagttaagcca,gccccgacacccgccaacacccgctgacgcgccctgacgggcttgtctgctcccggcatccgcttacagacaagctgtgaccgtctccgggagctgcatgtgtcagaggttttcaccgtcatcaccgaaacgcgcgagacgaaagggcctcgtgatacgcctatttttataggttaatgtcatgataataatggtttcttagacgtcaggtggcacttttcggggaaatgtgcgcggaacccctatttgtttatttttctaaatacattcaaatatgtatccgctcatgagacaataaccctgataaatgcttcaataatattgaaaaaggaagagtatgagtattcaacatttccgtgtcgcccttattcccttttttgcggcattttgccttcctgtttttgctcacccagaaacgctggtgaaagtaaaagatgctgaagatcagttgggtgcacgagtgggttacatcgaactggatctcaacagcggtaagatccttgagagttttcgccccgaagaacgttttccaatgatgagcacttttaaagttctgctatgtggcgcggtattatcccgtattgacgccgggcaagagcaactcggtcgccgcatacactattctcagaatgacttggttgagtactcaccagtcacagaaaagcatcttacggatggcatgacagtaagagaattatgcagtgctgccataaccatgagtgataacactgcggccaacttacttctgacaacgatcggaggaccgaaggagctaaccgcttttttgcacaacatgggggatcatgtaactcgccttgatcgttgggaaccggagctgaatgaagccataccaaacgacgagcgtgacaccacgatgcctgtagcaatggcaacaacgttgcgcaaactattaactggcgaactacttactctagcttcccggcaacaattaatagactggatggaggcggataaagttgcaggaccacttctgcgctcggcccttccggctggctggtttattgctgataaatctggagccggtgagcgtgggtctcgcggtatcattgcagcactggggccagatggtaagccctcccgtatcgtagttatctacacgacggggagtcaggcaactatggatgaacgaaatagacagatcgctgagataggtgcctcactgattaagcattggtaactgtcagaccaagtttactcatatatactttagattgatttaaaacttcatttttaatttaaaaggatctaggtgaagatcctttttgataatctcatgaccaaaatcccttaacgtgagttttcgttccactgagcgtcagaccccgtagaaaagatcaaaggatcttcttgaaatcctttttttctgcgcgtaatctgctgcttgcaaacaaaaaaaccaccgctaccagcggtggtttgtttgccggatcaagagctaccaactctttttccgaaggtaactggcttcagcagagcgcagataccaaatactgttcttctagtgtagccgtagttaggccaccacttcaagaactctgtagcaccgcctacatacctcgctctgctaatcctgttaccagtggctgctgccagtggcgataagtcgtgtcttaccgggttggactcaagacgatagttaccggataaggcgcagcggtcgggctgaacggggggttcgtgcacacagcccagcttggagcgaacgacctacaccgaactgagatacctacagcgtgagctatgagaaagcgccacgcttcccgaagggagaaaggcggacaggtatccggtaagcggcagggtcggaacaggagagcgcacgagggagcttccagggggaaacgcctggtatctttatagtcctgtcgggtttcgccacctctgacttgagcgtcgatttttgtgatgctcgtcaggggggcggagcctatggaaaaacgccagcaacgcggcctttttacggttcctggccttttgctggccttttgctcacatgtcctgcaggcag GENE CASSETTE OF PLASMID TM039 OCCURS AT BP 1 THROUGH 4702 OF SEQ ID NO: 29 54 ctgcgcgctcgctcgctcactgaggccgcccgggcgtcgggcgacctttggtcgcccggcctcagtgagcgagcgagcgcgcagagagggagtggccaactccatcactaggggttcctgcggccgcacgcgtactagttattaatagtaatcaattacggggtcattagttcatagcccatatatggagttccgcgttacataacttacggtaaatggcccgcctggctgaccgcccaacgacccccgcccattgacgtcaataatgacgtatgttcccatagtaacgccaatagggactttccattgacgtcaatgggtggagtatttacggtaaactgcccacttggcagtacatcaagtgtatcatatgccaagtacgccccctattgacgtcaatgacggtaaatggcccgcctggcattatgcccagtacatgaccttatgggactttcctacttggcagtacatctacgtattagtcatcgctattaccatggtcgaggtgagccccacgttctgcttcactctccccatctcccccccctccccacccccaattttgtatttatttattttttaattattttgtgcagcgatgggggcggggggggggggggggcgcgcgccaggcggggcggggcggggcgaggggcggggcggggcgaggcggagaggtgcggcggcagccaatcagagcggcgcgctccgaaagtttccttttatggcgaggcggcggcggcggcggccctataaaaagcgaagcgcgcggcgggcggggagtcgctgcgacgctgccttcgccccgtgccccgctccgccgccgcctcgcgccgcccgccccggctctgactgaccgcgttactcccacaggtgagcgggcgggacggcccttctcctccgggctgtaattagcgcttggtttaatgacggcttgtttcttttctgtggctgcgtgaaagccttgaggggctccgggagggccctttgtgcggggggagcggctcggggggtgcgtgcgtgtgtgtgtgcgtggggagcgccgcgtgcggctccgcgctgcccggcggctgtgagcgctgcgggcgcggcgcggggctttgtgcgctccgcagtgtgcgcgaggggagcgcggccgggggcggtgccccgcggtgcggggggggctgcgaggggaacaaaggctgcgtgcggggtgtgtgcgtgggggggtgagcagggggtgtgggcgcgtcggtcgggctgcaaccccccctgcacccccctccccgagttgctgagcacggcccggcttcgggtgcggggctccgtacggggcgtggcgcggggctcgccgtgccgggcggggggtggcggcaggtgggggtgccgggcggggcggggccgcctcgggccggggagggctcgggggaggggcgcggcggcccccggagcgccggcggctgtcgaggcgcggcgagccgcagccattgccttttatggtaatcgtgcgagagggcgcagggacttcctttgtcccaaatctgtgcggagccgaaatctgggaggcgccgccgcaccccctctagcgggcgcggggcgaagcggtgcggcgccggcaggaaggaaatgggcggggagggccttcgtgcgtcgccgcgccgccgtccccttctccctctccagcctcggggctgtccgcggggggacggctgccttcgggggggacggggcagggcggggttcggcttctggcgtgtgaccggcggcatcgattgaattcgccaccatgtcagaaggggtgggcacgttccgcatggtacctgaagaggaacaggagctccgtgcccaactggagcagctcacaaccaaggaccatggacctgtctttggcccgtgcagccagctgccccgccacaccttgcagaaggccaaggatgagctgaacgagagagaggagacccgggaggaggcagtgcgagagctgcaggagatggtgcaggcgcaggcggcctcgggggaggagctggcggtggccgtggcggagagggtgcaagagaaggacagcggcttcttcctgcgcttcatccgcgcacggaagttcaacgtgggccgtgcctatgagctgctcagaggctatgtgaatttccggctgcagtaccctgagctctttgacagcctgtccccagaggctgtccgctgcaccattgaagctggctaccctggtgtcctctctagtcgggacaagtatggccgagtggtcatgctcttcaacattgagaactggcaaagtcaagaaatcacctttgatgagatcttgcaggcatattgcttcatcctggagaagctgctggagaatgaggaaactcaaatcaatggcttctgcatcattgagaacttcaagggctttaccatgcagcaggctgctagtctccggacttcagatctcaggaagatggtggacatgctccaggattccttcccagcccggttcaaagccatccacttcatccaccagccatggtacttcaccacgacctacaatgtggtcaagcccttcttgaagagcaagctgcttgagagggtctttgtccacggggatgacctttctggtttctaccaggagatcgatgagaacatcctgccctctgacttcgggggcacgctgcccaagtatgatggcaaggccgttgctgagcagctctttggcccccaggcccaagctgagaacacagccttctgaggatcgtaccggtcgacctgcagaagcttgcctcgagcagcgctgctcgagagatctggatcataatcagccataccacatttgtagaggttttacttgctttaaaaaacctcccacacctccccctgaacctgaaacataaaatgaatgcaattgttgttgttaacttgtttattgcagcttataatggttacaaataaagcaatagcatcacaaatttcacaaataaagcatttttttcactgcattctagttgtggtttgtccaaactcatcaatgtatcttatcatgtctggtactagggttaccccagaacaggtcccattcatggcccacatgacaacctgcttccccagtgggtatttttggagacagctcttctgtttccaggttttctctcctgcctaaatgtcctgcctaagtgccttcaagaacccttcaccatcctgctcctgcatgtgaccaggttccatggtcagttcaatcacctagtcacagttggtaagtgacagagttgggacttgaacctatgcctgcctgacaccaagtctttttttgacacctagagccaagacatctgaagacaaactccctaggagagctggcgtcatagaaaccttaaaggttagggagacctgggtttgaatcaggctttgtcagttatgacttgtgtgaccctagcaagttatttaacctttctgggtctcagtttcctcatctgcaaactgaggataataacagtacctaccaaaaagaactgtcgtgaaaaccatataatttctgcaatgctcctggcacagtgtcctgttctaaagcatagttccccttctctttcttagctccatattgattattaccctaacttgcacaaagagacttggaggacccccatagagtatcggagggtcccccatttcctgctctttccactccacacccccagcaagcacagggaagttctgggggccataatccacccacaggaaccaaatctaagccacctttctggctggtagacatccaggtatgtgggcacagaggtagacaggctgaaatgctgctgtgctatcagttgggttttgctggaacaggaatggaaatggagaggctgacagaactgccctggggagcccaggcaagagggacagtggctggacacccccagccagttgtgcagaccatcagaacaagatcctagattttaggaatacagggttcaagtccgtgcggcaactcttttctaaatatgcccaagccattaactttgagttttaaaaatactgatttacaagctgtacacaatgaaaaaatgcctatccctcacaccatgctgatgctgttccctgccatctcagattaccaattaaatacagaatgcccagttaaatgtgaactttttttttttttttttttttgagatggagttttgttcttgtcgcccaggctagagtgcaatggtgcgatctcagctcactgcaacctctgcctcccaggttcaagcaattctcctgccttagcctcctgagtagctggaactacaggtgcccaccagcacgcctggctaatttttggtatttttagtggagatggggtttcaccatgttggccaggctggtctcgaactcctgacctcaggtgatctgcctgcctcggcctcccaaagtgctgggattacaggcgtgagcctaaatgtgaacttttttaatactaaaaaagtatttgctgttcatcggaaattcacatttaactgggtgtcctgtatttttatttgctaaatctaccatcaaattggtctggctcaacctggagaatggttaccctaggtaaccacgtgcggaccgagcggccgcaggaacccctagtgatggagttggccactccctctctgcgcgctcgctcgctcactgaggccgggcgaccaaaggtcgcccgacgcccgggctttgcccgggcggcctcagtgagcgagcgagcgcgcag Plasmid TM040 Composition 5′ ITR 2 occurs at bp 1 through bp 119 of SEQ ID NO: 30 Human RLBP1 Promoter(short) 3 occurs at bp 134 through bp 723 of SEQ ID NO: 30 Modified SV40 intron 4 occurs at bp 738 through bp 920 of SEQ ID NO: 30 Added Kozak 5 occurs at bp 934 through bp 939 of SEQ ID NO: 30 HUMAN RLBP1 GENE CDS 6 occurs at bp 940 through bp 1893 of SEQ ID NO: 30 SV40 POLYA 8 occurs at bp 1952 through bp 2187 of SEQ ID NO: 30 REVERSE COMPLEMENT OF RLBP1 INTRONIC SEQUENCE AS STUFFER SEQUENCE (NT 010274.17) 23 occurs at bp 2203 through bp 3705 of SEQ ID NO: 30 3′ ITR 9 occurs at bp 3744 through bp 3873 of SEQ ID NO: 30 AMP BACTERIAL BACKBONE 15 occurs at bp 3874 through bp 6492 of SEQ ID NO: 30 TM040 plasmid sequence 30 ctgcgcgctcgctcgctcactgaggccgcccgggcgtcgggcgacctttggtcgcccggcctcagtgagcgagcgagcgcgcagagagggagtggccaactccatcactaggggttcctgcggccgcacgcgtttgtcctctccctgcttggccttaaccagccacatttctcaactgaccccactcactgcagaggtgaaaactaccatgccaggtcctgctggctgggggaggggtgggcaataggcctggatttgccagagctgccactgtagatgtagtcatatttacga tttcccttcacctcttattaccctggtggtggtggtgggggggggggggtgctctctcagcaaccccaccccgggatcttgaggagaaagagggcagagaaaagagggaatgggactggcccagatcccagccccacagccgggcttccacatggccgagcaggaactccagagcaggagcacacaaaggagggctttgatgcgcctccagccaggcccaggcctctcccctctcccctttctctctgggtcttcctttgccccactgagggcctcctgtgagcccgatttaacggaaactgtgggcggtgagaagttccttatgacacactaatcccaacctgctgaccggaccacgcctccagcggagggaacctctagagctccaggacattcaggtaccaggtagccccaaggaggagctgccgaatcgatggatcgggaactgaaaaaccagaaagttaactggtaagtttagtctttttgtcttttatttcaggtcccggatccggtggtggtgcaaatcaaagaactgctcctcagtggatgttgcctttacttctaggcctgtacggaagtgttacttctgctctaaaagctgcggaattgtacccgccccgggatccatcgattgaattcgccaccatgtcagaaggggtgggcacgttccgcatggtacctgaagaggaacaggagctccgtgcccaactggagcagctcacaaccaaggaccatggacctgtctttggcccgtgcagccagctgccccgccacaccttgcagaaggccaaggatgagctgaacgagagagaggagacccgggaggaggcagtgcgagagctgcaggagatggtgcaggcgcaggcggcctcgggggaggagctggcggtggccgtggcggagagggtgcaagagaaggacagcggcttcttcctgcgcttcatccgcgcacggaagttcaacgtgggccgtgcctatgagctgctcagaggctatgtgaatttccggctgcagtaccctgagctctttgacagcctgtccccagaggctgtccgctgcaccattgaagctggctaccctggtgtcctctctagtcgggacaagtatggccgagtggtcatgctcttcaacattgagaactggcaaagtcaagaaatcacctttgatgagatcttgcaggcatattgcttcatcctggagaagctgctggagaatgaggaaactcaaatcaatggcttctgcatcattgagaacttcaagggctttaccatgcagcaggctgctagtctccggacttcagatctcaggaagatggtggacatgctccaggattccttcccagcccggttcaaagccatccacttcatccaccagccatggtacttcaccacgacctacaatgtggtcaagcccttcttgaagagcaag ctgcttgagagggtctttgtccacggggatgacctttctggtttctaccaggagatcgatgagaacatcctgccctctgacttcgggggcacgctgcccaagtatgatggcaaggccgttgctgagcagctctttggcccccaggcccaagctgagaacacagccttctgaggatcgtaccggtcgacctgcagaagcttgcctcgagcagcgctgctcgagagatctggatcataatcagccataccacatttgtagaggttttacttgctttaaaaaacctcccacacctccccctgaacctgaaacataaaatgaatgcaattgttgttgttaacttgtttattgcagcttataatggttacaaataaagcaatagcatcacaaatttcacaaataaagcatttttttcactgcattctagttgtggtttgtccaaactcatcaatgtatcttatcatgtctggtactagggttaccccagaacaggtcccattcatggcccacatgacaacctgcttccccagtgggtatttttggagacagctcttctgtttccaggttttctctcctgcctaaatgtcctgcctaagtgccttcaagaacccttcaccatcctgctcctgcatgtgaccaggttccatggtcagttcaatcacctagtcacagttggtaagtgacagagttgggacttgaacctatgcctgcctgacaccaagtctttttttgacacctagagccaagacatctgaagacaaactccctaggagagctggcgtcatagaaaccttaaaggttagggagacctgggtttgaatcaggctttgtcagttatgacttgtgtgaccctagcaagttatttaacctttctgggtctcagtttcctcatctgcaaactgaggataataacagtacctaccaaaaagaactgtcgtgaaaaccatataatttctgcaatgctcctggcacagtgtcctgttctaaagcatagttccccttctctttcttagctccatattgattattaccctaacttgcacaaagagacttggaggacccccatagagtatcggagggtcccccatttcctgctctttccactccacacccccagcaagcacagggaagttctgggggccataatccacccacaggaaccaaatctaagccacctttctggctggtagacatccaggtatgtgggcacagaggtagacaggctgaaatgctgctgtgctatcagttgggttttgctggaacaggaatggaaatggagaggctgacagaactgccctggggagcccaggcaagagggacagtggctggacacccccagccagttgtgcagaccatcagaacaagatcctagattttaggaatacagggttcaagtccgtgcggcaactcttttctaaatatgcccaagcc attaactttgagttttaaaaatactgatttacaagctgtacacaatgaaaaaatgcctatccctcacaccatgctgatgctgttccctgccatctcagattaccaattaaatacagaatgcccagttaaatgtgaactttttttttttttttttttttgagatggagttttgttcttgtcgcccaggctagagtgcaatggtgcgatctcagctcactgcaacctctgcctcccaggttcaagcaattctcctgccttagcctcctgagtagctggaactacaggtgcccaccagcacgcctggctaatttttggtatttttagtggagatggggtttcaccatgttggccaggctggtctcgaactcctgacctcaggtgatctgcctgcctcggcctcccaaagtgctgggattacaggcgtgagcctaaatgtgaacttttttaatactaaaaaagtatttgctgttcatcggaaattcacatttaactgggtgtcctgtatttttatttgctaaatctaccatcaaattggtctggctcaacctggagaatggttaccctaggtaaccacgtgcggaccgagcggccgcaggaacccctagtgatggagttggccactccctctctgcgcgctcgctcgctcactgaggccgggcgaccaaaggtcgcccgacgcccgggctttgcccgggcggcctcagtgagcgagcgagcgcgcagctgcctgcaggggcgcctgatgcggtattttctccttacgcatctgtgcggtatttcacaccgcatacgtcaaagcaaccatagtacgcgccctgtagcggcgcattaagcgcggcgggtgtggtggttacgcgcagcgtgaccgctacacttgccagcgccttagcgcccgctcctttcgctttcttcccttcctttctcgccacgttcgccggctttccccgtcaagctctaaatcgggggctccctttagggttccgatttagtgctttacggcacctcgaccccaaaaaacttgatttgggtgatggttcacgtagtgggccatcgccctgatagacggtttttcgccctttgacgttggagtccacgttctttaatagtggactcttgttccaaactggaacaacactcaactctatctcgggctattcttttgatttataagggattttgccgatttcggtctattggttaaaaaatgagctgatttaacaaaaatttaacgcgaattttaacaaaatattaacgtttacaattttatggtgcactctcagtacaatctgctctgatgccgcatagttaagccagccccgacacccgccaacacccgctgacgcgccctgacgggcttgtctgctcccggcatccgcttacagacaagctgtgaccgtctccgggagctgcatgtgtcagaggttttca ccgtcatcaccgaaacgcgcgagacgaaagggcctcgtgatacgcctatttttataggttaatgtcatgataataatggtttcttagacgtcaggtggcacttttcggggaaatgtgcgcggaacccctatttgtttatttttctaaatacattcaaatatgtatccgctcatgagacaataaccctgataaatgcttcaataatattgaaaaaggaagagtatgagtattcaacatttccgtgtcgcccttattcccttttttgcggcattttgccttcctgtttttgctcacccagaaacgctggtgaaagtaaaagatgctgaagatcagttgggtgcacgagtgggttacatcgaactggatctcaacagcggtaagatccttgagagttttcgccccgaagaacgttttccaatgatgagcacttttaaagttctgctatgtggcgcggtattatcccgtattgacgccgggcaagagcaactcggtcgccgcatacactattctcagaatgacttggttgagtactcaccagtcacagaaaagcatcttacggatggcatgacagtaagagaattatgcagtgctgccataaccatgagtgataacactgcggccaacttacttctgacaacgatcggaggaccgaaggagctaaccgcttttttgcacaacatgggggatcatgtaactcgccttgatcgttgggaaccggagctgaatgaagccataccaaacgacgagcgtgacaccacgatgcctgtagcaatggcaacaacgttgcgcaaactattaactggcgaactacttactctagcttcccggcaacaattaatagactggatggaggcggataaagttgcaggaccacttctgcgctcggcccttccggctggctggtttattgctgataaatctggagccggtgagcgtgggtctcgcggtatcattgcagcactggggccagatggtaagccctcccgtatcgtagttatctacacgacggggagtcaggcaactatggatgaacgaaatagacagatcgctgagataggtgcctcactgattaagcattggtaactgtcagaccaagtttactcatatatactttagattgatttaaaacttcatttttaatttaaaaggatctaggtgaagatcctttttgataatctcatgaccaaaatcccttaacgtgagttttcgttccactgagcgtcagaccccgtagaaaagatcaaaggatcttcttgaaatcctttttttctgcgcgtaatctgctgcttgcaaacaaaaaaaccaccgctaccagcggtggtttgtttgccggatcaagagctaccaactctttttccgaaggtaactggcttcagcagagcgcagataccaaatactgttcttctagtgtagccgtagttaggccac cacttcaagaactctgtagcaccgcctacatacctcgctctgctaatcctgttaccagtggctgctgccagtggcgataagtcgtgtcttaccgggttggactcaagacgatagttaccggataaggcgcagcggtcgggctgaacggggggttcgtgcacacagcccagcttggagcgaacgacctacaccgaactgagatacctacagcgtgagctatgagaaagcgccacgcttcccgaagggagaaaggcggacaggtatccggtaagcggcagggtcggaacaggagagcgcacgagggagcttccagggggaaacgcctggtatctttatagtcctgtcgggtttcgccacctctgacttgagcgtcgatttttgtgatgctcgtcaggggggcggagcctatggaaaaacgccagcaacgcggcctttttacggttcctggccttttgctggccttttgctcacatgtcctgcaggcag GENE CASSETTE OF PLASMID TM040 OCCURS AT BP 1 THROUGH 3873 OF SEQ ID NO: 30 55 ctgcgcgctcgctcgctcactgaggccgcccgggcgtcgggcgacctttggtcgcccggcctcagtgagcgagcgagcgcgcagagagggagtggccaactccatcactaggggttcctgcggccgcacgcgtttgtcctctccctgcttggccttaaccagccacatttctcaactgaccccactcactgcagaggtgaaaactaccatgccaggtcctgctggctgggggaggggtgggcaataggcctggatttgccagagctgccactgtagatgtagtcatatttacgatttcccttcacctcttattaccctggtggtggtggtgggggggggggggtgctctctcagcaaccccaccccgggatcttgaggagaaagagggcagagaaaagagggaatgggactggcccagatcccagccccacagccgggcttccacatggccgagcaggaactccagagcaggagcacacaaaggagggctttgatgcgcctccagccaggcccaggcctctcccctctcccctttctctctgggtcttcctttgccccactgagggcctcctgtgagcccgatttaacggaaactgtgggcggtgagaagttccttatgacacactaatcccaacctgctgaccggaccacgcctccagcggagggaacctctagagctccaggacattcaggtaccaggtagccccaaggaggagctgccgaatcgatggatcgggaactgaaaaaccagaaagttaactggtaagtttagtctttttgtcttttatttcaggtcccggatccggtggtggtgcaaatcaaagaactgctcctcagtggatgttgcctttacttctaggcctgtacggaagtgttacttct gctctaaaagctgcggaattgtacccgccccgggatccatcgattgaattcgccaccatgtcagaaggggtgggcacgttccgcatggtacctgaagaggaacaggagctccgtgcccaactggagcagctcacaaccaaggaccatggacctgtctttggcccgtgcagccagctgccccgccacaccttgcagaaggccaaggatgagctgaacgagagagaggagacccgggaggaggcagtgcgagagctgcaggagatggtgcaggcgcaggcggcctcgggggaggagctggcggtggccgtggcggagagggtgcaagagaaggacagcggcttcttcctgcgcttcatccgcgcacggaagttcaacgtgggccgtgcctatgagctgctcagaggctatgtgaatttccggctgcagtaccctgagctctttgacagcctgtccccagaggctgtccgctgcaccattgaagctggctaccctggtgtcctctctagtcgggacaagtatggccgagtggtcatgctcttcaacattgagaactggcaaagtcaagaaatcacctttgatgagatcttgcaggcatattgcttcatcctggagaagctgctggagaatgaggaaactcaaatcaatggcttctgcatcattgagaacttcaagggctttaccatgcagcaggctgctagtctccggacttcagatctcaggaagatggtggacatgctccaggattccttcccagcccggttcaaagccatccacttcatccaccagccatggtacttcaccacgacctacaatgtggtcaagcccttcttgaagagcaagctgcttgagagggtctttgtccacggggatgacctttctggtttctaccaggagatcgatgagaacatcctgccctctgacttcgggggcacgctgcccaagtatgatggcaaggccgttgctgagcagctctttggcccccaggcccaagctgagaacacagccttctgaggatcgtaccggtcgacctgcagaagcttgcctcgagcagcgctgctcgagagatctggatcataatcagccataccacatttgtagaggttttacttgctttaaaaaacctcccacacctccccctgaacctgaaacataaaatgaatgcaattgttgttgttaacttgtttattgcagcttataatggttacaaataaagcaatagcatcacaaatttcacaaataaagcatttttttcactgcattctagttgtggtttgtccaaactcatcaatgtatcttatcatgtctggtactagggttaccccagaacaggtcccattcatggcccacatgacaacctgcttccccagtgggtatttttggagacagctcttctgtttccaggttttctctcctgcctaaatgtcctgc ctaagtgccttcaagaacccttcaccatcctgctcctgcatgtgaccaggttccatggtcagttcaatcacctagtcacagttggtaagtgacagagttgggacttgaacctatgcctgcctgacaccaagtctttttttgacacctagagccaagacatctgaagacaaactccctaggagagctggcgtcatagaaaccttaaaggttagggagacctgggtttgaatcaggctttgtcagttatgacttgtgtgaccctagcaagttatttaacctttctgggtctcagtttcctcatctgcaaactgaggataataacagtacctaccaaaaagaactgtcgtgaaaaccatataatttctgcaatgctcctggcacagtgtcctgttctaaagcatagttccccttctctttcttagctccatattgattattaccctaacttgcacaaagagacttggaggacccccatagagtatcggagggtcccccatttcctgctctttccactccacacccccagcaagcacagggaagttctgggggccataatccacccacaggaaccaaatctaagccacctttctggctggtagacatccaggtatgtgggcacagaggtagacaggctgaaatgctgctgtgctatcagttgggttttgctggaacaggaatggaaatggagaggctgacagaactgccctggggagcccaggcaagagggacagtggctggacacccccagccagttgtgcagaccatcagaacaagatcctagattttaggaatacagggttcaagtccgtgcggcaactcttttctaaatatgcccaagccattaactttgagttttaaaaatactgatttacaagctgtacacaatgaaaaaatgcctatccctcacaccatgctgatgctgttccctgccatctcagattaccaattaaatacagaatgcccagttaaatgtgaactttttttttttttttttttttgagatggagttttgttcttgtcgcccaggctagagtgcaatggtgcgatctcagctcactgcaacctctgcctcccaggttcaagcaattctcctgccttagcctcctgagtagctggaactacaggtgcccaccagcacgcctggctaatttttggtatttttagtggagatggggtttcaccatgttggccaggctggtctcgaactcctgacctcaggtgatctgcctgcctcggcctcccaaagtgctgggattacaggcgtgagcctaaatgtgaacttttttaatactaaaaaagtatttgctgttcatcggaaattcacatttaactgggtgtcctgtatttttatttgctaaatctaccatcaaattggtctggctcaacctggagaatggttaccctaggtaaccacgtgcggaccgagcg gccgcaggaacccctagtgatggagttggccactccctctctgcgcgctcgctcgctcactgaggccgggcgaccaaaggtcgcccgacgcccgggctttgcccgggcggcctcagtgagcgagcgagcgcgcag Plasmid TM016 Composition Δ5′ ITR 1 occurs at bp 1 through bp 103 of SEQ ID NO: 31 Human RLBP1 Promoter(short) 3 occurs at bp 116 through bp 705 of SEQ ID NO: 31 Modified SV40 intron 4 occurs at bp 720 through bp 902 of SEQ ID NO: 31 Added Kozak 5 occurs at bp 943 through bp 948 of SEQ ID NO: 31 E_GFP 24 occurs at bp 949 through bp 1668 of SEQ ID NO: 31 SV40 POLYA 8 occurs at bp 1726 through bp 1961 of SEQ ID NO: 31 3′ ITR 9 occurs at bp 1990 through bp 2119 of SEQ ID NO: 31 AMP BACTERIAL BACKBONE 15 occurs at bp 2120 through bp 4738 of SEQ ID NO: 31 Sequence of TM016 Plasmid 31 cgcgctcgctcgctcactgaggccgcccgggcaaagcccgggcgtcgggcgacctttggtcgcccggcctcagtgagcgagcgagcgcgcagagagggagtggggtaccacgcgtttgtcctctccctgcttggccttaaccagccacatttctcaactgaccccact cactgcagaggtgaaaactaccatgccaggtcctgctggctgggggaggggtgggcaataggcctggatttgccagagctgccactgtagatgtagtcatatttacgatttcccttcacctcttattaccctggtggtggtggtgggggggggggggtgctctctcagcaaccccaccccgggatcttgaggagaaagagggcagagaaaagagggaatgggactggcccagatcccagccccacagccgggcttccacatggccgagcaggaactccagagcaggagcacacaaaggagggctttgatgcgcctccagccaggcccaggcctctcccctctcccctttctctctgggtcttcctttgccccactgagggcctcctgtgagcccgatttaacggaaactgtgggcggtgagaagttccttatgacacactaatcccaacctgctgaccggaccacgcctccagcggagggaacctctagagctccaggacattcaggtaccaggtagccccaaggaggagctgccgaatcgatggatcgggaactgaaaaaccagaaagttaactggtaagtttagtctttttgtcttttatttcaggtcccggatccggtggtggtgcaaatcaaagaactgctcctcagtggatgttgcctttacttctaggcctgtacggaagtgttacttctgctctaaaagctgcggaattgtacccgccccgggatccatcgattgaattccccggggatcctctagagtcgaaattcgccaccatggtgagcaagggcgaggagctgttcaccggggtggtgcccatcctggtcgagctggacggcgacgtaaacggccacaagttcagcgtgtccggcgagggcgagggcgatgccacctacggcaagctgaccctgaagttcatctgcaccaccggcaagctgcccgtgccctggcccaccctcgtgaccaccctgacctacggcgtgcagtgcttcagccgctaccccgaccacatgaagcagcacgacttcttcaagtccgccatgcccgaaggctacgtccaggagcgcaccatcttcttcaaggacgacggcaactacaagacccgcgccgaggtgaagttcgagggcgacaccctggtgaaccgcatcgagctgaagggcatcgacttcaaggaggacggcaacatcctggggcacaagctggagtacaactacaacagccacaacgtctatatcatggccgacaagcagaagaacggcatcaaggtgaacttcaagatccgccacaacatcgaggacggcagcgtgcagctcgccgaccactaccagcagaacacccccatcggcgacggccccgtgctgctgcccgacaaccactacctgagcacccagtccgccctgagcaaagaccccaacgagaagcgc gatcacatggtcctgctggagttcgtgaccgccgccgggatcactctcggcatggacgagctgtacaagtaatagggtaccggtcgacctgcagaagcttgcctcgagcagcgctgctcgagagatctggatcataatcagccataccacatttgtagaggttttacttgctttaaaaaacctcccacacctccccctgaacctgaaacataaaatgaatgcaattgttgttgttaacttgtttattgcagcttataatggttacaaataaagcaatagcatcacaaatttcacaaataaagcatttttttcactgcattctagttgtggtttgtccaaactcatcaatgtatcttatcatgtctggtaaccacgtgcggaccgagcggccgcaggaacccctagtgatggagttggccactccctctctgcgcgctcgctcgctcactgaggccgggcgaccaaaggtcgcccgacgcccgggctttgcccgggcggcctcagtgagcgagcgagcgcgcagctgcctgcaggggcgcctgatgcggtattttctccttacgcatctgtgcggtatttcacaccgcatacgtcaaagcaaccatagtacgcgccctgtagcggcgcattaagcgcggcgggtgtggtggttacgcgcagcgtgaccgctacacttgccagcgccttagcgcccgctcctttcgctttcttcccttcctttctcgccacgttcgccggctttccccgtcaagctctaaatcgggggctccctttagggttccgatttagtgctttacggcacctcgaccccaaaaaacttgatttgggtgatggttcacgtagtgggccatcgccctgatagacggtttttcgccctttgacgttggagtccacgttctttaatagtggactcttgttccaaactggaacaacactcaactctatctcgggctattcttttgatttataagggattttgccgatttcggtctattggttaaaaaatgagctgatttaacaaaaatttaacgcgaattttaacaaaatattaacgtttacaattttatggtgcactctcagtacaatctgctctgatgccgcatagttaagccagccccgacacccgccaacacccgctgacgcgccctgacgggcttgtctgctcccggcatccgcttacagacaagctgtgaccgtctccgggagctgcatgtgtcagaggttttcaccgtcatcaccgaaacgcgcgagacgaaagggcctcgtgatacgcctatttttataggttaatgtcatgataataatggtttcttagacgtcaggtggcacttttcggggaaatgtgcgcggaacccctatttgtttatttttctaaatacattcaaatatgtatccgctcatgagacaataaccctgataaatgcttca ataatattgaaaaaggaagagtatgagtattcaacatttccgtgtcgcccttattcccttttttgcggcattttgccttcctgtttttgctcacccagaaacgctggtgaaagtaaaagatgctgaagatcagttgggtgcacgagtgggttacatcgaactggatctcaacagcggtaagatccttgagagttttcgccccgaagaacgttttccaatgatgagcacttttaaagttctgctatgtggcgcggtattatcccgtattgacgccgggcaagagcaactcggtcgccgcatacactattctcagaatgacttggttgagtactcaccagtcacagaaaagcatcttacggatggcatgacagtaagagaattatgcagtgctgccataaccatgagtgataacactgcggccaacttacttctgacaacgatcggaggaccgaaggagctaaccgcttttttgcacaacatgggggatcatgtaactcgccttgatcgttgggaaccggagctgaatgaagccataccaaacgacgagcgtgacaccacgatgcctgtagcaatggcaacaacgttgcgcaaactattaactggcgaactacttactctagcttcccggcaacaattaatagactggatggaggcggataaagttgcaggaccacttctgcgctcggcccttccggctggctggtttattgctgataaatctggagccggtgagcgtgggtctcgcggtatcattgcagcactggggccagatggtaagccctcccgtatcgtagttatctacacgacggggagtcaggcaactatggatgaacgaaatagacagatcgctgagataggtgcctcactgattaagcattggtaactgtcagaccaagtttactcatatatactttagattgatttaaaacttcatttttaatttaaaaggatctaggtgaagatcctttttgataatctcatgaccaaaatcccttaacgtgagttttcgttccactgagcgtcagaccccgtagaaaagatcaaaggatcttcttgaaatcctttttttctgcgcgtaatctgctgcttgcaaacaaaaaaaccaccgctaccagcggtggtttgtttgccggatcaagagctaccaactctttttccgaaggtaactggcttcagcagagcgcagataccaaatactgttcttctagtgtagccgtagttaggccaccacttcaagaactctgtagcaccgcctacatacctcgctctgctaatcctgttaccagtggctgctgccagtggcgataagtcgtgtcttaccgggttggactcaagacgatagttaccggataaggcgcagcggtcgggctgaacggggggttcgtgcacacagcccagcttggagcgaacgacctacaccgaactgag atacctacagcgtgagctatgagaaagcgccacgcttcccgaagggagaaaggcggacaggtatccggtaagcggcagggtcggaacaggagagcgcacgagggagcttccagggggaaacgcctggtatctttatagtcctgtcgggtttcgccacctctgacttgagcgtcgatttttgtgatgctcgtcaggggggcggagcctatggaaaaacgccagcaacgcggcctttttacggttcctggccttttgctggccttttgctcacatgtcctgcaggcagctg GENE CASSETTE OF PLASMID TM016 OCCURS AT BP 1 THROUGH 2119 OF SEQ ID NO: 31 56 cgcgctcgctcgctcactgaggccgcccgggcaaagcccgggcgtcgggcgacctttggtcgcccggcctcagtgagcgagcgagcgcgcagagagggagtggggtaccacgcgtttgtcctctccctgcttggccttaaccagccacatttctcaactgaccccactcactgcagaggtgaaaactaccatgccaggtcctgctggctgggggaggggtgggcaataggcctggatttgccagagctgccactgtagatgtagtcatatttacgatttcccttcacctcttattaccctggtggtggtggtgggggggggggggtgctctctcagcaaccccaccccgggatcttgaggagaaagagggcagagaaaagagggaatgggactggcccagatcccagccccacagccgggcttccacatggccgagcaggaactccagagcaggagcacacaaaggagggctttgatgcgcctccagccaggcccaggcctctcccctctcccctttctctctgggtcttcctttgccccactgagggcctcctgtgagcccgatttaacggaaactgtgggcggtgagaagttccttatgacacactaatcccaacctgctgaccggaccacgcctccagcggagggaacctctagagctccaggacattcaggtaccaggtagccccaaggaggagctgccgaatcgatggatcgggaactgaaaaaccagaaagttaactggtaagtttagtctttttgtcttttatttcaggtcccggatccggtggtggtgcaaatcaaagaactgctcctcagtggatgttgcctttacttctaggcctgtacggaagtgttacttctgctctaaaagctgcggaattgtacccgccccgggatccatcgattgaattccccggggatcctctagagtcgaaattcgccaccatggtgagcaagggcgaggagctgttcaccggggtggtgcccatcctggtcgagctggacggcgacgtaaacggccacaagttcagcgtgtccggcgagggcgagggcgatgccacctacggcaagctgaccctgaagttcatc tgcaccaccggcaagctgcccgtgccctggcccaccctcgtgaccaccctgacctacggcgtgcagtgcttcagccgctaccccgaccacatgaagcagcacgacttcttcaagtccgccatgcccgaaggctacgtccaggagcgcaccatcttcttcaaggacgacggcaactacaagacccgcgccgaggtgaagttcgagggcgacaccctggtgaaccgcatcgagctgaagggcatcgacttcaaggaggacggcaacatcctggggcacaagctggagtacaactacaacagccacaacgtctatatcatggccgacaagcagaagaacggcatcaaggtgaacttcaagatccgccacaacatcgaggacggcagcgtgcagctcgccgaccactaccagcagaacacccccatcggcgacggccccgtgctgctgcccgacaaccactacctgagcacccagtccgccctgagcaaagaccccaacgagaagcgcgatcacatggtcctgctggagttcgtgaccgccgccgggatcactctcggcatggacgagctgtacaagtaatagggtaccggtcgacctgcagaagcttgcctcgagcagcgctgctcgagagatctggatcataatcagccataccacatttgtagaggttttacttgctttaaaaaacctcccacacctccccctgaacctgaaacataaaatgaatgcaattgttgttgttaacttgtttattgcagcttataatggttacaaataaagcaatagcatcacaaatttcacaaataaagcatttttttcactgcattctagttgtggtttgtccaaactcatcaatgtatcttatcatgtctggtaaccacgtgcggaccgagcggccgcaggaacccctagtgatggagttggccactccctctctgcgcgctcgctcgctcactgaggccgggcgaccaaaggtcgcccgacgcccgggctttgcccgggcggcctcagtgagcgagcgagcgcgcag Plasmid TM035 Composition Elements SEQUENCE IDENTIFIER (SEQ.ID.NO:)AND SEQUENCE INFORMATION 5′ ITR 2 occurs at bp 1 through bp 119 of SEQ ID NO: 32 Human RLBP1 Promoter(long) 10 occurs at bp 137 through bp 3293 of SEQ ID NO: 32 Added Kozak 5 occurs at bp 3327 through bp 3332 of SEQ ID NO: 32 E_GFP 24 occurs at bp 3333 through bp 4052 of SEQ ID NO: 32 SV40 POLYA 8 occurs at bp 4110 through bp 4345 of SEQ ID NO: 32 3′ ITR 9 occurs at bp 4374 through bp 4503 of SEQ ID NO: 32 AMP BACTERIAL BACKBONE 15 occurs at bp 4504 through bp 7122 of SEQ ID NO: 32 Sequence of TM035 Plasmid 32 ctgcgcgctcgctcgctcactgaggccgcccgggcgtcgggcgacctttggtcgcccggcctcagtgagcgagcgagcgcgcagagagggagtggccaactccatcactaggggttcctgcggccgcacgcagcttttgtcctctccctgcttggccttaaccagccacatttctcaactgaccccactcactgcagaggtgaaaactaccatgccaggtcctgctggctgggggaggggtgggcaataggcctggatttgccagagctgccactgtagatgtagtcatatttacgatttcccttcacctcttattaccctggtggtggtggtgggggggggggggtgctctctcagcaaccccaccccgggatcttgaggagaaagagggcagagaaaagagggaatgggactggcccagatcccagccccacagccgggcttccacatggccgagcaggaactccagagcaggagcacacaaaggagggctttgatgcgcctccagccaggcccaggcctctcccctctcccctttctctctgggtcttcctttgccccactgagggcctcctgtgagcccgatttaacggaaactgtgggcggtgagaagttccttatgacacactaatcccaacctgctgaccggaccacgcctccagcggagggaacctctagagctccaggacattcaggtaccaggtagccccaaggaggagctgccgacctggcaggtaagtcaatacctggggcttg cctgggccagggagcccaggactggggtgaggactcaggggagcagggagaccacgtcccaagatgcctgtaaaactgaaaccacctggccattctccaggttgagccagaccaatttgatggcagatttagcaaataaaaatacaggacacccagttaaatgtgaatttcagatgaacagcaaatacttttttagtattaaaaaagttcacatttaggctcacgcctgtaatcccagcactttgggaggccgaggcaggcagatcacctgaggtcaggagttcgagaccagcctggccaacatggtgaaaccccatctccactaaaaataccaaaaattagccaggcgtgctggtgggcacctgtagttccagctactcaggaggctaaggcaggagaattgcttgaacctgggaggcagaggttgcagtgagctgagatcgcaccattgcactctagcctgggcgacaagaacaaaactccatctcaaaaaaaaaaaaaaaaaaaaagttcacatttaactgggcattctgtatttaattggtaatctgagatggcagggaacagcatcagcatggtgtgagggataggcattttttcattgtgtacagcttgtaaatcagtatttttaaaactcaaagttaatggcttgggcatatttagaaaagagttgccgcacggacttgaaccctgtattcctaaaatctaggatcttgttctgatggtctgcacaactggctgggggtgtccagccactgtccctcttgcctgggctccccagggcagttctgtcagcctctccatttccattcctgttccagcaaaacccaactgatagcacagcagcatttcagcctgtctacctctgtgcccacatacctggatgtctaccagccagaaaggtggcttagatttggttcctgtgggtggattatggcccccagaacttccctgtgcttgctgggggtgtggagtggaaagagcaggaaatgggggaccctccgatactctatgggggtcctccaagtctctttgtgcaagttagggtaataatcaatatggagctaagaaagagaaggggaactatgctttagaacaggacactgtgccaggagcattgcagaaattatatggttttcacgacagttctttttggtaggtactgttattatcctcagtttgcagatgaggaaactgagacccagaaaggttaaataacttgctagggtcacacaagtcataactgacaaagcctgattcaaacccaggtctccctaacctttaaggtttctatgacgccagctctcctagggagtttgtcttcagatgtcttggctctaggtgtcaaaaaaagacttggtgtcaggcaggcataggttcaagtcccaactctgtcacttaccaactgtgactaggtgattgaactga ccatggaacctggtcacatgcaggagcaggatggtgaagggttcttgaaggcacttaggcaggacatttaggcaggagagaaaacctggaaacagaagagctgtctccaaaaatacccactggggaagcaggttgtcatgtgggccatgaatgggacctgttctggtaaccaagcattgcttatgtgtccattacatttcataacacttccatcctactttacagggaacaaccaagactggggttaaatctcacagcctgcaagtggaagagaagaacttgaacccaggtccaacttttgcgccacagcaggctgcctcttggtcctgacaggaagtcacaacttgggtctgagtactgatccctggctattttttggctgtgttaccttggacaagtcacttattcctcctcccgtttcctcctatgtaaaatggaaataataatgttgaccctgggtctgagagagtggatttgaaagtacttagtgcatcacaaagcacagaacacacttccagtctcgtgattatgtacttatgtaactggtcatcacccatcttgagaatgaatgcattggggaaagggccatccactaggctgcgaagtttctgagggactccttcgggctggagaaggatggccacaggagggaggagagattgccttatcctgcagtgatcatgtcattgagaacagagccagattctttttttcctggcagggccaacttgttttaacatctaaggactgagctatttgtgtctgtgccctttgtccaagcagtgtttcccaaagtgtagcccaagaaccatctccctcagagccaccaggaagtgctttaaattgcaggttcctaggccacagcctgcacctgcagagtcagaatcatggaggttgggacccaggcacctgcgtttctaacaaatgcctcgggtgattctgatgcaattgaaagtttgagatccacagttctgagacaataacagaatggtttttctaacccctgcagccctgacttcctatcctagggaaggggccggctggagaggccaggacagagaaagcagatcccttctttttccaaggactctgtgtcttccataggcaacgaattccccggggatcctctagagtcgaaattcgccaccatggtgagcaagggcgaggagctgttcaccggggtggtgcccatcctggtcgagctggacggcgacgtaaacggccacaagttcagcgtgtccggcgagggcgagggcgatgccacctacggcaagctgaccctgaagttcatctgcaccaccggcaagctgcccgtgccctggcccaccctcgtgaccaccctgacctacggcgtgcagtgcttcagccgctaccccgaccacatgaagcagcacgacttcttcaagtccgccatgcccgaaggctacg tccaggagcgcaccatcttcttcaaggacgacggcaactacaagacccgcgccgaggtgaagttcgagggcgacaccctggtgaaccgcatcgagctgaagggcatcgacttcaaggaggacggcaacatcctggggcacaagctggagtacaactacaacagccacaacgtctatatcatggccgacaagcagaagaacggcatcaaggtgaacttcaagatccgccacaacatcgaggacggcagcgtgcagctcgccgaccactaccagcagaacacccccatcggcgacggccccgtgctgctgcccgacaaccactacctgagcacccagtccgccctgagcaaagaccccaacgagaagcgcgatcacatggtcctgctggagttcgtgaccgccgccgggatcactctcggcatggacgagctgtacaagtaatagggtaccggtcgacctgcagaagcttgcctcgagcagcgctgctcgagagatctggatcataatcagccataccacatttgtagaggttttacttgctttaaaaaacctcccacacctccccctgaacctgaaacataaaatgaatgcaattgttgttgttaacttgtttattgcagcttataatggttacaaataaagcaatagcatcacaaatttcacaaataaagcatttttttcactgcattctagttgtggtttgtccaaactcatcaatgtatcttatcatgtctggtaaccacgtgcggaccgagcggccgcaggaacccctagtgatggagttggccactccctctctgcgcgctcgctcgctcactgaggccgggcgaccaaaggtcgcccgacgcccgggctttgcccgggcggcctcagtgagcgagcgagcgcgcagctgcctgcaggggcgcctgatgcggtattttctccttacgcatctgtgcggtatttcacaccgcatacgtcaaagcaaccatagtacgcgccctgtagcggcgcattaagcgcggcgggtgtggtggttacgcgcagcgtgaccgctacacttgccagcgccttagcgcccgctcctttcgctttcttcccttcctttctcgccacgttcgccggctttccccgtcaagctctaaatcgggggctccctttagggttccgatttagtgctttacggcacctcgaccccaaaaaacttgatttgggtgatggttcacgtagtgggccatcgccctgatagacggtttttcgccctttgacgttggagtccacgttctttaatagtggactcttgttccaaactggaacaacactcaactctatctcgggctattcttttgatttataagggattttgccgatttcggtctattggttaaaaaatgagctgatttaacaaaaatttaacgcgaattttaacaaaatattaacgtttaca attttatggtgcactctcagtacaatctgctctgatgccgcatagttaagccagccccgacacccgccaacacccgctgacgcgccctgacgggcttgtctgctcccggcatccgcttacagacaagctgtgaccgtctccgggagctgcatgtgtcagaggttttcaccgtcatcaccgaaacgcgcgagacgaaagggcctcgtgatacgcctatttttataggttaatgtcatgataataatggtttcttagacgtcaggtggcacttttcggggaaatgtgcgcggaacccctatttgtttatttttctaaatacattcaaatatgtatccgctcatgagacaataaccctgataaatgcttcaataatattgaaaaaggaagagtatgagtattcaacatttccgtgtcgcccttattcccttttttgcggcattttgccttcctgtttttgctcacccagaaacgctggtgaaagtaaaagatgctgaagatcagttgggtgcacgagtgggttacatcgaactggatctcaacagcggtaagatccttgagagttttcgccccgaagaacgttttccaatgatgagcacttttaaagttctgctatgtggcgcggtattatcccgtattgacgccgggcaagagcaactcggtcgccgcatacactattctcagaatgacttggttgagtactcaccagtcacagaaaagcatcttacggatggcatgacagtaagagaattatgcagtgctgccataaccatgagtgataacactgcggccaacttacttctgacaacgatcggaggaccgaaggagctaaccgcttttttgcacaacatgggggatcatgtaactcgccttgatcgttgggaaccggagctgaatgaagccataccaaacgacgagcgtgacaccacgatgcctgtagcaatggcaacaacgttgcgcaaactattaactggcgaactacttactctagcttcccggcaacaattaatagactggatggaggcggataaagttgcaggaccacttctgcgctcggcccttccggctggctggtttattgctgataaatctggagccggtgagcgtgggtctcgcggtatcattgcagcactggggccagatggtaagccctcccgtatcgtagttatctacacgacggggagtcaggcaactatggatgaacgaaatagacagatcgctgagataggtgcctcactgattaagcattggtaactgtcagaccaagtttactcatatatactttagattgatttaaaacttcatttttaatttaaaaggatctaggtgaagatcctttttgataatctcatgaccaaaatcccttaacgtgagttttcgttccactgagcgtcagaccccgtagaaaagatcaaaggatcttcttgaaat cctttttttctgcgcgtaatctgctgcttgcaaacaaaaaaaccaccgctaccagcggtggtttgtttgccggatcaagagctaccaactctttttccgaaggtaactggcttcagcagagcgcagataccaaatactgttcttctagtgtagccgtagttaggccaccacttcaagaactctgtagcaccgcctacatacctcgctctgctaatcctgttaccagtggctgctgccagtggcgataagtcgtgtcttaccgggttggactcaagacgatagttaccggataaggcgcagcggtcgggctgaacggggggttcgtgcacacagcccagcttggagcgaacgacctacaccgaactgagatacctacagcgtgagctatgagaaagcgccacgcttcccgaagggagaaaggcggacaggtatccggtaagcggcagggtcggaacaggagagcgcacgagggagcttccagggggaaacgcctggtatctttatagtcctgtcgggtttcgccacctctgacttgagcgtcgatttttgtgatgctcgtcaggggggcggagcctatggaaaaacgccagcaacgcggcctttttacggttcctggccttttgctggccttttgctcacatgtcctgcaggcag GENE CASSETTE OF PLASMID TM035 OCCURS AT BP 1 THROUGH 4503 OF SEQ ID NO: 32 57 ctgcgcgctcgctcgctcactgaggccgcccgggcgtcgggcgacctttggtcgcccggcctcagtgagcgagcgagcgcgcagagagggagtggccaactccatcactaggggttcctgcggccgcacgcagcttttgtcctctccctgcttggccttaaccagccacatttctcaactgaccccactcactgcagaggtgaaaactaccatgccaggtcctgctggctgggggaggggtgggcaataggcctggatttgccagagctgccactgtagatgtagtcatatttacgatttcccttcacctcttattaccctggtggtggtggtgggggggggggggtgctctctcagcaaccccaccccgggatcttgaggagaaagagggcagagaaaagagggaatgggactggcccagatcccagccccacagccgggcttccacatggccgagcaggaactccagagcaggagcacacaaaggagggctttgatgcgcctccagccaggcccaggcctctcccctctcccctttctctctgggtcttcctttgccccactgagggcctcctgtgagcccgatttaacggaaactgtgggcggtgagaagttccttatgacacactaatcccaacctgctgaccggaccacgcctccagcggagggaac ctctagagctccaggacattcaggtaccaggtagccccaaggaggagctgccgacctggcaggtaagtcaatacctggggcttgcctgggccagggagcccaggactggggtgaggactcaggggagcagggagaccacgtcccaagatgcctgtaaaactgaaaccacctggccattctccaggttgagccagaccaatttgatggcagatttagcaaataaaaatacaggacacccagttaaatgtgaatttcagatgaacagcaaatacttttttagtattaaaaaagttcacatttaggctcacgcctgtaatcccagcactttgggaggccgaggcaggcagatcacctgaggtcaggagttcgagaccagcctggccaacatggtgaaaccccatctccactaaaaataccaaaaattagccaggcgtgctggtgggcacctgtagttccagctactcaggaggctaaggcaggagaattgcttgaacctgggaggcagaggttgcagtgagctgagatcgcaccattgcactctagcctgggcgacaagaacaaaactccatctcaaaaaaaaaaaaaaaaaaaaagttcacatttaactgggcattctgtatttaattggtaatctgagatggcagggaacagcatcagcatggtgtgagggataggcattttttcattgtgtacagcttgtaaatcagtatttttaaaactcaaagttaatggcttgggcatatttagaaaagagttgccgcacggacttgaaccctgtattcctaaaatctaggatcttgttctgatggtctgcacaactggctgggggtgtccagccactgtccctcttgcctgggctccccagggcagttctgtcagcctctccatttccattcctgttccagcaaaacccaactgatagcacagcagcatttcagcctgtctacctctgtgcccacatacctggatgtctaccagccagaaaggtggcttagatttggttcctgtgggtggattatggcccccagaacttccctgtgcttgctgggggtgtggagtggaaagagcaggaaatgggggaccctccgatactctatgggggtcctccaagtctctttgtgcaagttagggtaataatcaatatggagctaagaaagagaaggggaactatgctttagaacaggacactgtgccaggagcattgcagaaattatatggttttcacgacagttctttttggtaggtactgttattatcctcagtttgcagatgaggaaactgagacccagaaaggttaaataacttgctagggtcacacaagtcataactgacaaagcctgattcaaacccaggtctccctaacctttaaggtttctatgacgccagctctcctagggagtttgtcttcagatgtcttggctctaggtg tcaaaaaaagacttggtgtcaggcaggcataggttcaagtcccaactctgtcacttaccaactgtgactaggtgattgaactgaccatggaacctggtcacatgcaggagcaggatggtgaagggttcttgaaggcacttaggcaggacatttaggcaggagagaaaacctggaaacagaagagctgtctccaaaaatacccactggggaagcaggttgtcatgtgggccatgaatgggacctgttctggtaaccaagcattgcttatgtgtccattacatttcataacacttccatcctactttacagggaacaaccaagactggggttaaatctcacagcctgcaagtggaagagaagaacttgaacccaggtccaacttttgcgccacagcaggctgcctcttggtcctgacaggaagtcacaacttgggtctgagtactgatccctggctattttttggctgtgttaccttggacaagtcacttattcctcctcccgtttcctcctatgtaaaatggaaataataatgttgaccctgggtctgagagagtggatttgaaagtacttagtgcatcacaaagcacagaacacacttccagtctcgtgattatgtacttatgtaactggtcatcacccatcttgagaatgaatgcattggggaaagggccatccactaggctgcgaagtttctgagggactccttcgggctggagaaggatggccacaggagggaggagagattgccttatcctgcagtgatcatgtcattgagaacagagccagattctttttttcctggcagggccaacttgttttaacatctaaggactgagctatttgtgtctgtgccctttgtccaagcagtgtttcccaaagtgtagcccaagaaccatctccctcagagccaccaggaagtgctttaaattgcaggttcctaggccacagcctgcacctgcagagtcagaatcatggaggttgggacccaggcacctgcgtttctaacaaatgcctcgggtgattctgatgcaattgaaagtttgagatccacagttctgagacaataacagaatggtttttctaacccctgcagccctgacttcctatcctagggaaggggccggctggagaggccaggacagagaaagcagatcccttctttttccaaggactctgtgtcttccataggcaacgaattccccggggatcctctagagtcgaaattcgccaccatggtgagcaagggcgaggagctgttcaccggggtggtgcccatcctggtcgagctggacggcgacgtaaacggccacaagttcagcgtgtccggcgagggcgagggcgatgccacctacggcaagctgaccctgaagttcatctgcaccaccggcaagctgcccgtgccctggcccaccctcgtgaccaccctga cctacggcgtgcagtgcttcagccgctaccccgaccacatgaagcagcacgacttcttcaagtccgccatgcccgaaggctacgtccaggagcgcaccatcttcttcaaggacgacggcaactacaagacccgcgccgaggtgaagttcgagggcgacaccctggtgaaccgcatcgagctgaagggcatcgacttcaaggaggacggcaacatcctggggcacaagctggagtacaactacaacagccacaacgtctatatcatggccgacaagcagaagaacggcatcaaggtgaacttcaagatccgccacaacatcgaggacggcagcgtgcagctcgccgaccactaccagcagaacacccccatcggcgacggccccgtgctgctgcccgacaaccactacctgagcacccagtccgccctgagcaaagaccccaacgagaagcgcgatcacatggtcctgctggagttcgtgaccgccgccgggatcactctcggcatggacgagctgtacaagtaatagggtaccggtcgacctgcagaagcttgcctcgagcagcgctgctcgagagatctggatcataatcagccataccacatttgtagaggttttacttgctttaaaaaacctcccacacctccccctgaacctgaaacataaaatgaatgcaattgttgttgttaacttgtttattgcagcttataatggttacaaataaagcaatagcatcacaaatttcacaaataaagcatttttttcactgcattctagttgtggtttgtccaaactcatcaatgtatcttatcatgtctggtaaccacgtgcggaccgagcggccgcaggaacccctagtgatggagttggccactccctctctgcgcgctcgctcgctcactgaggccgggcgaccaaaggtcgcccgacgcccgggctttgcccgggcggcctcagtgagcgagcgagcgcgcag Plasmid AG012 Composition Elements SEQUENCE IDENTIFIER (SEQ.ID.NO:)AND SEQUENCE INFORMATION 5′ ITR 2 occurs @ bp 1 through bp 119 of SEQ ID NO: 33 SYNUCLEIN INTRONIC SEQUENCE AS STUFFER SEQUENCE 13 occurs @ bp 148 through bp 2601 of SEQ ID NO: 33 SV40 POLYA 8 occurs @ bp 2640 through bp 2875 of SEQ ID NO: 33 RLBP1 INTRONIC SEQUENCE AS STUFFER SEQUENCE 14 occurs at bp 2883 through bp 4385 of SEQ ID NO: 33 3′ ITR 9 occurs at bp 4414 through bp 4543 of SEQ ID NO: 33 AMP BACTERIAL BACKBONE 15 occurs at bp 4544 through bp 7162 of SEQ ID NO: 33 Sequence of AG012 Plasmid 33 ctgcgcgctcgctcgctcactgaggccgcccgggcgtcgggcgacctttggtcgcccggcctcagtgagcgagcgagcgcgcagagagggagtggccaactccatcactaggggttcctgcggccgcacgcgtgacgtcgtttaaacgggccccggtgttatctcattcttttttctcctctgtaagttgacatgtgatgtgggaacaaaggggataaagtcattattttgtgctaaaatcgtaattggagaggacctcctgttagctgggctttcttctatttattgtggtggttactggagttccttcttctagttttaggatatatatatatattttttttttttctttccctgaagatataataatatatatacttctgaagattgagatttttaaattagttgtattgaaaactagctaatcagcaatttaaggctagcttgagacttatgtcttgaatttgtttttgtaggctccaaaaccaaggagggagtggtgcatggtgtggcaacaggtaagctccattgtgcttatatccaaagatgatatttaaagtatctagtgattagtgtggcccagtattcaagattcctatgaaattgtaaaacaatcactgagcattctaagaacatatcagtcttattgaaactgaattctttataaagtatttttaaaaaggtaaatattgattataaataaaaaatatacttgccaagaataatgagggctttgaattgataagctatgtttaa tttatagtaagtgggcatttaaatattctgaccaaaaatgtattgacaaactgctgacaaaaataaaatgtgaatattgccataattttaaaaaaagagtaaaatttctgttgattacagtaaaatattttgaccttaaattatgttgattacaatattcctttgataattcagagtgcatttcaggaaacacccttggacagtcagtaaattgtttattgtatttatctttgtattgttatggtatagctatttgtacaaatattattgtgcaattattacatttctgattatattattcatttggcctaaatttaccaagaatttgaacaagtcaattaggtttacaatcaagaaatatcaaaaatgatgaaaaggatgataatcatcatcagatgttgaggaagatgacgatgagagtgccagaaatagagaaatcaaaggagaaccaaaatttaacaaattaaaagcccacagacttgctgtaattaagttttctgttgtaagtactccacgtttcctggcagatgtggtgaagcaaaagatataatcagaaatataatttatatgatcggaaagcattaaacacaatagtgcctatacaaataaaatgttcctatcactgacttctaaaatggaaatgaggacaatgatatgggaatcttaatacagtgttgtggataggactaaaaacacaggagtcagatcttcttggttcaacttcctgcttactccttaccagctgtgtgttttttgcaaggttcttcacctctatgtgatttagcttcctcatctataaaataattcagtgaattaatgtacacaaaacatctggaaaacaaaagcaaacaatatgtattttataagtgttacttatagttttatagtgaactttcttgtgcaacatttttacaactagtggagaaaaatatttctttaaatgaatacttttgatttaaaaatcagagtgtaaaaataaaacagactcctttgaaactagttctgttagaagttaattgtgcacctttaatgggctctgttgcaatccaacagagaagtagttaagtaagtggactatgatggcttctagggacctcctataaatatgatattgtgaagcatgattataataagaactagataacagacaggtggagactccactatctgaagagggtcaacctagatgaatggtgttccatttagtagttgaggaagaacccatgaggtttagaaagcagacaagcatgtggcaagttctggagtcagtggtaaaaattaaagaacccaactattactgtcacctaatgatctaatggagactgtggagatgggctgcatttttttaatcttctccagaatgccaaaatgtaaacacatatctgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgagagagagagaga gagagagagagactgaagtttgtacaattagacattttataaaatgttttctgaaggacagtggctcacaatcttaagtttctaacattgtacaatgttgggagactttgtatactttattttctctttagcatattaaggaatctgagatgtcctacagtaaagaaatttgcattacatagttaaaatcagggttattcaaactttttgattattgaaacctttcttcattagttactagggttgaatgaaactagtgttccacagaaaactatgggaaatgttgctaggcagtaaggacatggtgatttcagcatgtgcaatatttacagcgattgcacccatggaccaccctggcagtagtgaaataaccaaaaatgctgtcataactagtatggctatgagaaacacattgggcagaagcttgcctcgagcagcgctgctcgagagatctggatcataatcagccataccacatttgtagaggttttacttgctttaaaaaacctcccacacctccccctgaacctgaaacataaaatgaatgcaattgttgttgttaacttgtttattgcagcttataatggttacaaataaagcaatagcatcacaaatttcacaaataaagcatttttttcactgcattctagttgtggtttgtccaaactcatcaatgtatcttatcatgtctggtaaccattctccaggttgagccagaccaatttgatggtagatttagcaaataaaaatacaggacacccagttaaatgtgaatttccgatgaacagcaaatacttttttagtattaaaaaagttcacatttaggctcacgcctgtaatcccagcactttgggaggccgaggcaggcagatcacctgaggtcaggagttcgagaccagcctggccaacatggtgaaaccccatctccactaaaaataccaaaaattagccaggcgtgctggtgggcacctgtagttccagctactcaggaggctaaggcaggagaattgcttgaacctgggaggcagaggttgcagtgagctgagatcgcaccattgcactctagcctgggcgacaagaacaaaactccatctcaaaaaaaaaaaaaaaaaaaaagttcacatttaactgggcattctgtatttaattggtaatctgagatggcagggaacagcatcagcatggtgtgagggataggcattttttcattgtgtacagcttgtaaatcagtatttttaaaactcaaagttaatggcttgggcatatttagaaaagagttgccgcacggacttgaaccctgtattcctaaaatctaggatcttgttctgatggtctgcacaactggctgggggtgtccagccactgtccctcttgcctgggctccccagggcagttctgtcagcctctccatttccattcctgttccag caaaacccaactgatagcacagcagcatttcagcctgtctacctctgtgcccacatacctggatgtctaccagccagaaaggtggcttagatttggttcctgtgggtggattatggcccccagaacttccctgtgcttgctgggggtgtggagtggaaagagcaggaaatgggggaccctccgatactctatgggggtcctccaagtctctttgtgcaagttagggtaataatcaatatggagctaagaaagagaaggggaactatgctttagaacaggacactgtgccaggagcattgcagaaattatatggttttcacgacagttctttttggtaggtactgttattatcctcagtttgcagatgaggaaactgagacccagaaaggttaaataacttgctagggtcacacaagtcataactgacaaagcctgattcaaacccaggtctccctaacctttaaggtttctatgacgccagctctcctagggagtttgtcttcagatgtcttggctctaggtgtcaaaaaaagacttggtgtcaggcaggcataggttcaagtcccaactctgtcacttaccaactgtgactaggtgattgaactgaccatggaacctggtcacatgcaggagcaggatggtgaagggttcttgaaggcacttaggcaggacatttaggcaggagagaaaacctggaaacagaagagctgtctccaaaaatacccactggggaagcaggttgtcatgtgggccatgaatgggacctgttctggggtaaccacgtgcggaccgagcggccgcaggaacccctagtgatggagttggccactccctctctgcgcgctcgctcgctcactgaggccgggcgaccaaaggtcgcccgacgcccgggctttgcccgggcggcctcagtgagcgagcgagcgcgcagctgcctgcaggggcgcctgatgcggtattttctccttacgcatctgtgcggtatttcacaccgcatacgtcaaagcaaccatagtacgcgccctgtagcggcgcattaagcgcggcgggtgtggtggttacgcgcagcgtgaccgctacacttgccagcgccttagcgcccgctcctttcgctttcttcccttcctttctcgccacgttcgccggctttccccgtcaagctctaaatcgggggctccctttagggttccgatttagtgctttacggcacctcgaccccaaaaaacttgatttgggtgatggttcacgtagtgggccatcgccctgatagacggtttttcgccctttgacgttggagtccacgttctttaatagtggactcttgttccaaactggaacaacactcaactctatctcgggctattcttttgatttataagggattttgccgatttcggtctattggttaaaaaatgagctgatttaaca aaaatttaacgcgaattttaacaaaatattaacgtttacaattttatggtgcactctcagtacaatctgctctgatgccgcatagttaagccagccccgacacccgccaacacccgctgacgcgccctgacgggcttgtctgctcccggcatccgcttacagacaagctgtgaccgtctccgggagctgcatgtgtcagaggttttcaccgtcatcaccgaaacgcgcgagacgaaagggcctcgtgatacgcctatttttataggttaatgtcatgataataatggtttcttagacgtcaggtggcacttttcggggaaatgtgcgcggaacccctatttgtttatttttctaaatacattcaaatatgtatccgctcatgagacaataaccctgataaatgcttcaataatattgaaaaaggaagagtatgagtattcaacatttccgtgtcgcccttattcccttttttgcggcattttgccttcctgtttttgctcacccagaaacgctggtgaaagtaaaagatgctgaagatcagttgggtgcacgagtgggttacatcgaactggatctcaacagcggtaagatccttgagagttttcgccccgaagaacgttttccaatgatgagcacttttaaagttctgctatgtggcgcggtattatcccgtattgacgccgggcaagagcaactcggtcgccgcatacactattctcagaatgacttggttgagtactcaccagtcacagaaaagcatcttacggatggcatgacagtaagagaattatgcagtgctgccataaccatgagtgataacactgcggccaacttacttctgacaacgatcggaggaccgaaggagctaaccgcttttttgcacaacatgggggatcatgtaactcgccttgatcgttgggaaccggagctgaatgaagccataccaaacgacgagcgtgacaccacgatgcctgtagcaatggcaacaacgttgcgcaaactattaactggcgaactacttactctagcttcccggcaacaattaatagactggatggaggcggataaagttgcaggaccacttctgcgctcggcccttccggctggctggtttattgctgataaatctggagccggtgagcgtgggtctcgcggtatcattgcagcactggggccagatggtaagccctcccgtatcgtagttatctacacgacggggagtcaggcaactatggatgaacgaaatagacagatcgctgagataggtgcctcactgattaagcattggtaactgtcagaccaagtttactcatatatactttagattgatttaaaacttcatttttaatttaaaaggatctaggtgaagatcctttttgataatctcatgaccaaaatcccttaacgtgagttttcgttccactgagc gtcagaccccgtagaaaagatcaaaggatcttcttgaaatcctttttttctgcgcgtaatctgctgcttgcaaacaaaaaaaccaccgctaccagcggtggtttgtttgccggatcaagagctaccaactctttttccgaaggtaactggcttcagcagagcgcagataccaaatactgttcttctagtgtagccgtagttaggccaccacttcaagaactctgtagcaccgcctacatacctcgctctgctaatcctgttaccagtggctgctgccagtggcgataagtcgtgtcttaccgggttggactcaagacgatagttaccggataaggcgcagcggtcgggctgaacggggggttcgtgcacacagcccagcttggagcgaacgacctacaccgaactgagatacctacagcgtgagctatgagaaagcgccacgcttcccgaagggagaaaggcggacaggtatccggtaagcggcagggtcggaacaggagagcgcacgagggagcttccagggggaaacgcctggtatctttatagtcctgtcgggtttcgccacctctgacttgagcgtcgatttttgtgatgctcgtcaggggggcggagcctatggaaaaacgccagcaacgcggcctttttacggttcctggccttttgctggccttttgctcacatgtcctgcaggcag INSERT OF PLASMID AG012 OCCURS AT BP 1 THROUGH 4543 OF SEQ ID NO: 33 (USED AS NEGATIVE CONTROL FOR GENE CASSETTE) 58 ctgcgcgctcgctcgctcactgaggccgcccgggcgtcgggcgacctttggtcgcccggcctcagtgagcgagcgagcgcgcagagagggagtggccaactccatcactaggggttcctgcggccgcacgcgtgacgtcgtttaaacgggccccggtgttatctcattcttttttctcctctgtaagttgacatgtgatgtgggaacaaaggggataaagtcattattttgtgctaaaatcgtaattggagaggacctcctgttagctgggctttcttctatttattgtggtggttactggagttccttcttctagttttaggatatatatatatattttttttttttctttccctgaagatataataatatatatacttctgaagattgagatttttaaattagttgtattgaaaactagctaatcagcaatttaaggctagcttgagacttatgtcttgaatttgtttttgtaggctccaaaaccaaggagggagtggtgcatggtgtggcaacaggtaagctccattgtgcttatatccaaagatgatatttaaagtatctagtgattagtgtggcccagtattcaagattcctatgaaattgtaaaacaatcactgagcattctaagaacatatcagtcttattgaaactgaattctttataaagtat ttttaaaaaggtaaatattgattataaataaaaaatatacttgccaagaataatgagggctttgaattgataagctatgtttaatttatagtaagtgggcatttaaatattctgaccaaaaatgtattgacaaactgctgacaaaaataaaatgtgaatattgccataattttaaaaaaagagtaaaatttctgttgattacagtaaaatattttgaccttaaattatgttgattacaatattcctttgataattcagagtgcatttcaggaaacacccttggacagtcagtaaattgtttattgtatttatctttgtattgttatggtatagctatttgtacaaatattattgtgcaattattacatttctgattatattattcatttggcctaaatttaccaagaatttgaacaagtcaattaggtttacaatcaagaaatatcaaaaatgatgaaaaggatgataatcatcatcagatgttgaggaagatgacgatgagagtgccagaaatagagaaatcaaaggagaaccaaaatttaacaaattaaaagcccacagacttgctgtaattaagttttctgttgtaagtactccacgtttcctggcagatgtggtgaagcaaaagatataatcagaaatataatttatatgatcggaaagcattaaacacaatagtgcctatacaaataaaatgttcctatcactgacttctaaaatggaaatgaggacaatgatatgggaatcttaatacagtgttgtggataggactaaaaacacaggagtcagatcttcttggttcaacttcctgcttactccttaccagctgtgtgttttttgcaaggttcttcacctctatgtgatttagcttcctcatctataaaataattcagtgaattaatgtacacaaaacatctggaaaacaaaagcaaacaatatgtattttataagtgttacttatagttttatagtgaactttcttgtgcaacatttttacaactagtggagaaaaatatttctttaaatgaatacttttgatttaaaaatcagagtgtaaaaataaaacagactcctttgaaactagttctgttagaagttaattgtgcacctttaatgggctctgttgcaatccaacagagaagtagttaagtaagtggactatgatggcttctagggacctcctataaatatgatattgtgaagcatgattataataagaactagataacagacaggtggagactccactatctgaagagggtcaacctagatgaatggtgttccatttagtagttgaggaagaacccatgaggtttagaaagcagacaagcatgtggcaagttctggagtcagtggtaaaaattaaagaacccaactattactgtcacctaatgatctaatggagactgtggagatgggctgcatttt tttaatcttctccagaatgccaaaatgtaaacacatatctgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgagagagagagagagagagagagagactgaagtttgtacaattagacattttataaaatgttttctgaaggacagtggctcacaatcttaagtttctaacattgtacaatgttgggagactttgtatactttattttctctttagcatattaaggaatctgagatgtcctacagtaaagaaatttgcattacatagttaaaatcagggttattcaaactttttgattattgaaacctttcttcattagttactagggttgaatgaaactagtgttccacagaaaactatgggaaatgttgctaggcagtaaggacatggtgatttcagcatgtgcaatatttacagcgattgcacccatggaccaccctggcagtagtgaaataaccaaaaatgctgtcataactagtatggctatgagaaacacattgggcagaagcttgcctcgagcagcgctgctcgagagatctggatcataatcagccataccacatttgtagaggttttacttgctttaaaaaacctcccacacctccccctgaacctgaaacataaaatgaatgcaattgttgttgttaacttgtttattgcagcttataatggttacaaataaagcaatagcatcacaaatttcacaaataaagcatttttttcactgcattctagttgtggtttgtccaaactcatcaatgtatcttatcatgtctggtaaccattctccaggttgagccagaccaatttgatggtagatttagcaaataaaaatacaggacacccagttaaatgtgaatttccgatgaacagcaaatacttttttagtattaaaaaagttcacatttaggctcacgcctgtaatcccagcactttgggaggccgaggcaggcagatcacctgaggtcaggagttcgagaccagcctggccaacatggtgaaaccccatctccactaaaaataccaaaaattagccaggcgtgctggtgggcacctgtagttccagctactcaggaggctaaggcaggagaattgcttgaacctgggaggcagaggttgcagtgagctgagatcgcaccattgcactctagcctgggcgacaagaacaaaactccatctcaaaaaaaaaaaaaaaaaaaaagttcacatttaactgggcattctgtatttaattggtaatctgagatggcagggaacagcatcagcatggtgtgagggataggcattttttcattgtgtacagcttgtaaatcagtatttttaaaactcaaagttaatggcttgggcatatttagaaaagagttgccgcacggacttgaaccctgtattcctaaaatctaggatcttgttctgatggtctgcacaactg gctgggggtgtccagccactgtccctcttgcctgggctccccagggcagttctgtcagcctctccatttccattcctgttccagcaaaacccaactgatagcacagcagcatttcagcctgtctacctctgtgcccacatacctggatgtctaccagccagaaaggtggcttagatttggttcctgtgggtggattatggcccccagaacttccctgtgcttgctgggggtgtggagtggaaagagcaggaaatgggggaccctccgatactctatgggggtcctccaagtctctttgtgcaagttagggtaataatcaatatggagctaagaaagagaaggggaactatgctttagaacaggacactgtgccaggagcattgcagaaattatatggttttcacgacagttctttttggtaggtactgttattatcctcagtttgcagatgaggaaactgagacccagaaaggttaaataacttgctagggtcacacaagtcataactgacaaagcctgattcaaacccaggtctccctaacctttaaggtttctatgacgccagctctcctagggagtttgtcttcagatgtcttggctctaggtgtcaaaaaaagacttggtgtcaggcaggcataggttcaagtcccaactctgtcacttaccaactgtgactaggtgattgaactgaccatggaacctggtcacatgcaggagcaggatggtgaagggttcttgaaggcacttaggcaggacatttaggcaggagagaaaacctggaaacagaagagctgtctccaaaaatacccactggggaagcaggttgtcatgtgggccatgaatgggacctgttctggggtaaccacgtgcggaccgagcggccgcaggaacccctagtgatggagttggccactccctctctgcgcgctcgctcgctcactgaggccgggcgaccaaaggtcgcccgacgcccgggctttgcccgggcggcctcagtgagcgagcgagcgcgcag Plasmid AG004 Composition Elements SEQUENCE IDENTIFIER (SEQ.ID.NO:) AND SEQUENCE INFORMATION 5′ ITR 2 occurs @ bp 1 through bp 119 of SEQ ID NO: 34 Human RPE65 Promoter 11 occurs @ bp 134 through bp 1718 of SEQ ID NO: 34 Added Kozak 5 occurs @ bp 1752 through 1757 of of SEQ ID NO: 34 E-GFP 24 occurs @ bp 1758 through bp 2477 of SEQ ID NO: 34 SV40 POLYA 8 occurs at bp 2535 through bp 2770 of SEQ ID NO: 34 RLBP1 INTRONIC SEQUENCE AS STUFFER SEQUENCE 14 occurs at bp 2778 through bp 4280 of SEQ ID NO: 34 3′ ITR 9 occurs at bp 4309 through bp 4438 of SEQ ID NO: 34 AMP BACTERIAL BACKBONE 15 occurs at bp 4439 through bp 7057 of SEQ ID NO: 34 Sequence of plasmid AG004 34 ctgcgcgctcgctcgctcactgaggccgcccgggcgtcgggcgacctttggtcgcccggcctcagtgagcgagcgagcgcgcagagagggagtggccaactccatcactaggggttcctgcggccgcacgcgttacgtaatatttattgaagtttaatattgtgtttgtgatacagaagtatttgctttaattctaaataaaaattttatgcttttattgctggtttaagaagatttggattatccttgtactttgaggagaagtttcttatttgaaatattttggaaacaggtcttttaatgtggaaagatagatattaatctcctcttctattactctccaagatccaacaaaagtgattataccccccaaaatatgatggtagtatcttatactaccatcattttataggcatagggctcttagctgcaaataatggaactaactctaataaagcagaacgcaaatattgtaaatattagagagctaacaatctctgggatggctaaaggatggagcttggaggctacccagccagtaacaatattccgggctccactgttgaatggagacactacaactgcctt ggatgggcagagatattatggatgctaagccccaggtgctaccattaggacttctaccactgtccctaacgggtggagcccatcacatgcctatgccctcactgtaaggaaatgaagctactgttgtatatcttgggaagcacttggattaattgttatacagttttgttgaagaagacccctagggtaagtagccataactgcacactaaatttaaaattgttaatgagtttctcaaaaaaaatgttaaggttgttagctggtatagtatatatcttgcctgttttccaaggacttctttgggcagtaccttgtctgtgctggcaagcaactgagacttaatgaaagagtattggagatatgaatgaattgatgctgtatactctcagagtgccaaacatataccaatggacaagaaggtgaggcagagagcagacaggcattagtgacaagcaaagatatgcagaatttcattctcagcaaatcaaaagtcctcaacctggttggaagaatattggcactgaatggtatcaataaggttgctagagagggttagaggtgcacaatgtgcttccataacattttatacttctccaatcttagcactaatcaaacatggttgaatactttgtttactataactcttacagagttataagatctgtgaagacagggacagggacaatacccatctctgtctggttcataggtggtatgtaatagatatttttaaaaataagtgagttaatgaatgagggtgagaatgaaggcacagaggtattagggggaggtgggccccagagaatggtgccaaggtccagtggggtgactgggatcagctcaggcctgacgctggccactcccacctagctcctttctttctaatctgttctcattctccttgggaaggattgaggtctctggaaaacagccaaacaactgttatgggaacagcaagcccaaataaagccaagcatcagggggatctgagagctgaaagcaacttctgttccccctccctcagctgaaggggtggggaagggctcccaaagccataactccttttaagggatttagaaggcataaaaaggcccctggctgagaacttccttcttcattctgcagttggtgaattccccggggatcctctagagtcgaaattcgccaccatggtgagcaagggcgaggagctgttcaccggggtggtgcccatcctggtcgagctggacggcgacgtaaacggccacaagttcagcgtgtccggcgagggcgagggcgatgccacctacggcaagctgaccctgaagttcatctgcaccaccggcaagctgcccgtgccctggcccaccctcgtgaccaccctgacctacggcgtgcagtgcttcagccgctaccccgaccacatgaagcagcacgacttcttcaagt ccgccatgcccgaaggctacgtccaggagcgcaccatcttcttcaaggacgacggcaactacaagacccgcgccgaggtgaagttcgagggcgacaccctggtgaaccgcatcgagctgaagggcatcgacttcaaggaggacggcaacatcctggggcacaagctggagtacaactacaacagccacaacgtctatatcatggccgacaagcagaagaacggcatcaaggtgaacttcaagatccgccacaacatcgaggacggcagcgtgcagctcgccgaccactaccagcagaacacccccatcggcgacggccccgtgctgctgcccgacaaccactacctgagcacccagtccgccctgagcaaagaccccaacgagaagcgcgatcacatggtcctgctggagttcgtgaccgccgccgggatcactctcggcatggacgagctgtacaagtaatagggtaccggtcgacctgcagaagcttgcctcgagcagcgctgctcgagagatctggatcataatcagccataccacatttgtagaggttttacttgctttaaaaaacctcccacacctccccctgaacctgaaacataaaatgaatgcaattgttgttgttaacttgtttattgcagcttataatggttacaaataaagcaatagcatcacaaatttcacaaataaagcatttttttcactgcattctagttgtggtttgtccaaactcatcaatgtatcttatcatgtctggtaaccattctccaggttgagccagaccaatttgatggtagatttagcaaataaaaatacaggacacccagttaaatgtgaatttccgatgaacagcaaatacttttttagtattaaaaaagttcacatttaggctcacgcctgtaatcccagcactttgggaggccgaggcaggcagatcacctgaggtcaggagttcgagaccagcctggccaacatggtgaaaccccatctccactaaaaataccaaaaattagccaggcgtgctggtgggcacctgtagttccagctactcaggaggctaaggcaggagaattgcttgaacctgggaggcagaggttgcagtgagctgagatcgcaccattgcactctagcctgggcgacaagaacaaaactccatctcaaaaaaaaaaaaaaaaaaaaagttcacatttaactgggcattctgtatttaattggtaatctgagatggcagggaacagcatcagcatggtgtgagggataggcattttttcattgtgtacagcttgtaaatcagtatttttaaaactcaaagttaatggcttgggcatatttagaaaagagttgccgcacggacttgaaccctgtattcctaaaatctaggatcttgttctgatggtctgcacaactggctgggggtgtccagccactg tccctcttgcctgggctccccagggcagttctgtcagcctctccatttccattcctgttccagcaaaacccaactgatagcacagcagcatttcagcctgtctacctctgtgcccacatacctggatgtctaccagccagaaaggtggcttagatttggttcctgtgggtggattatggcccccagaacttccctgtgcttgctgggggtgtggagtggaaagagcaggaaatgggggaccctccgatactctatgggggtcctccaagtctctttgtgcaagttagggtaataatcaatatggagctaagaaagagaaggggaactatgctttagaacaggacactgtgccaggagcattgcagaaattatatggttttcacgacagttctttttggtaggtactgttattatcctcagtttgcagatgaggaaactgagacccagaaaggttaaataacttgctagggtcacacaagtcataactgacaaagcctgattcaaacccaggtctccctaacctttaaggtttctatgacgccagctctcctagggagtttgtcttcagatgtcttggctctaggtgtcaaaaaaagacttggtgtcaggcaggcataggttcaagtcccaactctgtcacttaccaactgtgactaggtgattgaactgaccatggaacctggtcacatgcaggagcaggatggtgaagggttcttgaaggcacttaggcaggacatttaggcaggagagaaaacctggaaacagaagagctgtctccaaaaatacccactggggaagcaggttgtcatgtgggccatgaatgggacctgttctggggtaaccacgtgcggaccgagcggccgcaggaacccctagtgatggagttggccactccctctctgcgcgctcgctcgctcactgaggccgggcgaccaaaggtcgcccgacgcccgggctttgcccgggcggcctcagtgagcgagcgagcgcgcagctgcctgcaggggcgcctgatgcggtattttctccttacgcatctgtgcggtatttcacaccgcatacgtcaaagcaaccatagtacgcgccctgtagcggcgcattaagcgcggcgggtgtggtggttacgcgcagcgtgaccgctacacttgccagcgccttagcgcccgctcctttcgctttcttcccttcctttctcgccacgttcgccggctttccccgtcaagctctaaatcgggggctccctttagggttccgatttagtgctttacggcacctcgaccccaaaaaacttgatttgggtgatggttcacgtagtgggccatcgccctgatagacggtttttcgccctttgacgttggagtccacgttctttaatagtggactcttgttccaaactggaacaacactcaactctatctcgggctattc ttttgatttataagggattttgccgatttcggtctattggttaaaaaatgagctgatttaacaaaaatttaacgcgaattttaacaaaatattaacgtttacaattttatggtgcactctcagtacaatctgctctgatgccgcatagttaagccagccccgacacccgccaacacccgctgacgcgccctgacgggcttgtctgctcccggcatccgcttacagacaagctgtgaccgtctccgggagctgcatgtgtcagaggttttcaccgtcatcaccgaaacgcgcgagacgaaagggcctcgtgatacgcctatttttataggttaatgtcatgataataatggtttcttagacgtcaggtggcacttttcggggaaatgtgcgcggaacccctatttgtttatttttctaaatacattcaaatatgtatccgctcatgagacaataaccctgataaatgcttcaataatattgaaaaaggaagagtatgagtattcaacatttccgtgtcgcccttattcccttttttgcggcattttgccttcctgtttttgctcacccagaaacgctggtgaaagtaaaagatgctgaagatcagttgggtgcacgagtgggttacatcgaactggatctcaacagcggtaagatccttgagagttttcgccccgaagaacgttttccaatgatgagcacttttaaagttctgctatgtggcgcggtattatcccgtattgacgccgggcaagagcaactcggtcgccgcatacactattctcagaatgacttggttgagtactcaccagtcacagaaaagcatcttacggatggcatgacagtaagagaattatgcagtgctgccataaccatgagtgataacactgcggccaacttacttctgacaacgatcggaggaccgaaggagctaaccgcttttttgcacaacatgggggatcatgtaactcgccttgatcgttgggaaccggagctgaatgaagccataccaaacgacgagcgtgacaccacgatgcctgtagcaatggcaacaacgttgcgcaaactattaactggcgaactacttactctagcttcccggcaacaattaatagactggatggaggcggataaagttgcaggaccacttctgcgctcggcccttccggctggctggtttattgctgataaatctggagccggtgagcgtgggtctcgcggtatcattgcagcactggggccagatggtaagccctcccgtatcgtagttatctacacgacggggagtcaggcaactatggatgaacgaaatagacagatcgctgagataggtgcctcactgattaagcattggtaactgtcagaccaagtttactcatatatactttagattgatttaaaacttcatttttaatttaaaaggatctaggt gaagatcctttttgataatctcatgaccaaaatcccttaacgtgagttttcgttccactgagcgtcagaccccgtagaaaagatcaaaggatcttcttgaaatcctttttttctgcgcgtaatctgctgcttgcaaacaaaaaaaccaccgctaccagcggtggtttgtttgccggatcaagagctaccaactctttttccgaaggtaactggcttcagcagagcgcagataccaaatactgttcttctagtgtagccgtagttaggccaccacttcaagaactctgtagcaccgcctacatacctcgctctgctaatcctgttaccagtggctgctgccagtggcgataagtcgtgtcttaccgggttggactcaagacgatagttaccggataaggcgcagcggtcgggctgaacggggggttcgtgcacacagcccagcttggagcgaacgacctacaccgaactgagatacctacagcgtgagctatgagaaagcgccacgcttcccgaagggagaaaggcggacaggtatccggtaagcggcagggtcggaacaggagagcgcacgagggagcttccagggggaaacgcctggtatctttatagtcctgtcgggtttcgccacctctgacttgagcgtcgatttttgtgatgctcgtcaggggggcggagcctatggaaaaacgccagcaacgcggcctttttacggttcctggccttttgctggccttttgctcacatgtcctgcaggcag GENE CASSETTE AG004 OCCURS AT BP 1 THROUGH 4438 OF SEQ ID NO: 34 59 ctgcgcgctcgctcgctcactgaggccgcccgggcgtcgggcgacctttggtcgcccggcctcagtgagcgagcgagcgcgcagagagggagtggccaactccatcactaggggttcctgcggccgcacgcgttacgtaatatttattgaagtttaatattgtgtttgtgatacagaagtatttgctttaattctaaataaaaattttatgcttttattgctggtttaagaagatttggattatccttgtactttgaggagaagtttcttatttgaaatattttggaaacaggtcttttaatgtggaaagatagatattaatctcctcttctattactctccaagatccaacaaaagtgattataccccccaaaatatgatggtagtatcttatactaccatcattttataggcatagggctcttagctgcaaataatggaactaactctaataaagcagaacgcaaatattgtaaatattagagagctaacaatctctgggatggctaaaggatggagcttggaggctacccagccagtaacaatattccgggctccactgttgaatggagacactacaactgcctt ggatgggcagagatattatggatgctaagccccaggtgctaccattaggacttctaccactgtccctaacgggtggagcccatcacatgcctatgccctcactgtaaggaaatgaagctactgttgtatatcttgggaagcacttggattaattgttatacagttttgttgaagaagacccctagggtaagtagccataactgcacactaaatttaaaattgttaatgagtttctcaaaaaaaatgttaaggttgttagctggtatagtatatatcttgcctgttttccaaggacttctttgggcagtaccttgtctgtgctggcaagcaactgagacttaatgaaagagtattggagatatgaatgaattgatgctgtatactctcagagtgccaaacatataccaatggacaagaaggtgaggcagagagcagacaggcattagtgacaagcaaagatatgcagaatttcattctcagcaaatcaaaagtcctcaacctggttggaagaatattggcactgaatggtatcaataaggttgctagagagggttagaggtgcacaatgtgcttccataacattttatacttctccaatcttagcactaatcaaacatggttgaatactttgtttactataactcttacagagttataagatctgtgaagacagggacagggacaatacccatctctgtctggttcataggtggtatgtaatagatatttttaaaaataagtgagttaatgaatgagggtgagaatgaaggcacagaggtattagggggaggtgggccccagagaatggtgccaaggtccagtggggtgactgggatcagctcaggcctgacgctggccactcccacctagctcctttctttctaatctgttctcattctccttgggaaggattgaggtctctggaaaacagccaaacaactgttatgggaacagcaagcccaaataaagccaagcatcagggggatctgagagctgaaagcaacttctgttccccctccctcagctgaaggggtggggaagggctcccaaagccataactccttttaagggatttagaaggcataaaaaggcccctggctgagaacttccttcttcattctgcagttggtgaattccccggggatcctctagagtcgaaattcgccaccatggtgagcaagggcgaggagctgttcaccggggtggtgcccatcctggtcgagctggacggcgacgtaaacggccacaagttcagcgtgtccggcgagggcgagggcgatgccacctacggcaagctgaccctgaagttcatctgcaccaccggcaagctgcccgtgccctggcccaccctcgtgaccaccctgacctacggcgtgcagtgcttcagccgctaccccgaccacatgaagcagcacgacttcttcaagtccgccatgcccgaaggctacgtccaggagcgcaccatcttcttcaaggacgacggcaactacaagacccgcgccgaggtgaagttcgagggcgacaccctggtgaaccgcatcgagctgaagggcatcgacttcaaggaggacggcaacatcctggggcacaagctggagtacaactacaacagccacaacgtctatatcatggccgacaagcagaagaacggcatcaaggtgaacttcaagatccgccacaacatcgaggacggcagcgtgcagctcgccgaccactaccagcagaacacccccatcggcgacggccccgtgctgctgcccgacaaccactacctgagcacccagtccgccctgagcaaagaccccaacgagaagcgcgatcacatggtcctgctggagttcgtgaccgccgccgggatcactctcggcatggacgagctgtacaagtaatagggtaccggtcgacctgcagaagcttgcctcgagcagcgctgctcgagagatctggatcataatcagccataccacatttgtagaggttttacttgctttaaaaaacctcccacacctccccctgaacctgaaacataaaatgaatgcaattgttgttgttaacttgtttattgcagcttataatggttacaaataaagcaatagcatcacaaatttcacaaataaagcatttttttcactgcattctagttgtggtttgtccaaactcatcaatgtatcttatcatgtctggtaaccattctccaggttgagccagaccaatttgatggtagatttagcaaataaaaatacaggacacccagttaaatgtgaatttccgatgaacagcaaatacttttttagtattaaaaaagttcacatttaggctcacgcctgtaatcccagcactttgggaggccgaggcaggcagatcacctgaggtcaggagttcgagaccagcctggccaacatggtgaaaccccatctccactaaaaataccaaaaattagccaggcgtgctggtgggcacctgtagttccagctactcaggaggctaaggcaggagaattgcttgaacctgggaggcagaggttgcagtgagctgagatcgcaccattgcactctagcctgggcgacaagaacaaaactccatctcaaaaaaaaaaaaaaaaaaaaagttcacatttaactgggcattctgtatttaattggtaatctgagatggcagggaacagcatcagcatggtgtgagggataggcattttttcattgtgtacagcttgtaaatcagtatttttaaaactcaaagttaatggcttgggcatatttagaaaagagttgccgcacggacttgaaccctgtattcctaaaatctaggatcttgttctgatggtctgcacaactggctgggggtgtccagccactg tccctcttgcctgggctccccagggcagttctgtcagcctctccatttccattcctgttccagcaaaacccaactgatagcacagcagcatttcagcctgtctacctctgtgcccacatacctggatgtctaccagccagaaaggtggcttagatttggttcctgtgggtggattatggcccccagaacttccctgtgcttgctgggggtgtggagtggaaagagcaggaaatgggggaccctccgatactctatgggggtcctccaagtctctttgtgcaagttagggtaataatcaatatggagctaagaaagagaaggggaactatgctttagaacaggacactgtgccaggagcattgcagaaattatatggttttcacgacagttctttttggtaggtactgttattatcctcagtttgcagatgaggaaactgagacccagaaaggttaaataacttgctagggtcacacaagtcataactgacaaagcctgattcaaacccaggtctccctaacctttaaggtttctatgacgccagctctcctagggagtttgtcttcagatgtcttggctctaggtgtcaaaaaaagacttggtgtcaggcaggcataggttcaagtcccaactctgtcacttaccaactgtgactaggtgattgaactgaccatggaacctggtcacatgcaggagcaggatggtgaagggttcttgaaggcacttaggcaggacatttaggcaggagagaaaacctggaaacagaagagctgtctccaaaaatacccactggggaagcaggttgtcatgtgggccatgaatgggacctgttctggggtaaccacgtgcggaccgagcggccgcaggaacccctagtgatggagttggccactccctctctgcgcgctcgctcgctcactgaggccgggcgaccaaaggtcgcccgacgcccgggctttgcccgggcggcctcagtgagcgagcgagcgcgcag Plasmid AG006 Composition Elements SEQUENCE IDENTIFIER (SEQ.ID.NO:)AND SEQUENCE INFORMATION 5′ ITR 2 occurs @ bp 1 through bp 119 of SEQ ID NO: 35 Human VMD2 Promoter 12 occurs @ bp 134 through bp 761 of SEQ ID NO: 35 Added Kozak 5 occurs @ bp 795 through 800 of SEQ ID NO: 34 E-GFP 24 occurs @ bp 801 through bp 1520 of SEQ ID NO: 35 SV40 POLYA 8 occurs at bp 1578 through bp 1813 of SEQ ID NO: 35 RLBP1 INTRONIC SEQUENCE AS STUFFER SEQUENCE 14 occurs at bp 1821 through bp 3323 of SEQ ID NO: 35 3′ ITR 9 occurs at bp 3352 through bp 3481 of SEQ ID NO: 35 AMP BACTERIAL BACKBONE 15 occurs at bp 3482 through bp 6100 of SEQ ID NO: 35 Sequence of plasmid AG006 35 ctgcgcgctcgctcgctcactgaggccgcccgggcgtcgggcgacctttggtcgcccggcctcagtgagcgagcgagcgcgcagagagggagtggccaactccatcactaggggttcctgcggccgcacgcgttacgtaattctgtcattttactagggtgatgaaattcccaagcaacaccatccttttcagataagggcactgaggctgagagaggagctgaaacctacccggcgtcaccacacacaggtggcaaggctgggaccagaaaccaggactgttgactgcagcccggtattcattctttccatagcccacagggctgtcaaagaccccagggcctagtcagaggctcctccttcctggagagttcctggcacagaagttgaagctcagcacagccccctaacccccaactctctctgcaaggcctcaggggtcagaacactggtggagcagatcctttagcctctggattttagggccatggtagagggggtgttgccctaaattccagccctggtctcagcccaacaccctccaagaagaaattagaggggccatggccaggctgtgctagccgttgcttctgagcagattacaagaagggactaagacaaggactcctt tgtggaggtcctggcttagggagtcaagtgacggcggctcagcactcacgtgggcagtgccagcctctaagagtgggcaggggcactggccacagagtcccagggagtcccaccagcctagtcgccagaccgaattccccggggatcctctagagtcgaaattcgccaccatggtgagcaagggcgaggagctgttcaccggggtggtgcccatcctggtcgagctggacggcgacgtaaacggccacaagttcagcgtgtccggcgagggcgagggcgatgccacctacggcaagctgaccctgaagttcatctgcaccaccggcaagctgcccgtgccctggcccaccctcgtgaccaccctgacctacggcgtgcagtgcttcagccgctaccccgaccacatgaagcagcacgacttcttcaagtccgccatgcccgaaggctacgtccaggagcgcaccatcttcttcaaggacgacggcaactacaagacccgcgccgaggtgaagttcgagggcgacaccctggtgaaccgcatcgagctgaagggcatcgacttcaaggaggacggcaacatcctggggcacaagctggagtacaactacaacagccacaacgtctatatcatggccgacaagcagaagaacggcatcaaggtgaacttcaagatccgccacaacatcgaggacggcagcgtgcagctcgccgaccactaccagcagaacacccccatcggcgacggccccgtgctgctgcccgacaaccactacctgagcacccagtccgccctgagcaaagaccccaacgagaagcgcgatcacatggtcctgctggagttcgtgaccgccgccgggatcactctcggcatggacgagctgtacaagtaatagggtaccggtcgacctgcagaagcttgcctcgagcagcgctgctcgagagatctggatcataatcagccataccacatttgtagaggttttacttgctttaaaaaacctcccacacctccccctgaacctgaaacataaaatgaatgcaattgttgttgttaacttgtttattgcagcttataatggttacaaataaagcaatagcatcacaaatttcacaaataaagcatttttttcactgcattctagttgtggtttgtccaaactcatcaatgtatcttatcatgtctggtaaccattctccaggttgagccagaccaatttgatggtagatttagcaaataaaaatacaggacacccagttaaatgtgaatttccgatgaacagcaaatacttttttagtattaaaaaagttcacatttaggctcacgcctgtaatcccagcactttgggaggccgaggcaggcagatcacctgaggtcaggagttcgagaccagcctggccaacatggtgaaaccccatctccactaaaaa taccaaaaattagccaggcgtgctggtgggcacctgtagttccagctactcaggaggctaaggcaggagaattgcttgaacctgggaggcagaggttgcagtgagctgagatcgcaccattgcactctagcctgggcgacaagaacaaaactccatctcaaaaaaaaaaaaaaaaaaaaagttcacatttaactgggcattctgtatttaattggtaatctgagatggcagggaacagcatcagcatggtgtgagggataggcattttttcattgtgtacagcttgtaaatcagtatttttaaaactcaaagttaatggcttgggcatatttagaaaagagttgccgcacggacttgaaccctgtattcctaaaatctaggatcttgttctgatggtctgcacaactggctgggggtgtccagccactgtccctcttgcctgggctccccagggcagttctgtcagcctctccatttccattcctgttccagcaaaacccaactgatagcacagcagcatttcagcctgtctacctctgtgcccacatacctggatgtctaccagccagaaaggtggcttagatttggttcctgtgggtggattatggcccccagaacttccctgtgcttgctgggggtgtggagtggaaagagcaggaaatgggggaccctccgatactctatgggggtcctccaagtctctttgtgcaagttagggtaataatcaatatggagctaagaaagagaaggggaactatgctttagaacaggacactgtgccaggagcattgcagaaattatatggttttcacgacagttctttttggtaggtactgttattatcctcagtttgcagatgaggaaactgagacccagaaaggttaaataacttgctagggtcacacaagtcataactgacaaagcctgattcaaacccaggtctccctaacctttaaggtttctatgacgccagctctcctagggagtttgtcttcagatgtcttggctctaggtgtcaaaaaaagacttggtgtcaggcaggcataggttcaagtcccaactctgtcacttaccaactgtgactaggtgattgaactgaccatggaacctggtcacatgcaggagcaggatggtgaagggttcttgaaggcacttaggcaggacatttaggcaggagagaaaacctggaaacagaagagctgtctccaaaaatacccactggggaagcaggttgtcatgtgggccatgaatgggacctgttctggggtaaccacgtgcggaccgagcggccgcaggaacccctagtgatggagttggccactccctctctgcgcgctcgctcgctcactgaggccgggcgaccaaaggtcgcccgacgcccgggctttgcccgggcggcctcagtgagcgagcgagcgcgcagctgcc tgcaggggcgcctgatgcggtattttctccttacgcatctgtgcggtatttcacaccgcatacgtcaaagcaaccatagtacgcgccctgtagcggcgcattaagcgcggcgggtgtggtggttacgcgcagcgtgaccgctacacttgccagcgccttagcgcccgctcctttcgctttcttcccttcctttctcgccacgttcgccggctttccccgtcaagctctaaatcgggggctccctttagggttccgatttagtgctttacggcacctcgaccccaaaaaacttgatttgggtgatggttcacgtagtgggccatcgccctgatagacggtttttcgccctttgacgttggagtccacgttctttaatagtggactcttgttccaaactggaacaacactcaactctatctcgggctattcttttgatttataagggattttgccgatttcggtctattggttaaaaaatgagctgatttaacaaaaatttaacgcgaattttaacaaaatattaacgtttacaattttatggtgcactctcagtacaatctgctctgatgccgcatagttaagccagccccgacacccgccaacacccgctgacgcgccctgacgggcttgtctgctcccggcatccgcttacagacaagctgtgaccgtctccgggagctgcatgtgtcagaggttttcaccgtcatcaccgaaacgcgcgagacgaaagggcctcgtgatacgcctatttttataggttaatgtcatgataataatggtttcttagacgtcaggtggcacttttcggggaaatgtgcgcggaacccctatttgtttatttttctaaatacattcaaatatgtatccgctcatgagacaataaccctgataaatgcttcaataatattgaaaaaggaagagtatgagtattcaacatttccgtgtcgcccttattcccttttttgcggcattttgccttcctgtttttgctcacccagaaacgctggtgaaagtaaaagatgctgaagatcagttgggtgcacgagtgggttacatcgaactggatctcaacagcggtaagatccttgagagttttcgccccgaagaacgttttccaatgatgagcacttttaaagttctgctatgtggcgcggtattatcccgtattgacgccgggcaagagcaactcggtcgccgcatacactattctcagaatgacttggttgagtactcaccagtcacagaaaagcatcttacggatggcatgacagtaagagaattatgcagtgctgccataaccatgagtgataacactgcggccaacttacttctgacaacgatcggaggaccgaaggagctaaccgcttttttgcacaacatgggggatcatgtaactcgccttgatcgttgggaaccggagctgaatga agccataccaaacgacgagcgtgacaccacgatgcctgtagcaatggcaacaacgttgcgcaaactattaactggcgaactacttactctagcttcccggcaacaattaatagactggatggaggcggataaagttgcaggaccacttctgcgctcggcccttccggctggctggtttattgctgataaatctggagccggtgagcgtgggtctcgcggtatcattgcagcactggggccagatggtaagccctcccgtatcgtagttatctacacgacggggagtcaggcaactatggatgaacgaaatagacagatcgctgagataggtgcctcactgattaagcattggtaactgtcagaccaagtttactcatatatactttagattgatttaaaacttcatttttaatttaaaaggatctaggtgaagatcctttttgataatctcatgaccaaaatcccttaacgtgagttttcgttccactgagcgtcagaccccgtagaaaagatcaaaggatcttcttgaaatcctttttttctgcgcgtaatctgctgcttgcaaacaaaaaaaccaccgctaccagcggtggtttgtttgccggatcaagagctaccaactctttttccgaaggtaactggcttcagcagagcgcagataccaaatactgttcttctagtgtagccgtagttaggccaccacttcaagaactctgtagcaccgcctacatacctcgctctgctaatcctgttaccagtggctgctgccagtggcgataagtcgtgtcttaccgggttggactcaagacgatagttaccggataaggcgcagcggtcgggctgaacggggggttcgtgcacacagcccagcttggagcgaacgacctacaccgaactgagatacctacagcgtgagctatgagaaagcgccacgcttcccgaagggagaaaggcggacaggtatccggtaagcggcagggtcggaacaggagagcgcacgagggagcttccagggggaaacgcctggtatctttatagtcctgtcgggtttcgccacctctgacttgagcgtcgatttttgtgatgctcgtcaggggggcggagcctatggaaaaacgccagcaacgcggcctttttacggttcctggccttttgctggccttttgctcacatgtcctgcaggcag GENE CASSETTE OF PLASMID AG006 OCCURS AT BP 1 THROUGH 3481 OF SEQ ID NO: 35 60 ctgcgcgctcgctcgctcactgaggccgcccgggcgtcgggcgacctttggtcgcccggcctcagtgagcgagcgagcgcgcagagagggagtggccaactccatcactaggggttcctgcggccgcacgcgttacgtaattctgtcattttactagggtgatgaaat tcccaagcaacaccatccttttcagataagggcactgaggctgagagaggagctgaaacctacccggcgtcaccacacacaggtggcaaggctgggaccagaaaccaggactgttgactgcagcccggtattcattctttccatagcccacagggctgtcaaagaccccagggcctagtcagaggctcctccttcctggagagttcctggcacagaagttgaagctcagcacagccccctaacccccaactctctctgcaaggcctcaggggtcagaacactggtggagcagatcctttagcctctggattttagggccatggtagagggggtgttgccctaaattccagccctggtctcagcccaacaccctccaagaagaaattagaggggccatggccaggctgtgctagccgttgcttctgagcagattacaagaagggactaagacaaggactcctttgtggaggtcctggcttagggagtcaagtgacggcggctcagcactcacgtgggcagtgccagcctctaagagtgggcaggggcactggccacagagtcccagggagtcccaccagcctagtcgccagaccgaattccccggggatcctctagagtcgaaattcgccaccatggtgagcaagggcgaggagctgttcaccggggtggtgcccatcctggtcgagctggacggcgacgtaaacggccacaagttcagcgtgtccggcgagggcgagggcgatgccacctacggcaagctgaccctgaagttcatctgcaccaccggcaagctgcccgtgccctggcccaccctcgtgaccaccctgacctacggcgtgcagtgcttcagccgctaccccgaccacatgaagcagcacgacttcttcaagtccgccatgcccgaaggctacgtccaggagcgcaccatcttcttcaaggacgacggcaactacaagacccgcgccgaggtgaagttcgagggcgacaccctggtgaaccgcatcgagctgaagggcatcgacttcaaggaggacggcaacatcctggggcacaagctggagtacaactacaacagccacaacgtctatatcatggccgacaagcagaagaacggcatcaaggtgaacttcaagatccgccacaacatcgaggacggcagcgtgcagctcgccgaccactaccagcagaacacccccatcggcgacggccccgtgctgctgcccgacaaccactacctgagcacccagtccgccctgagcaaagaccccaacgagaagcgcgatcacatggtcctgctggagttcgtgaccgccgccgggatcactctcggcatggacgagctgtacaagtaatagggtaccggtcgacctgcagaagcttgcctcgagcagcgctgctcgagagatctggatcataatcagccatacc acatttgtagaggttttacttgctttaaaaaacctcccacacctccccctgaacctgaaacataaaatgaatgcaattgttgttgttaacttgtttattgcagcttataatggttacaaataaagcaatagcatcacaaatttcacaaataaagcatttttttcactgcattctagttgtggtttgtccaaactcatcaatgtatcttatcatgtctggtaaccattctccaggttgagccagaccaatttgatggtagatttagcaaataaaaatacaggacacccagttaaatgtgaatttccgatgaacagcaaatacttttttagtattaaaaaagttcacatttaggctcacgcctgtaatcccagcactttgggaggccgaggcaggcagatcacctgaggtcaggagttcgagaccagcctggccaacatggtgaaaccccatctccactaaaaataccaaaaattagccaggcgtgctggtgggcacctgtagttccagctactcaggaggctaaggcaggagaattgcttgaacctgggaggcagaggttgcagtgagctgagatcgcaccattgcactctagcctgggcgacaagaacaaaactccatctcaaaaaaaaaaaaaaaaaaaaagttcacatttaactgggcattctgtatttaattggtaatctgagatggcagggaacagcatcagcatggtgtgagggataggcattttttcattgtgtacagcttgtaaatcagtatttttaaaactcaaagttaatggcttgggcatatttagaaaagagttgccgcacggacttgaaccctgtattcctaaaatctaggatcttgttctgatggtctgcacaactggctgggggtgtccagccactgtccctcttgcctgggctccccagggcagttctgtcagcctctccatttccattcctgttccagcaaaacccaactgatagcacagcagcatttcagcctgtctacctctgtgcccacatacctggatgtctaccagccagaaaggtggcttagatttggttcctgtgggtggattatggcccccagaacttccctgtgcttgctgggggtgtggagtggaaagagcaggaaatgggggaccctccgatactctatgggggtcctccaagtctctttgtgcaagttagggtaataatcaatatggagctaagaaagagaaggggaactatgctttagaacaggacactgtgccaggagcattgcagaaattatatggttttcacgacagttctttttggtaggtactgttattatcctcagtttgcagatgaggaaactgagacccagaaaggttaaataacttgctagggtcacacaagtcataactgacaaagcctgattcaaacccaggtctccctaacctttaaggtttctatg acgccagctctcctagggagtttgtcttcagatgtcttggctctaggtgtcaaaaaaagacttggtgtcaggcaggcataggttcaagtcccaactctgtcacttaccaactgtgactaggtgattgaactgaccatggaacctggtcacatgcaggagcaggatggtgaagggttcttgaaggcacttaggcaggacatttaggcaggagagaaaacctggaaacagaagagctgtctccaaaaatacccactggggaagcaggttgtcatgtgggccatgaatgggacctgttctggggtaaccacgtgcggaccgagcggccgcaggaacccctagtgatggagttggccactccctctctgcgcgctcgctcgctcactgaggccgggcgaccaaaggtcgcccgacgcccgggctttgcccgggcggcctcagtgagcgagcgagcgcgcag Plasmid TM042 Composition ΔITR 1 occurs at bp 4 through bp 106 of SEQ ID NO: 50 Human RLBP1 Promoter(short) 3 occurs at bp 119 through bp 708 of SEQ ID NO: 50 MODIFIED SV40INTRON 4 occurs at bp 723 through bp 905 of SEQ ID NO: 50 Added Kozak 5 occurs at bp 919 through bp 924 of SEQ ID NO: 50 HUMAN RLBP1 GENE CDS 6 occurs at bp 925 through bp 1878 of SEQ ID NO: 50 SV40 POLYA 8 occurs at bp 1937 through bp 2172 of SEQ ID NO: 50 3′ ITR 9 occurs at bp 2201 through bp 2330 of SEQ ID NO: 50 KAN-R BACTERIAL BACKBONE 49 occurs at bp 2331 through bp 4989 of SEQ ID NO: 50 Sequence of plasmid TM042 50 ctgcgcgctcgctcgctcactgaggccgcccgggcaaagcccgggcgtcgggcgacctttggtcgcccggcctcagtgagcgagcgagcgcgcagagagggagtggggtaccacgcgtttgtcctctccctgcttggccttaaccagccacatttctcaactgaccccactcactgcagaggtgaaaactaccatgccaggtcctgctggctgggggaggggtgggcaataggcctggatttgccagagctgccactgtagatgtagtcatatttacgatttcccttcacctcttattaccctggtggtggtggtgggggggggggggtgctctctcagcaaccccaccccgggatcttgaggagaaagagggcagagaaaagagggaatgggactggcccagatcccagccccacagccgggcttccacatggccgagcaggaactccagagcaggagcacacaaaggagggctttgatgcgcctccagccaggcccaggcctctcccctctcccctttctctctgggtcttcctttgccccactgagggcctcctgtgagcccgatttaacggaaactgtgggcggtgagaagttccttatgacacactaatcccaacctgctgaccggaccacgcctccagcggagggaacctctagagctccaggacattcaggtaccaggtagccccaaggaggagctgccgaatcgatggatcgggaactgaaaaaccagaaagttaactggtaagtttagtctttttgtcttttatttcaggtcccggatccggtggtggtgcaaatcaaagaactgctcctcagtggatgttgcctttacttctaggcctgtacggaagtgttacttctgctctaaaagctgcggaattgtacccgccccgggatccatcgattgaattcgccaccatgtcagaaggggtgggcacgttccgcatggtacctgaagaggaacaggagctccgtgcccaactggagcagctcacaaccaaggaccatggacctgtctttggcccgtgcagccagctgccccgccacaccttgcagaaggccaaggatgagctgaacgagagagaggagacccgggaggaggcagtgcgagagctgcaggagatggtgcaggcgcaggcggcctcgggggaggagctggcggtggccgtggcggagagggtgcaagagaaggacagcggcttcttcctgcgcttcatccgcgcacggaagttcaacgtgggccgtgcctatgag ctgctcagaggctatgtgaatttccggctgcagtaccctgagctctttgacagcctgtccccagaggctgtccgctgcaccattgaagctggctaccctggtgtcctctctagtcgggacaagtatggccgagtggtcatgctcttcaacattgagaactggcaaagtcaagaaatcacctttgatgagatcttgcaggcatattgcttcatcctggagaagctgctggagaatgaggaaactcaaatcaatggcttctgcatcattgagaacttcaagggctttaccatgcagcaggctgctagtctccggacttcagatctcaggaagatggtggacatgctccaggattccttcccagcccggttcaaagccatccacttcatccaccagccatggtacttcaccacgacctacaatgtggtcaagcccttcttgaagagcaagctgcttgagagggtctttgtccacggggatgacctttctggtttctaccaggagatcgatgagaacatcctgccctctgacttcgggggcacgctgcccaagtatgatggcaaggccgttgctgagcagctctttggcccccaggcccaagctgagaacacagccttctgaggatcgtaccggtcgacctgcagaagcttgcctcgagcagcgctgctcgagagatctggatcataatcagccataccacatttgtagaggttttacttgctttaaaaaacctcccacacctccccctgaacctgaaacataaaatgaatgcaattgttgttgttaacttgtttattgcagcttataatggttacaaataaagcaatagcatcacaaatttcacaaataaagcatttttttcactgcattctagttgtggtttgtccaaactcatcaatgtatcttatcatgtctggtaaccacgtgcggaccgagcggccgcaggaacccctagtgatggagttggccactccctctctgcgcgctcgctcgctcactgaggccgggcgaccaaaggtcgcccgacgcccgggctttgcccgggcggcctcagtgagcgagcgagcgcgcagctgcctgcagggttccatcccaatggcgcgtcaattcactggccgtcgttttacaacgtcgtgactgggaaaaccctggcgttacccaacttaatcgccttgcagcacatccccctttcgccagctggcgtaatagcgaagaggcccgcaccgatcgcccttcccaacagttgcgcagcctgaatggcgaatggcgcctgatgcggtattttctccttacgcatctgtgcggtatttcacaccgcatatggtgcactctcagtacaatctgctctgatgccgcatagttaagccagccccgacacccgccaacacccgctgacgcgccctgacgggcttgtctgctcccggcatccgc ttacagacaagctgtgaccgtctccgggagctgcatgtgtcagaggttttcaccgtcatcaccgaaacgcgcgagacgaaagggcctcgtgatacgcctatttttataggttaatgtcatgataataatggtttcttagacgtcaggtggcacttttcggggaaatgtgcgcggaacccctatttgtttatttttctaaatacattcaaatatgtatccgctcatgagacaataaccctgataaatgcttcaataatattgaaaaaggaagagtatgagccatattcaacgggaaacgtcttgctctaggccgcgattaaattccaacatggatgctgatttatatgggtataaatgggctcgcgataatgtcgggcaatcaggtgcgacaatctatcgattgtatgggaagcccgatgcgccagagttgtttctgaaacatggcaaaggtagcgttgccaatgatgttacagatgagatggtcagactaaactggctgacggaatttatgcctcttccgaccatcaagcattttatccgtactcctgatgatgcatggttactcaccactgcgatccctgggaaaacagcattccaggtattagaagaatatcctgattcaggtgaaaatattgttgatgcgctggcagtgttcctgcgccggttgcattcgattcctgtttgtaattgtccttttaacagcgatcgcgtatttcgtctcgctcaggcgcaatcacgaatgaataacggtttggttgatgcgagtgattttgatgacgagcgtaatggctggcctgttgaacaagtctggaaagaaatgcataaacttttgccattctcaccggattcagtcgtcactcatggtgatttctcacttgataaccttatttttgacgaggggaaattaataggttgtattgatgttggacgagtcggaatcgcagaccgataccaggatcttgccatcctatggaactgcctcggtgagttttctccttcattacagaaacggctttttcaaaaatatggtattgataatcctgatatgaataaattgcagtttcatttgatgctcgatgagtttttctaactgtcagaccaagtttactcatatatactttagattgatttaaaacttcatttttaatttaaaaggatctaggtgaagatcctttttgataatctcatgaccaaaatcccttaacgtgagttttcgttccactgagcgtcagaccccgtagaaaagatcaaaggatcttcttgagatcctttttttctgcgcgtaatctgctgcttgcaaacaaaaaaaccaccgctaccagcggtggtttgtttgccggatcaagagctaccaactctttttccgaaggtaactggcttcagcagagcgcagataccaaatactgttcttctagtgtagccgtagtt aggccaccacttcaagaactctgtagcaccgcctacatacctcgctctgctaatcctgttaccagtggctgctgccagtggcgataagtcgtgtcttaccgggttggactcaagacgatagttaccggataaggcgcagcggtcgggctgaacggggggttcgtgcacacagcccagcttggagcgaacgacctacaccgaactgagatacctacagcgtgagctatgagaaagcgccacgcttcccgaagggagaaaggcggacaggtatccggtaagcggcagggtcggaacaggagagcgcacgagggagcttccagggggaaacgcctggtatctttatagtcctgtcgggtttcgccacctctgacttgagcgtcgatttttgtgatgctcgtcaggggggcggagcctatggaaaaacgccagcaacgcggcctttttacggttcctggccttttgctggccttttgctcacatgttctttcctgcgttatcccctgattctgtggataaccgtattaccgcctttgagtgagctgataccgctcgccgcagccgaacgaccgagcgcagcgagtcagtgagcgaggaagcggaagagcgcccaatacgcaaaccgcctctccccgcgcgttggccgattcattaatgcagctggcacgacaggtttcccgactggaaagcgggcagtgagcgcaacgcaattaatgtgagttagctcactcattaggcaccccaggctttacactttatgcttccggctcgtatgttgtgtggaattgtgagcggataacaatttcacacaggaaacagctatgaccatgattacgccaagctcggcgcgccattgggatggaaccctgcaggcag GENE CASSETTE TM042 OCCURS AT BP 4 THROUGH 2330 OF SEQ ID NO: 50 61 cgcgctcgctcgctcactgaggccgcccgggcaaagcccgggcgtcgggcgacctttggtcgcccggcctcagtgagcgagcgagcgcgcagagagggagtggggtaccacgcgtttgtcctctccctgcttggccttaaccagccacatttctcaactgaccccactcactgcagaggtgaaaactaccatgccaggtcctgctggctgggggaggggtgggcaataggcctggatttgccagagctgccactgtagatgtagtcatatttacgatttcccttcacctcttattaccctggtggtggtggtgggggggggggggtgctctctcagcaaccccaccccgggatcttgaggagaaagagggcagagaaaagagggaatgggactggcccagatcccagccccacagccgggcttccacatggccgagcaggaactccagagcaggagcacacaaaggagggctttgatgcgcctccagccaggcccaggcctctc ccctctcccctttctctctgggtcttcctttgccccactgagggcctcctgtgagcccgatttaacggaaactgtgggcggtgagaagttccttatgacacactaatcccaacctgctgaccggaccacgcctccagcggagggaacctctagagctccaggacattcaggtaccaggtagccccaaggaggagctgccgaatcgatggatcgggaactgaaaaaccagaaagttaactggtaagtttagtctttttgtcttttatttcaggtcccggatccggtggtggtgcaaatcaaagaactgctcctcagtggatgttgcctttacttctaggcctgtacggaagtgttacttctgctctaaaagctgcggaattgtacccgccccgggatccatcgattgaattcgccaccatgtcagaaggggtgggcacgttccgcatggtacctgaagaggaacaggagctccgtgcccaactggagcagctcacaaccaaggaccatggacctgtctttggcccgtgcagccagctgccccgccacaccttgcagaaggccaaggatgagctgaacgagagagaggagacccgggaggaggcagtgcgagagctgcaggagatggtgcaggcgcaggcggcctcgggggaggagctggcggtggccgtggcggagagggtgcaagagaaggacagcggcttcttcctgcgcttcatccgcgcacggaagttcaacgtgggccgtgcctatgagctgctcagaggctatgtgaatttccggctgcagtaccctgagctctttgacagcctgtccccagaggctgtccgctgcaccattgaagctggctaccctggtgtcctctctagtcgggacaagtatggccgagtggtcatgctcttcaacattgagaactggcaaagtcaagaaatcacctttgatgagatcttgcaggcatattgcttcatcctggagaagctgctggagaatgaggaaactcaaatcaatggcttctgcatcattgagaacttcaagggctttaccatgcagcaggctgctagtctccggacttcagatctcaggaagatggtggacatgctccaggattccttcccagcccggttcaaagccatccacttcatccaccagccatggtacttcaccacgacctacaatgtggtcaagcccttcttgaagagcaagctgcttgagagggtctttgtccacggggatgacctttctggtttctaccaggagatcgatgagaacatcctgccctctgacttcgggggcacgctgcccaagtatgatggcaaggccgttgctgagcagctctttggcccccaggcccaagctgagaacacagccttctgaggatcgtaccggtcgacctgcagaagcttgcctcgagcagcgctgctcgagagatct ggatcataatcagccataccacatttgtagaggttttacttgctttaaaaaacctcccacacctccccctgaacctgaaacataaaatgaatgcaattgttgttgttaacttgtttattgcagcttataatggttacaaataaagcaatagcatcacaaatttcacaaataaagcatttttttcactgcattctagttgtggtttgtccaaactcatcaatgtatcttatcatgtctggtaaccacgtgcggaccgagcggccgcaggaacccctagtgatggagttggccactccctctctgcgcgctcgctcgctcactgaggccgggcgaccaaaggtcgcccgacgcccgggctttgcccgggcggcctcagtgagcgagcgagcgcgcag

TABLE 3 Plasmid Construction SEQUENCE IDENTIFIER (SEQ.ID.NO:) Construction summary Plasmid TM017 1 PvuII/MluI restriction fragment of Δ5′ ITR element cloned into PvuII/MluI restriction fragment of plasmid backbone ΔITR 3 Blunted BamHI/MluI restriction fragment of human RLBP1 promoter (short) was cloned into blunted SacII/MluI restriction fragment of plasmid backbone Human RLBP1 Promoter(short) 4 MluI/ClaI restriction fragment a clone containing an hCMV promoter and modified SV40 intron was cloned into MluI/ClaI restriction fragment of plasmid backbone. The hCMV promoter was removed during subsequent cloning to insert human RLBP1 promoter (short) MODIFIED SV40INTRON 5, 6 EcoRI/AgeI restriction fragment containing Kozak and human RLBP1 gene CDS was cloned into EcoRI/AgeI restriction fragment of plasmid backbone Added Kozak AND HUMAN RLBP1 GENE CDS 8 BglII/BstEII restriction fragment of SV40 polyA was cloned into BglII/BsteII restriction fragment of the plasmid backbone SV40 POLYA 9 Present in original Amp resistant backbone, AAV-MCS (Stratagene) 3′ ITR Plasmid TM037 construction summary 2 Present in original Amp resistant backbone, AAV-MCS (Stratagene) 5′ ITR 10 Blunted HindIII/EcoRI restriction fragment of human RLBP1 promoter (long) was cloned into blunted MluI/EcoRI restriction fragment of plasmid backbone Human RLBP1 Promoter(long) 5, 6 EcoRI/AgeI restriction fragment containing Kozak and human RLBP1 gene CDS cloned into EcoRI/AgeI restriction fragment of plasmid backbone Added Kozak AND HUMAN RLBP1 GENE CDS 8 BglII/BstEII restriction fragment containing SV40 polyA was cloned into BglII/BsteII restriction fragment of the plasmid backbone SV40 POLYA 9 Present in original Amp resistant backbone, AAV-MCS (Stratagene) 3′ ITR Plasmid AG007 construction summary 2 Present in original Amp resistant backbone, pAAV-MCS (Stratagene) 5′ ITR 11 MluI/EcoRI restriction fragment containing human RPE65 promoter cloned into MluI/EcoRI restriction fragment of the plasmid backbone Human RPE65 Promoter 5, 6 EcoRI/AgeI restriction fragment containing Kozak and human RLBP1 gene CDS cloned into EcoRI/AgeI restriction fragment of plasmid backbone ADDED-KOZAK and HUMAN RLBP1 GENE CDS 8 BglII/BstEII restriction fragment containing SV40 polyA was cloned into BglII/BsteII restriction fragment of the plasmid backbone SV40 POLYA 14 BstEII restriction fragment containing RLBP1 intron1 stuffer sequence was cloned into BstEII restriction fragment of the plasmid backbone RLBP1 INTRONIC SEQUENCE AS STUFFER SEQUENCE 9 Present in original Amp resistant backbone, pAAV-MCS (Stratagene) 3′ ITR Plasmid TM039 construction summary 2 Present in original Amp resistant backbone, AAV-MCS purchased from Stratagene 5′ ITR 22 EcoRI/MluI restriction fragment containing CMV-enhancer with CBA promoter was cloned into EcoRI/MluI restriction fragment of plasmid backbone CMV-enhancer with CBA promoter 5, 6 EcoRI/SalI restriction fragment containing Kozak and human RLBP1 gene CDS was cloned into EcoRI/SalI restriction fragment of plasmid backbone Added Kozak AND HUMAN RLBP1 GENE CDS 8 BglII/BstEII restriction fragment containing SV40 polyA was cloned into BglII/BsteII restriction fragment of the plasmid backbone SV40 POLYA 23 Plasmid backbone was cut with BstEII then blunted. The stuffer was PCR amplified from human cell line (HEK293 or ARPE19) genomic DNA, the product was phosphorylated and ligated into backbone. REVERSE COMPLEMENT OF RLBP1 INTRON STUFFER 9 Present in original Amp resistant backbone, AAV-MCS (Stratagene) 3′ ITR Plasmid TM040 construction summary 2 Present in original Amp resistant backbone, AAV-MCS (Stratagene) 5′ ITR 3 Blunted BamHI/MluI restriction fragment of human RLBP1 promoter (short) was cloned into blunted SacII/MluI restriction fragment of plasmid backbone Human RLBP1 promoter (short) 4 MluI/ClaI restriction fragment containing an hCMV promoter and modified SV40 intron was cloned into MluI/ClaI restriction fragment of plasmid backbone. The hCMV promoter was removed during subsequent cloning to insert human RLBP1 promoter (short) MODIFIED SV40INTRON 5, 6 EcoRI/SalI restriction fragment containing Kozak and human RLBP1 gene CDS cloned into EcoRI/SalI restriction fragment of plasmid backbone Added Kozak AND HUMAN RLBP1 GENE CDS 8 BglII/BstEII restriction fragment containing SV40 polyA was cloned into BglII/BsteII restriction fragment of the plasmid backbone SV40 POLYA 23 Plasmid backbone was cut with BstEII then blunted. The stuffer was PCR amplified from human cell line (HEK293 or ARPE19) genomic DNA, the product was phosphorylated and ligated into backbone. REVERSE COMPLEMENT OF RLBP1 INTRON STUFFER 9 Present in original Amp resistant backbone, AAV-MCS purchased from Stratagene 3′ ITR Plasmid TM016 construction summary 1 PvuII/MluI restriction of Δ5′ ITR element cloned into PvuII/MluI restriction fragment of plasmid backbone Δ5′ ITR 3 Blunted BamHI/MluI restriction fragment of human RLBP1 promoter (short) was cloned into blunted SacII/MluI restriction fragment of plasmid backbone Human RLBP1 promoter (short) 4 MluI/ClaI restriction fragment of containing an hCMV promoter and modified SV40 intron was cloned into MluI/ClaI restriction fragment of plasmid backbone. The hCMV promoter was removed during subsequent cloning to insert human RLBP1 promoter (short) MODIFIED SV40INTRON 24 EcoRI/Age fragment containing GFP was blunted then cloned into the SalI digested and blunted backbone E_GFP 8 BglII/BstEII restriction fragment containing SV40 polyA was cloned into BglII/BsteII restriction fragment of the plasmid backbone SV40 POLYA 9 Present in original Amp resistant backbone, AAV-MCS purchased from Stratagene 3′ ITR Plasmid TM035 construction summary 2 Present in original Amp resistant backbone, AAV-MCS purchased from Stratagene 5′ ITR 10 Blunted HindIII/EcoRI restriction fragment of human RLBP1 promoter (long) was cloned into blunted MluI/EcoRI restriction fragment of plasmid backbone Human RLBP1 promoter (long) 24 EcoRI/Age I digested fragment containing GFP was blunted then cloned into the SalI digested and blunted backbone E_GFP 8 SV40 POLYA BglII/BstEII restriction fragment containing SV40 polyA was cloned into BglII/BstEII restriction fragment of the plasmid backbone 9 Present in original Amp resistant backbone, AAV-MCS purchased from Stratagene 3′ ITR Plasmid AG012 construction summary 2 Present in original Amp resistant backbone, AAV-MCS purchased from Stratagene 5′ ITR 13 The plasmid backbone was digested with MluI/AgeI. The synuclein stuffer was PCR amplified from plasmid pBV5, the product was digested with MluI/AgeI, phosphorylated and ligated into the plasmid backbone. SYNUCLEIN INTRONIC SEQUENCE AS STUFFER SEQUENCE 8 BglII/BstEII restriction fragment from GeneArt synthesized clone containing SV40 polyA was cloned into BglII/BstEII restriction fragment of the plasmid backbone SV40 POLYA 14 BstEII restriction fragment from intermediary clone containing RLBP1 intron1 stuffer sequence cloned into BstEII restriction fragment of the plasmid backbone RLBP1 INTRONIC SEQUENCE AS STUFFER SEQUENCE 9 Present in original Amp resistant backbone, AAV-MCS purchased from Stratagene 3′ ITR Plasmid AG004 construction summary 2 Present in original Amp resistant backbone, AAV-MCS purchased from Stratagene 5′ ITR 11 MluI/EcoRI restriction fragment from GeneArt synthesized clone containing human RPE65 promoter cloned into MluI/EcoRI restriction fragment of the plasmid backbone Human RPE65 Promoter 24 An EcoRI/AgeI digested fragment from an intermediary clone was blunted then cloned into the SalI digested and blunted backbone E_GFP 8 BglII/BstEII restriction fragment from GeneArt synthesized clone containing SV40 polyA was cloned into BglII/BstEII restriction fragment of the plasmid backbone SV40 POLYA 14 BstEII restriction fragment from intermediary clone containing RLBP1 intron1 stuffer sequence cloned into BstEII restriction fragment of the plasmid backbone RLBP1 INTRONIC SEQUENCE AS STUFFER SEQUENCE 9 Present in original Amp resistant backbone, AAV-MCS purchased from Stratagene 3′ ITR Plasmid AG006 construction summary 2 Present in original Amp resistant backbone, AAV-MCS purchased from Stratagene 5′ ITR 12 MluI/EcoRI restriction fragment from GeneArt synthesized clone containing human VMD2 promoter cloned into MluI/EcoRI restriction fragment of the plasmid backbone HUMAN VMD2 PROMOTER 24 An EcoRI/AgeI digested fragment from an intermediary clone was blunted then cloned into the SalI digested and blunted backbone E_GFP 8 BglII/BstEII restriction fragment from GeneArt synthesized clone containing SV40 polyA was cloned into BglII/BstEII restriction fragment of the plasmid backbone SV40 POLYA 14 BstEII restriction fragment from intermediary clone containing RLBP1 intron1 stuffer sequence cloned into BstEII restriction fragment of the plasmid backbone RLBP1 INTRONIC SEQUENCE AS STUFFER SEQUENCE 9 Present in original Amp resistant backbone, AAV-MCS purchased from Stratagene 3′ ITR Plasmid TM042 Construction Summary 1-ΔITR, 3-Human RLBP1 Promoter (short), 4- MODIFIED SV40INTRON, 5,6- Added Kozak AND HUMAN RLBP1 GENE,8- SV40 POLYA, and 9-3′ ITR SbfI restriction fragment of Plamsid pTM017 was cloned into a SbfI restriction fragment of Puc57 with kanamycin resistance gene backbone.

TABLE 4 Viral Vector Composition: Vector Genome and Caspid SEQUENCE ELEMENTS SEQUENCE IDENTIFIER (SEQ.ID.NO:) Viral Vector NVS1 (Generated from plasmid TM017 or TM042, and AAVRep2/Cap2 plasmid) The viral vector contains a self complementary genome with the following genomic elements in the 5′ to 3′ direction packaged in the viral capsid AAV2. SC5′ITR 36 Reverse Complementary sequence of SV40polyA 62 Reverse Complementary sequence of HUMAN RLBP1 GENE CDS 63 Reverse Complementary sequence of Added KOZAK 64 Reverse Complementary sequence of Modified SV40INTRON 65 Reverse Complementary sequence of Human RLBP1 PROMOTER (short) 66 ΔITR 1 Human RLBP1 PROMOTER (short) 3 Modified SV40INTRON 4 Added Kozak 5 HUMAN RLBP1 GENE CDS 6 SV40 POLYA 8 3′ ITR 9 CAPSID PROTEIN SEQUENCE OF NVS1 AAV2 CAPSID SEQUENCE 19, 68 and 69 (Encoded by 18) Viral Vector NVS2 (Generated from plasmid TM017 or TM042, and AAVRep2/Cap8 plasmid) The viral vector contains a self complementary genome with the following genomic elements in the 5′ to 3′ direction packaged in the viral capsid AAV8. SC5′ITR 36 Reverse Complementary sequence of SV40polyA 62 Reverse Complementary sequence of HUMAN RLBP1 GENE CDS 63 Reverse Complementary sequence of Added KOZAK 64 Reverse Complementary sequence of Modified SV40INTRON 65 Reverse Complementary sequence of Human RLBP1 PROMOTER (short) 66 ΔITR 1 Human RLBP1 PROMOTER (short) 3 Modified SV40INTRON 4 Added Kozak 5 HUMAN RLBP1 GENE CDS 6 SV40 POLYA 8 3′ ITR 9 CAPSID PROTEIN SEQUENCE OF NVS2 AAV8 CAPSID SEQUENCE 21, 70, and 71 (Encoded by 20) Viral Vector NVS3 (Generated from plasmid TM035 and AAVRep2/Cap2 plasmid) The viral vector genome contains the following genomic elements in the 5′ to 3′ direction 5′ ITR 2 HUMAN RLBP1 PROMOTER (long) 10 ADDED KOZAK 5 HUMAN RLBP1 GENE CDS 6 SV40 POLYA 8 3′ ITR 9 CAPSID PROTEIN SEQUENCE OF NVS3 AAV2 CAPSID SEQUENCE 19, 68 and 69 (Encoded by 18) Viral Vector NVS4 (Generated from plasmid TM037 and AAVRep2/Cap8 plasmid) The viral vector genome contains the following genomic elements in the 5′ to 3′ direction 5′ ITR 2 HUMAN RLBP1 PROMOTER (long) 10 ADDED KOZAK 5 HUMAN RLBP1 GENE CDS 6 SV40 POLYA 8 3′ ITR 9 CAPSID PROTEIN SEQUENCE OF NVS4 AAV8 CAPSID SEQUENCE 21, 70, and 71 (Encoded by 20) Viral Vector NVS5 (Generated from plasmid AG007 and AAVRep2/Cap2 plasmid) The viral vector genome contains the following genomic elements in the 5′ to 3′ direction 5′ ITR 2 HUMAN RPE65 PROMOTER 11 ADDED-KOZAK 5 HUMAN RLBP1 GENE CDS 6 SV40 POLYA 8 RLBP1 INTRONIC SEQUENCE AS STUFFER SEQUENCE 14 3′ ITR 9 CAPSID PROTEIN SEQUENCE OF NVS5 AAV2 CAPSID SEQUENCE 19, 68 and 69 (Encoded by 18) Viral Vector NVS6 (Generated from plasmid AG007 and AAVRep2/Cap8 plasmid) The viral vector genome contains the following genomic elements in the 5′ to 3′ direction 5′ ITR 2 HUMAN RPE65 PROMOTER 11 ADDED-KOZAK 5 HUMAN RLBP1 GENE CDS 6 SV40 POLYA 8 RLBP1 INTRONIC SEQUENCE AS STUFFER SEQUENCE 14 3′ ITR 9 CAPSID PROTEIN SEQUENCE OF NVS6 AAV8 CAPSID SEQUENCE 21, 70, and 71 (Encoded by 20) Viral Vector NVS7 (Generated from plasmid TM039 and AAVRep2/Cap2 plasmid) The viral vector genome contains the following genomic elements in the 5′ to 3′ direction 5′ ITR 2 CMV Enhancer and CBA PROMOTER (GENEBANK ACCESSION DD215332 FROM BP 1 to BP 161) 22 ADDED KOZAK 5 HUMAN RLBP1 GENE CDS 6 SV40 POLYA 8 REVERSE COMPLEMENT OF RLBP1 INTRONIC SEQUENCE AS STUFFER SEQUENCE (NT 010274.17) 23 3′ ITR 9 CAPSID PROTEIN SEQUENCE OF NVS7 AAV2 CAPSID SEQUENCE 19, 68 and 69 (Encoded by 18) Viral Vector NVS8 (Generated from plasmid TM039 and AAVRep2/Cap8 plasmid) The viral vector genome contains the following genomic elements in the 5′ to 3′ direction 5′ ITR 2 CMV Enhancer and CBA PROMOTER (GENEBANK ACCESSION DD215332 FROM BP 1 to BP 161) 22 ADDED KOZAK 5 HUMAN RLBP1 GENE CDS 6 SV40 POLYA 8 REVERSE COMPLEMENT OF RLBP1 INTRONIC SEQUENCE AS STUFFER SEQUENCE (NT 010274.17) 23 3′ ITR 9 CAPSID PROTEIN SEQUENCE OF NVS8 AAV8 CAPSID SEQUENCE 21, 70, and 71 (Encoded by 20) Viral Vector NVS9 (Generated from plasmid TM040 and AAVRep2/Cap2 plasmid) The viral vector genome contains the following genomic elements in the 5′ to 3′ direction 5′ ITR 2 HUMAN RLBP1 PROMOTER (short) 3 MODIFIED SV40 INTRON 4 ADDED KOZAK 5 HUMAN RLBP1 GENE CDS 6 SV40 POLYA 8 REVERSE COMPLEMENT OF RLBP1 INTRONIC SEQUENCE AS STUFFER SEQUENCE (NT_010274.17) 23 3′ ITR 9 CAPSID PROTEIN SEQUENCE OF NVS9 AAV2 CAPSID SEQUENCE 19, 68 and 69 (Encoded by 18) Viral Vector NVS10 (Generated from plasmid TM040 and AAVRep2/Cap8 plasmid) The viral vector genome contains the following genomic elements in the 5′ to 3′ direction 5′ ITR 2 HUMAN RLBP1 PROMOTER (short) 3 MODIFIED SV40 INTRON 4 ADDED KOZAK 5 HUMAN RLBP1 GENE CDS 6 SV40 POLYA 8 REVERSE COMPLEMENT OF RLBP1 INTRONIC SEQUENCE AS STUFFER SEQUENCE (NT_010274.17) 23 3′ ITR 9 CAPSID PROTEIN SEQUENCE OF NVS10 AAV8 CAPSID SEQUENCE 21, 70, and 71 (Encoded by 20) Viral vector scAAV8-pRLBP1 (short) –eGFP (eGFP Reporter viral vector generated from plasmid TM016 and AAVRep2/Cap8 plasmid) The viral vector contains a self complementary genome with the following genomic elements in the 5′ to 3′ direction packaged in the viral capsid AAV8. SC5′ITR 36 Reverse Complementary sequence of SV40polyA 62 Reverse Complementary sequence of eGFP 67 Reverse Complementary sequence of Added KOZAK 64 Reverse Complementary sequence of Modified SV40INTRON 65 Reverse Complementary sequence of Human RLBP1 PROMOTER (short) 66 ΔITR 1 HUMAN RLBP1 PROMOTER (short) 3 MODIFIED SV40 INTRON 4 ADDED KOZAK 5 eGFP 24 SV40 POLYA 8 3′ ITR 9 CAPSID PROTEIN SEQUENCE OF Viral vector scAAV8-pRLBP1 (short)-eGFP AAV8 CAPSID SEQUENCE 21, 70, and 71 (Encoded by 20) Viral Vector AAV8-pRLBP1 (long) –eGFP (eGFP Reporter viral vector generated from plasmid TM035 and AAVRep2/Cap8 plasmid) The viral vector genome contains the following genomic elements in the 5′ to 3′ direction 5′ ITR 2 HUMAN RLBP1 PROMOTER (long) 10 ADDED KOZAK 5 eGFP 24 SV40 POLYA 8 3′ ITR 9 CAPSID PROTEIN SEQUENCE OF Viral Vector AAV8-pRLBP1(long)-eGFP AAV8 CAPSID SEQUENCE 21, 70, and 71 (Encoded by 20) Viral Vector AAV8-pRPE65-eGFP (eGFP Reporter viral vector generated from plasmid AG004 and AAVRep2/Cap8 plasmid) The viral vector genome contains the following genomic elements in the 5′ to 3′ direction 5′ ITR 2 HUMAN RPE65 PROMOTER 11 ADDED KOZAK 5 eGFP 24 SV40 POLYA 8 RLBP1 INTRONIC SEQUENCE AS STUFFER SEQUENCE (NT_010274.17) 14 3′ ITR 9 CAPSID PROTEIN SEQUENCE OF Viral Vector AAV8-pRPE65-eGFP AAV8 CAPSID SEQUENCE 21, 70, and 71 (Encoded by 20) Viral Vector AAV8-pVMD2–eGFP (eGFP Reporter viral vector generated from plasmid AG006 and AAVRep2/Cap8 plasmid) The viral vector genome contains the following genomic elements in the 5′ to 3′ direction 5′ ITR 2 HUMAN VMD2 PROMOTER 12 ADDED KOZAK 5 eGFP 24 SV40 POLYA 8 RLBP1 INTRONIC SEQUENCE AS STUFFER SEQUENCE (NT_010274.17) 14 3′ ITR 9 CAPSID PROTEIN SEQUENCE OF Viral Vector AAV8-pVMD2-eGFP AAV8 CAPSID SEQUENCE 21, 70, and 71 (Encoded by 20) Viral Vector NVS11 (Generated from plasmid AG012 and AAVRep2/Cap8 plasmid) The viral vector genome contains the following genomic elements in the 5′ to 3′ direction 5′ ITR 2 SYNUCLEIN INTRONIC SEQUENCE AS STUFFER SEQUENCE 13 SV40 POLYA 8 RLBP1 INTRONIC SEQUENCE AS STUFFER SEQUENCE (NT_010274.17) 14 3′ ITR 9 CAPSID PROTEIN SEQUENCE OF NVS11 AAV8 CAPSID SEQUENCE 21, 70, and 71 (Encoded by 20)

Example 2: Subretinal Injection of rAAV Vectors in Mice 2.1 Subretinal Injection of rAAV Vectors in Mice

Subretinal injection of an rAAV vector can achieve efficient transduction of RPE and other retinal cells because subretinal injection induces a bleb of concentrated virus in intimate contact with RPE cells and the neural retina. In addition, the subretinal space has a relatively high degree of immunoprivilege and typically very little evidence of inflammation is seen in the vicinity of the injection site. Thus, subretinal injection was a preferred route for delivery of rAAV vectors in mouse retina. However, other routes of delivery may be used, for example, intravitreal injection.

Supplies/reagents:

-   Leica M844 F40 Ophthalmic Surgical Microscope -   1% cyclopentolate: Bausch & Lomb Cat# 965911 -   2.5%-10% phenylephrine: Altaire Pharmaceuticals Cat#05626 -   0.5% Proparacaine: Bausch & Lomb Cat# NDC 54799-500-12 -   10 µl Hamilton syringe: VWR Cat# 89184-476 -   33G blunt-ended needle: Hamilton Cat# 7803-05 -   Fluorescein sodium salt: Sigma Cat# F6377

Test articles used in this example:

-   scAAV8-pRLBP1(short)-eGFP viral vector 1×10⁹ vg/eye -   AAV8-pRLBP1(long)-eGFP viral vector 1×10⁹ vg/eye -   AAV8-pRPE-eGFP viral vector 1×10⁹ vg/eye -   AAV8-VMD2-eGFP viral vector 1×10⁹ vg/eye

Protocol:

The subretinal injection was performed either in both eyes or unilaterally in the right eye. All procedures were performed under aseptic conditions, using sterile reagents, syringes and appropriate personal protection equipment.

Subretinal Injection Procedures:

-   The mouse pupils were dilated by 1 drop of 1% cyclopentolate and     followed by 1 drop of 2.5%-10% phenylephrine -   The mouse was anesthetized by using Avertin (250 mg/kg) i.p. and a     drop of 0.5% Proparacine topically (local anesthetic) in the eye -   An approximately 0.5 mm incision was made nasally, posterior to the     limbus with a microscalpel -   The blunt-ended needle on the 10 µl Hamilton syringe was inserted     tangentially through the scleral incision toward the temporal     retina. The needle was advanced until resistance was felt. The 1 µl     of diluted rAAV vector (containing fluorescein with the     concentration of 1:50) was then injected slowly into the subretinal     space, and the needle is withdrawn through the incision -   The eye was examined and the success of the subretinal injection was     confirmed by visualization of a bleb containing fluorescein. The     success of injection and the degree of retinal damage (hemorrhage)     were scored. -   An antibiotic ointment was applied to the eye immediately after the     injection

2.2. rAAV Vectors Induced GFP Expression and Its Cell-Type Specifics in Mouse Retina

To study the rAAV vector-induced gene transduction and cell-type specifics in the mouse retina, the eGFP expression in retinal cross sections and RPE/retina flatmounts were examined. One approach used to identify the eGFP expressing cell types was to co-label eGFP positive cells with retinal cell markers by immunocytochemistry staining in cryosections.

Supplies/Reagents

Primary antibodies for immunocytochemistry staining:

-   Anti-CRALBP antibody: Thermo cat# MA1-813 -   Anti-GFAP antibody: Covance cat# SMI- 21 -   Anti-Opsin Blue antibody: Millipore cat# AB 5407 -   Anti-Opsin Red antibody: Millipore cat# AB5405 -   Anti-Vimentin antibody: Santa Cruz cat# sc-7557 -   Anti-PKC α antibody: C-20 Santa Cruz cat# sc -208

Secondary antibodies for immunocytochemistry staining:

-   Goat anti-mouse IgG: Invitrogen Cat#A1 1005 -   Goat anti-rat IgG: Invitrogen Cat#A11007 -   Donkey anti-rabbit IgG: Invitrogen Cat#A21207

Other supplies/reagents:

-   Vectashield Mounting Medium with DAPI: Vector Laboratories,     Burlingame Cat# H-1200), -   Zeiss Imaging system, AxioVision Software -   Zeiss LSM 510 confocal microscope, ZEN version of the Zeiss software

Protocol:

The mouse eyeball was removed and placed in 4% PFA (paraformaldehyde) for 2 hours at 25° C. and then in PBS buffer for 1-3 days in 4° C. till dissection. The cornea, lens and vitreous were removed from the eye ball and the retinal and RPE/choroid was flatmounted with Vectashield mounting medium on to the slide. The GFP expression in flatmount was captured by Zeiss Imaging system and quantified using AxioVision Software. After imaging, the slides with retinal flatmounts were placed in 0.25% triton buffer at 25° C. for 30 min and then the retinal flatmounts were removed from the slides. The eGFP positive areas of the retina flatmounts were cut and embedded in OCT and then cryosectioned. The immunocytochemistry staining using retinal cell markers was applied in the cryosections. The images were captured by Zeiss LSM 510 confocal microscope and ZEN version of the Zeiss software.

The Immunocytochemistry Staining Procedures:

Day 1.

-   air dry sections at room temperature 1 hour. -   place slides in PBS + 0.25% Triton 15 min x 2 -   block in 1% BSA + PBS + 0.25% Triton 90 min -   incubate slides with primary antibody in 1% BSA + PBS + 0.25% Triton     at 4° C. overnight

Day 2.

-   take out slides from 4° C., leave them at 25° C. for 30 min -   wash slides in PBS + 0.25% Triton 15 min x 2 -   incubate slides with secondary 1:800 at 25° C. for 90 min -   wash slides in PBS + 0.25% Triton 15 min x 2 -   mount slides with Vectashield Mounting Medium with DAPI

TABLE 5 The retinal cell markers and dilutions used in the study Cell Type Cell Marker Dilutions Muller cell Anti-CRALBP 1:1000 Anti-Vimentin 1:100 Anti-GFAP 1:1000 Photoreceptor Anti-Opsin Red/Green 1:250 Anti-Opsin Blue 1:250 Neuron in INL Anti-PKCα 1:200 Astrocytes Anti-GFAP 1:1000

TABLE 6 Immunohistochemistry results that describe the transduction of cell types by test viral vectors Cell Type Cell Marker scAAV8-pRLBP1 (short)-eGFP AAV8-pRLBP1(long)-eGFP AAV8-pRPE65-eGFP AAV8 pVMD2-eGFP RPE + + + + Muller cell CRALBP + + - - Vimentin + + - - GFAP + + - - Photoreceptor Opsin Red/Green - + + + Opsin Blue - - + + Recoverin ND ND + ND Neuron in INL PKCα - - - - Ganglion Cell NeuN - ND ND ND Astrocytes GFAP - - - - +, indicates expression of GFP in a given cell type -, no GFP expression ND, Not Determined

Results:

-   All tested viral vectors were functional in the mouse retina. -   scAAV8-pRLBP1(short)-eGFP vector leads to selective expression of     GFP in RPE and the Muller cells in the neural retina. -   AAV8-pRLBP1(long)-eGFP leads to expression of GFP in RPE, Muller     cells and photoreceptors in the neural retina. -   AAV8-pRPE65-eGFP and AAV8-pVMD2-eGFP lead to GFP expression in RPE     and photoreceptors in the neural retina.

Conclusion

These results demonstrate that the combination of promoter, AAV genome conformation and AAV capsid sequence can lead to different transduction properties in specific cell types, to achieve the desired effect. Expression of the RLBP1 gene product in RPE and Muller cells of the retina, represents the desired on-target cell type expression. RLBP1 short promoter packaged in a self-complementary genome in conjunction with an AAV8 serotype capsid induces gene expression in RPE and Muller cells in the neural retina without off-target cell expression.

The RLBP1-long promoter packaged in a single-stranded genome in conjunction with an AAV8 serotype capsid induces gene expression in RPE and Muller cells, which are on-target cell types, and also in photoreceptors, which is an off-target cell type.

The RPE65 and VMD2 promoter packaged in a single-stranded genome in conjunction with an AAV8 serotype capsid induces gene expression in RPE cells but also in photoreceptors, which is an off-target cell type.

Example 3: mRNA Based Assay to Measure Vector-mediated Expression of a Human RLBP1 Transgene Relative to Endogenous Mouse RLBP1 mRNA Expression.

The expression levels and tissue specificity of an rAAV-transduced transgene will vary depending on the vector serotype, the vector genome, the tissue-specific promoter used and the dose injected. A goal of gene replacement therapy is to achieve a level of expression that is sufficient to compensate for the missing endogenous gene expression while not over expressing the gene to toxic levels.

An assay has been developed to measure the vector-mediated expression of human RLBP1 mRNA relative to the endogenous levels of mouse RLBP1 mRNA following subretinal injections of various AAV vectors at different doses in wild-type mice. This assay utilized Taqman® Gene Expression Assays containing primers and probes for specifically detecting human or mouse RLBP1 cDNA. Prior to performing the experiment the Taqman® Gene Expression Assays were tested for species specificity using plasmid DNA containing either human or mouse RLBP1 cDNA sequences. In brief, Taqman® reagents were used to co-amplify either mouse or human RLBP1 cDNA with mouse GAPDH cDNA as an endogenous control. The levels of the mouse or human RLBP1 were normalized to the internal GAPDH control and then these normalized levels were compared with one another. Supplies/reagents:

-   RNA extraction     -   Qiagen RNeasy micro kit (Qiagen cat # 74004)     -   Qiagen RNase-Free DNase Set (Qiagen cat# 79254)     -   Beta-Mercaptoethanol (Sigma cat# 63689)     -   Qiagen Stainless-Steel 5 mm beads (Qiagen cat#69989)     -   2.0 ml Seal Rite Microcentrifuge tube (USA Scientific         cat#1620-2700)     -   Qiagen TissueLyser II(cat# 85300) -   cDNA synthesis     -   High Capacity cDNA Reverse Transcription Kit (Applied Biosystems         cat# 4368814)     -   RNase Inhibitor (Applied Biosystems cat#N8080119)     -   BioRad Thermal cycler -   Relative Quantitation PCR     -   2X TaqMan® Universal PCR Master Mix (Applied Biosystems         cat#4304437)     -   20X TaqMan® Gene Expression Assay for human RLBP1 (Applied         Biosystems cat# 4331182: Hs00165632.m1)     -   20X TaqMan® Gene Expression Assay for mouse RLBP1 (Applied         Biosystems cat# 4331182: Mm00445129.m1)     -   20X Applied Biosystems® Mouse GAPD (GAPDH) Endogenous Control         (VIC®/MGB Probe, Primer Limited) (Applied Biosystems cat#         4352339E)     -   Applied Biosystems Real-Time PCR machine model 7900HT. -   Test articles used in this example:     -   NVS8 viral vector     -   NVS10 viral vector     -   NVS4 viral vector     -   NVS2 viral vector     -   NVS6 viral vector

Protocol:

At the termination of the in vivo experiment neural retina was dissected out of the eyes, placed in a 2 ml microcentrifuge tube and flash frozen on dry ice. The remaining eye cup (minus retina and lens) was frozen in a separate tube. Samples were stored at -80° C. until RNA isolation. Total RNA was extracted using a Qiagen RNeasy micro kit with DNase treatment. For tissue homogenization and lysis, a Qiagen TissueLyzerwas used. In particular, a 5 mm stainless-steel bead was added to each tissue-containing tube while on dry ice. Samples were transferred to room temperature and 350 µl of buffer RLT containing 1% beta-mercaptoethanol was added. Samples were processed on the TissueLyzer with a shaking frequency of 30 Hz for two 2 minute cycles. The standard Qiagen RNeasy micro kit protocol for RNA extraction with DNase treatment was then followed with one minor modification. Prior to elution the RNA column was allowed to air dry for >10 minutes to ensure elimination of residual ethanol. Total RNA was stored at -80° C. until ready for cDNA synthesis.

Total RNA concentration was determined using a Nanodrop spectrophotometer. Each sample was adjusted to a final concentration of 50 ng/µl. cDNA was generated using the Applied Biosystems High Capacity cDNA reverse transcriptase kit. A master mix of reagents from the High Capacity cDNA RT kit was prepared such that each 10 µl contained 2 µl of 10X High Capacity RT buffer, 0.8 µl of 25X dNTPs (100 mM), 2 µl of Reverse Transcriptase random primers, 0.4 µl of RNase inhibitor, 1 µl of Multiscribe Reverse transcriptase and 3.8 µl of RNAse-free water. 10 µl of the 50 ng/µl stock of each total RNA was dispensed into a well of a 96-well PCR amplification plate and then 10 µl of the RT master mix was added to each well. The plate was placed in a Bio-Rad thermal cycler and operated using the following parameters: 25° C. for 10 min, 37° C. for 120 min., 85° C. for 5 min then hold at 4 degrees until terminate program. cDNA was stored at -20° C. prior to Relative quantitative PCR reaction set-up.

The cDNA concentration was adjusted to a final concentration of 20 ng/µl by adding 5 µl of RNAse-free water to each well of the cDNA reaction (this is based on the initial total RNA concentration and assuming 100% conversion to cDNA). For each cDNA sample set up two different multiplex qPCR reactions; one using the mouse RLBP1 Taqman Expression Assay probes with the mouse GAPDH endogenous control, and the other using the human RLBP1 Taqman Expression Assay probes with the mouse GAPDH endogenous control. Each of these two reactions were performed in duplicate for each sample. For each sample, 5 µl of the 20 ng/µl cDNA sample was dispensed into a well of a 385-well plate. Two separate master mixes were prepared, one for the mouse RLBP1 Taqman assay and one for the human RLBP1 assay such that each 15 µl of mixture contained 10 µl of 2X TaqMan® Universal PCR Master Mix, 1 µl of 20X TaqMan® Gene Expression Assay for either mouse or human RLBP1, 1 µl of 20X Applied Biosystems® Mouse GAPD (GAPDH) Endogenous Control, and 3 µl of RNAse-free water. 15 µl of the appropriate master mix was dispensed into the well containing the cDNA. The plate was placed in an ABI 7900HT Real Time PCR machine and run using the relative quantitation program with the following parameters: an initial incubation at 50° C. for 2 min then 40 cycles of the following two steps, 15 sec. at 95° C. and 1 min. at 60° C.

The relative quantitation plate results were imported into a RQ study document using the ABI RQ Manager 1.2. The data were analyzed using the automatic threshold setting to generate average and average ΔCt which is the difference in Ct readings of the RLBP1 cDNA (mouse or human) minus the Ct of the internal endogenous GAPDH. The data were exported into Microsoft Excel and used to calculate the ΔΔCt value by subtracting the mouse RLBP1 ΔCt value from the human RLBP1 ΔCt for each sample. The relative expression was calculated using the calculation 2^(-ΔΔCt) this expresses the relative expression of human RLBP1 as a fold change of the mouse endogenous RLBP1 expression. To portray the results as expression of human RLBP1 as a percent of the mouse endogenous expression the relative expression value was multiplied by 100.

Results: mRNA Expression

FIG. 1A illustrates that NVS8, NVS4, NVS2 and NVS6 successfully transduce both the neural retina cells and the RPE cells in the posterior eyecup. Vector NVS10 transduces the RPE cells but barely at the level of detection limit in the neural retina.

FIG. 1B illustrates that NVS2 is the only vector to show mRNA expression in the neural retina at a lower dose of 1×10⁸ vg/eye.

Conclusion

These surprising results demonstrated that the specific combination of promoter, AAV genome conformation, and AAV capsid sequence can lead to different transduction properties in different cell types in the retina. In general, all tested vectors successfully lead to vector-mediated human RLBP1 mRNA expression. More specifically, NVS2 is the most potent vector in expressing human RLBP1 mRNA in the RPE cells (in the posterior eyecup) and in the neural retina in both doses tested (1×10⁹ and 1×10⁸ vg/eye), while NVS4 and NVS6 lead to detectable vector-mediated human RLBP1 mRNA expression at the dose of 1×10⁹ vg/eye, and only in the RPE at the dose of 1×10⁸ vg/eye. NVS8 and NVS10 lead to detectable mRNA expression in the RPE and neural retina at the dose of 1×10⁹ vg/eye but almost at the detection limit at the dose of 1×10⁸ vg/eye.

Example 4: Electroretinogram-Based Dark Adaptation Assay

One approach for assessing treatments that modify the visual cycle is to quantify the recovery of visual function in the dark following a bright light exposure (i.e. dark adaptation). Dark adaptation after extensive light exposure is driven largely by the ability of the eye to regenerate photopigment via the visual cycle. Modifications to the visual cycle achieved through treatment will therefore lead to a change in the kinetics of dark adaptation.

An assay has been developed to monitor the recovery of visual function in mice that is based on quantifying dark adaptation using an electroretinogram (ERG). The ERG-based assay typically proceeds over two days with an initial baseline and subsequent follow-up measurement to assess recovery after exposure to light that bleaches a fraction of the photopigment (photobleach). This procedure developed for testing the invention first determines the maximum electrical response of each eye 5 ms after a flash of light during the a-wave portion of the ERG trace. The test subsequently compares the 5 ms a-wave amplitude 4 hours after a photobleach to assess the fraction of maximum amplitude recovered in that time. If the visual cycle is functioning normally, the ERG amplitude will approach baseline values in 4 hours. A delayed visual cycle will result in lower recovery of photopigment with a corresponding reduction in ERG a-wave amplitude recovery after photobleach.

Supplies/reagents:

-   ERG system: Diagnosys, Espion E2 console with ColorDome full field     ganzfeld stimulator -   Ketamine -   Xylazine -   2.5% phenylephrine -   1% cyclopentolate -   0.5% proparacaine -   Active electrode: Gold loop contact lens electrode (Mayo, part     number N30) -   Reference electrode: Nasopharyngeal electrode (Grass, part number     F-ERG-G) -   Ground electrode: Platinum needle electrode (Grass, part number     F-E2) -   Hydrating drops: Novartis, Genteal Mild to Moderate -   Syringe pump: Harvard Apparatus, part number Pump 11 Plus

Protocol:

Mice are placed in the dark overnight for approximately 20 hours before baseline ERGs are recorded. Immediately preceding recording, eyes are dilated with 1-2 drops of 1% cyclopentolate and 1-2 drops of 2.5% phenylephrine. 1-2 drops of 0.5% proparacaine (a topical anesthetic) are also applied. Mice are then anesthetized with an intraperitoneal injection of a cocktail of ketamine and xylazine (100-150 mg/kg and 5-10 mg/kg, respectively). Three electrodes are then placed to enable recording an ERG from one eye per mouse. The active electrode on the eye is a gold loop contact lens, the reference is a nasopharyngeal electrode placed in the mouth and the ground is a subdermal platinum needle electrode placed on the back just behind the head. Eyes are kept moist and electrical contact is maintained through continuous application of hydrating drops with a syringe pump (300 µl/hour). ERG amplitude is recorded by averaging the electrical response to three white flashes (2.7 log scotopic candela second per square meter) delivered by the xenon lamp in the ganzfeld dome. A-wave amplitude reported is the voltage measured 5 ms after the xenon flash as assessed using software analysis routines developed for this purpose (Mathworks, Matlab).

Dark adaptation is assessed by quantifying the ERG a-wave amplitude 4 hours after a photobleach. These experiments typically occur 48 hours after baseline determination. Mice are first housed in the dark overnight just as with the baseline measurements so that ERG recordings occur approximately 20 hours later. Eyes are dilated with 1-2 drops of 2.5% phenylephrine and 1-2 drops of 1% cyclopentolate immediately preceding photobleach. A sequence of 16 flashes of light (3.7 log scotopic candela second per square meter) is then delivered to the eye resulting in a photopigment bleach. Mice are placed back in the dark for 4 hours to recover visual function. ERGs are then recorded utilizing the same protocol used for the baseline determination. The recovery of visual function for each eye is defined as:

$DA = \frac{a - wave\mspace{6mu} amplitude\mspace{6mu} 4\mspace{6mu} hours\mspace{6mu} post - bleach}{baseline\mspace{6mu} a - wave\mspace{6mu} amplitude}$

FIG. 2 illustrates the results of the assay when applied to RLBP1 -/- and RLBP1 +/+ mice. RLBP1 +/+ mice exhibit nearly full recovery (up to 96%) 4 hours post-bleach. In contrast, RLBP1-/- mice recover minimal visual function (11%) at the same time point due to severely delayed visual cycle kinetics (Saari et al 2001). This 8-9 fold window between RLBP1+/+ and -/- mice is the assay window achievable for testing vectors injected into RLBP1-/- mice.

Using the ERG-based dark adaptation assay described above, the improvement of dark adaptation efficiency is tested in RLBP1 knockout (KO) mice where therapeutic vectors are introduced subretinally. Since the subretinal injection involves the displacement of neural retina from the RPE, it is crucial to determine if the neural retina is reattached to the RPE to avoid false negative results for the test articles in the ERG assay. One week after subretinal injection of viral vectors into mouse eyes, optical coherence tomography (OCT) is performed to visualize the condition of the retina. Eyes with unresolved retinal detachment were excluded from ERG measurement.

At each time point, mice were dark adapted overnight (>12 hours) and the ERG a-wave amplitude from each eye was established as the maximum dark adapted response to light (100%). The fully dark adapted eyes were then exposed to a series of bright flashes (as described in previous section) and a-wave amplitude was quantified 4 hours later. The term “percentage of normal” is defined as the percentage of the second a-wave recovery measurement with respect to the value obtained from the maximum a-wave recovery measurement.

Positive efficacy, or efficacious effect, is defined as the difference between test measurement and negative (naïve) control being statistically significant at a given time point post-injection.

Test articles used in this example includes:

-   NVS1 viral vector -   NVS2 viral vector -   NVS3 viral vector -   NVS4 viral vector -   NVS5 viral vector -   NVS11 viral vector

FIGS. 3A-D illustrate that viral vectors expressing RLBP1 improve the rate of dark adaptation in RLBP1 KO mice. Efficacy assessments were performed for each group vs. naïve controls with statistics calculated using a one way ANOVA with a Newman-Keuls multiple comparison test. The mean +3 standard deviations (SD) for naïve (uninjected) eyes and eyes receiving 1×10⁹ vg/eye of the negative control AAV-null vector (NVS11) for all related studies are shown to indicate the approximate threshold for efficacy (a-wave recoveries above this line typically exhibit statistically significant efficacy). This approach for displaying the degree of efficacy is similar to that presented in gene therapy publications (Jacobson et al. 2006 and Roman et al. 2007).

FIG. 3A shows that at a dose of 3×10⁸ vg/eye, NVS2 is efficacious in improving the rate of dark adaptation as early as 14 days post treatment, and the efficacy endures at least 350 days. A dose of 3×10⁸ vg/eye of NVS4 is also efficacious for at least 30-204 days post-treatment. NVS2 at the dose of approximately 3×10⁸ vg/eye has been tested in RLBP1 KO mouse model in 3 independent experiments. In each experiment at all time points tested up to 350 days post injection the vector demonstrated efficacy.

FIG. 3B shows that NVS1 at the same dose (3×10⁸ vg/eye ) demonstrated efficacy starting 84 days post-injection, with efficacy enduring to at least 350 days. NVS5 and NVS3 at the same dose did not demonstrate efficacy for up to 154 days post drug administration. Data presented in FIGS. 3A and 3B suggested that even though the viral vector genome is equivalent, the vector can be of different potency when packaged in different AAV capsid serotype (NVS1 versus NVS2). In addition, the specific combination of vector serotype, promoter, and vector genome conformation can affect the potency of the vector (NVS1 carries a self-complementary genome while NVS3 and NVS4 carry a single-stranded genome, all with different promoter sequences). This result further confirms that the combination of genome conformation and capsid serotype can affect the efficiency of recovery outcome.

FIG. 3C shows that, at the dose of 1×10⁹ vg/eye, NVS2 is efficacious as early as 18 days post treatment, and the efficacy endures at least 375 days. At the dose of 1×10⁹ vg/eye, NVS11, which is a negative control AAV-null vector, did not show significant difference in improvement of rate of dark adaptation when compared to uninjected control (individual data points not shown, but the historical mean +3SD line is displayed for comparison). A dose of 1×10⁹ vg/eye of NVS4 is also efficacious for at least 30-204 days post-treatment.

FIG. 3D shows that at a dose of 3×10⁹ vg/eye, NVS3 and NVS5, respectively, are efficacious in improving the rate of dark adaptation as early as day 26 post-treatment, and the efficacy endures at least 371 days.

FIG. 4A demonstrates that NVS2 at multiple doses is efficacious at improving the rate of dark adaptation for at least 94 days post-injection. Both the 3×10⁸ and 1×10⁹ vg/eye groups were efficacious compared to naïve controls based on a one way ANOVA with a Newman-Keuls multiple comparison test. FIG. 4B displays the data from FIG. 4A in a different format. In this case, the plot displayes the percentage of eyes/group with an a-wave recovery greater than that defined by the mean +3SD of the naïve group from several experiments. The results indicate that for NVS2, 50% of 3×10⁷ vg/eye treated eyes and 100% of 3×10⁸ and 1×10⁹ vg/eye treated eyes demonstrated efficacious a-wave recovery, and that a dose-response curve is established.

FIG. 5A demonstrates that NVS4 at multiple doses is efficacious at improving the rate of dark adaptation for at least 93 days post-injection. Both the 3×10⁸ and 1×10⁹ vg/eye groups were efficacious compared to naïve controls based on a one way ANOVA with a Newman-Keuls multiple comparison test. FIG. 5B displays the data from FIG. 5A in a different format. In this case, the plot displays the percentage of eyes/group with an a-wave recovery greater than that defined by the mean +3SD of the naïve group from several experiments. The results suggest that for NVS4, ≥85% of eyes treated with 3×10⁸ and 1×10⁹ vg/eye exhibited an increase in dark adaptation rate.

FIG. 6 demonstrates the increase in dark adaptation rate achieved with vector NVS2 generated by various production methods. NVS2 and NVS2a were both produced using two different CsCI gradient centrifugation methods while NVS2b was purified using column chromatography. Efficacy achieved 84 days post-injection with all three purification methods is indistinguishable based on a one way ANOVA with a Tukey’s test. This result indicates that 3 independent productions of NVS2 in 2 independent laboratories yielded functional material resulting in similar efficacy in RLBP1 KO mice.

Summary of Example 4 Results:

-   Eyes injected with viral vector NVS2 exhibit an increased rate of     dark adaption at doses ranging from ≥3×10⁷ to 1×10⁹ vg/eye, where     efficacy lasts for at least 350 days post injection in the RLBP1 KO     mouse model. -   Eyes injected with viral vector NVS4 exhibit an increased rate of     dark adaption at doses ranging from 3×10⁸ to 1×10⁹ vg/eye and the     efficacy endures at least 204 days at both doses. -   Eyes injected with viral vector NVS1 exhibit an increased rate of     dark adaptation at the dose of 3×10⁸ vg/eye and the efficacy endures     at least 350 days. -   Eyes injected with viral vector NVS3 and NVS5 exhibit an increased     rate of dark adaptation at the dose of 3×10⁹ vg/eye and efficacy     endures at least 371 days.

Efficacy of NVS3 and NVS5 was not observed at 3×10⁸ vg/eye for any time point tested.

Conclusion:

Viral vector NVS2 exhibits higher maximum recovery than equivalent doses of the other vectors tested. Additionally, the NVS2 vector-mediated efficacy appears to be indistinguishable when prepared using CsCI or column chromatography purification.

Summary of Results

The results demonstrated that self-complementary AAV8-pRLBP1(short)-eGFP vector, the reporter gene surrogate version of the therapeutic vector NVS2, leads to RPE and Müller cell type specific expression with no detectable off-target expression, where the therapeutic vector NVS2 leads to at least 350 days of visual function recovery measured by a-wave recovery in RLBP1 mice at doses ranging from ≥3×10⁷ to 1×10⁹ vg/eye. This specific gene cassette when packaged in a single-stranded genome and packaged with the same serotype capsid 8 exhibits significantly lower level of gene expression in mice, as demonstrated by the measurement of mRNA expression level. The same self-complementary genome as NVS2 and packaged in AAV2 capsid, which is NVS1, demonstrated efficacious a-wave recovery (i.e.: an increased rate of dark adaption) at the dose of 3×10⁸ vg/eye for at least 350 days. This result suggests that NVS2 is a more potent viral vector than NVS1, which is likely due to the more efficient infection of AAV8 capsid than AAV2 capsid to the target cell types.

The results also demonstrated that AAV8-pRLBP1(long)-eGFP vector, the reporter gene surrogate version of the therapeutic vector NVS4, leads to RPE and Müller cell expression but also to photoreceptors. The therapeutic vector NVS4 leads to at least 204 days of efficacy at doses ranging from 3×10⁸ to 1×10⁹ vg/eye. The same genome in NVS4 but packaged in AAV 2 capsid, which is NVS3, leads to efficacious a-wave recovery at the dose of 3×10⁹ but not at lower dose tested (3×10⁸ vg/eye). The results demonstrated that AAV8-pRPE65-eGFP vector, the reporter gene surrogate version of the therapeutic vector NVS6, leads to RPE cell type expression with extensive photoreceptor off-target expression. When therapeutic vector NVS5, which carries the same genome as NVS6 but packaged into AAV2 capsid, is tested in RLBP1 KO mouse efficacy model, the results demonstrated that NVS5 endures positive a-wave recovery efficacy at the dose of 3×10⁹ vg/eye but not at lower dose tested (3×10⁸ vg/eye).

REFERENCES

Burstedt MS, Forsman-Semb K, Golovleva I, et al (2001) Ocular phenotype of Bothnia dystrophy, an autosomal recessive retinitis pigmentosa associated with an R234W mutation in the RLBP1 gene. Arch Ophthalmol; 119:260-267.

Burstedt MS and Mönestam E (2010) Self-reported quality of life in patients with retinitis pigmentosa and maculopathy of Bothnia type. Clin Ophthalmol; 4:147-54.

Choi VW, Asokan A, Haberman RA, and Samulski RJ (2007) Production of Recombinant Adeno-Associated Viral Vectors for In Vitro and In Vivo Use. CURRENT PROTOCOLS IN MOLECULAR BIOLOGY. 16:25, Supplement 78.

Choi VW, McCarty DM, and Samulski RJ (2005) AAV Hybrid Serotypes: Improved Vectors for Gene Delivery. Curr Gene Ther; 5(3):299-310.

Demirci FYK, Rigatti BW, Mah TS, et al (2004) A novel compound heterozygous mutation in the cellular retinaldehyde-binding protein gene (RLBP1) in a patient with retinitis punctata albescens. Am J Ophthalmol.; 138:171-173.

Eichers ER, Green JS, Stockton DW, et al (2002) Newfoundland rod-cone dystrophy, an early-onset retinal dystrophy, is caused by splice-junction mutations in RLBP1. Am J Hum Genet; 70:955-964.

Ferrari FK, Xiao X, McCarty D et al (1997) New developments in the generation of Ad-free, high-titer rAAV gene therapy vectors. Nat Med 3(11); 1295-1297.

Fishman GA, Roberts MF, Derlacki DJ, et al (2004) Novel mutations in the cellular retinaldehyde-binding protein gene (RLBP1) associated with retinitis punctata albescens: evidence of interfamilial genetic heterogeneity and fundus changes in heterozygotes. Arch Ophthalmol.; 122:70-75.

Golovleva I and Burstedt M (2012) Retinitis Pigmentosa in Northern Sweden - From Gene to Treatment. March 2012. Advances in Ophthalmology, chapter 25, p.451-472. Published by InTech.

Golovleva I, Köhn L, Burstedt M, et al (2010) Mutation spectra in autosomal dominant and recessive retinitis pigmentosa in northern Sweden. Adv Exp Med Biol. 664:255-262.

Grieger JC, Choi VW and Samulski RJ. (2006) Production and characterization of adeno-associated viral vectors. Nat Protoc. 1(3); 1412-1428.

He X, Lobsiger J and Stocker A (2009) Bothnia dystrophy is caused by domino-like rearrangements in cellular retinaldehyde-binding protein mutant R234W. Proc. Natl Acad Sci USA. 106(44): 18545-50.

Jacobson SG, Acland GM, Aguirre GD et al (2006) Safety of Recombinant Adeno-Associated Virus Type 2-RPE65 Vector Delivered by Ocular Subretinal Injection. Molecular Therapy. 13(6); 1074-1084.

Katsanis N, Shroyer NF, Lewis RA, et al (2001) Fundus albipunctatus and retinitis punctata albescens in a pedigree with an R150Q mutation in RLBP1. Clin Genet; 59:424-429.

Kohn L, Burstedt MS, Jonsson F, et al (2008) Carrier of R14W in carbonic anhydrase IV presents Bothnia dystrophy phenotype caused by two allelic mutations in RLBP1. Invest Opthalmol Vis Sci. 49(7): 3172-3177.

Lock M, Alvira M, Vandenberghe LH, et al. (2010) Rapid, Simple, and Versatile Manufacturing of Recombinant Adeno-Associated Viral Vectors at scale. Human Gene Therapy. 21; 1-13.

Maw MA, Kennedy B, Knight A, et al (1997) Mutation of the gene encoding cellular retinaldehyde-binding protein in autosomal recessive retinitis pigmentosa. Nat Genet; 17:198-200.

McCarty DM (2008) Self-Complementary AAV Vectors; Advances and Applications. Molecular Therapy. 16(10): 1648-1656.

McCarty DM, Fu H, Monohan PE et al (2003) Adeno-associated virus terminal repeat (TR) mutant generates self-complementary vectors to overcome the rate-limiting step t transduction in vivo. Gene Therapy. 10; 2112-2118.

Morimura H, Berson EL, Dryja TP (1999) Recessive mutations in the RLBP1 gene encoding cellular retinaldehyde-binding protein in a form of retinitis punctata albescens. Invest Ophthalmol Visual Sci; 40:1000-1004.

Muzyczka N and Berns KI (2001) Chapter 69, Fields Virology. Lippincott Williams & Wilkins.

Naz S, Ali S, Riazuddin SA, et al (2011) Mutations in RLBP1 associated with fundus albipunctatus in consanguineous Pakistani families. Br J Ophthalmol; 95:1019-24.

Nojima K, Hosono K, Zhao Y, et al (2011) Clinical features of a Japanese case with Bothnia dystrophy. Ophthalmic Genet [Epub ahead of print]

Phelan JK and Bok D (2000) A Brief Review of Retinitis Pigmentosa and the Identified Retinitis Pigmentosa Genes. Mol Vis; 6:116-124.

Roman AJ, Boye SL, Aleman TS, et al (2007) Electroretinographic Analyses of RPE65-mutant rd12 Mice: Developing an In Vivo Bioassay for Human Gene Therapy Trials of Leber Congenital Amaurosis. Mol Vis. 13; 1701-1710.

Saari JC, Huang J, Possin DE, et al (1997) Cellular retinaldehyde-binding protein is expressed by oligodendrocytes in optic nerve and brain. Glia.; 21:259-268.

SAMBROOK et al (1989) MOLECULAR CLONING: A LABORATORY MANUAL 2nd Ed. (Cold Spring Harbor, N.Y)

Saari JC, Nawrot M, Kennedy BN et al. (2001) Visual Cycle Impairment in Cellular Retinaldehyde Binding Protein (CRALBP) Knockout Mice Results in Delayed Dark Adaptation. Neuron; 29:739-748.

Samulski RJ, Srivastava A, Berns KI, et al. (1983) Rescue of adeno-associated virus from recombinant plasmids: gene correction within the terminal repeats of AAV. Cell. 33(1):135-143.

Schmidt M, Vouteaakis A, Afione S et al. (2008) Adeno-Associated Virus Type 12 (AAV12): a Novel AAV Serotype with Sialic Acid- and Heparan Sulfate Proteoglycan-Independent Transduction Activity. J of Virology. 82(3):1399-1406.

Smith RH, Levy JR and Kotin RM. (2009) A Simplified Baculovirus-AAV Expression Vector System Coupled with One-Step Affinity Purification Yields High-Titer rAAV Stocks from Insect Cells. Molecular Therapy. 17(11); 1888-1896.

Travis GH, Golczak M, Moise AR, et al (2007) Diseases caused by defects in the visual cycle: retinoids as potential therapeutic agents. Annu Rev Pharmacol Toxicol.; 47: 469-512.

Vandenberghe LH, Xiao R, Lock M, et al. (2010) Efficient Serotype-Dependent Release of Functional Vector into the Culture Medium During Adeno-Associated Virus Manufacturing. Human Gene Therapy. 21; 1251-1257.

Wang J and Kefalov JV (2011) The Cone-specific visual cycle. Progress in retinal and eye research. 30: 115-128. 

1. A viral vector having a vector genome comprising a retinaldehyde binding protein 1 (RLBP1) coding sequence, wherein said vector is adapted to direct expression of an RLBP1 coding sequence in retinal pigment epithelial (RPE) cells and Muller cells of the retina.
 2. The viral vector of claim 1, wherein said vector comprises an adeno-associated virus (AAV) serotype 2 or 8 capsid.
 3. The viral vector of claim 2, said vector genome comprising in the 5′ to 3′ direction: (i) a 5′ ITR; (ii) a recombinant nucleotide sequence comprising an RLBP1 coding sequence; and (iii) a 3′ ITR.
 4. The viral vector of claim 3 where in the recombinant nucleotide sequence comprises in the 5′ to 3′ direction: (i) a promoter; (ii) an RLBP1 coding sequence; and (iii) an SV40 polyA sequence.
 5. The viral vector of 4, wherein the nucleotide sequence of said promoter is selected from SEQ ID NO: 3 and
 10. 6. The viral vector of claim 4 wherein the vector genome comprises in the 5′ to 3′ direction nucleic acid sequences selected from the group consisting of: a) SEQ ID NO: 2, 10, 5, 6, 8, and 9; b) SEQ ID NO: 2, 11, 5, 6, 8, 14, 9; c) SEQ ID NO: 2, 22, 5, 6, 8, 23, and 9; and d) SEQ ID NO: 2, 3, 4, 5, 6, 8, 23, and
 9. 7. The viral vector of claim 2, wherein said vector genome comprises in the 5′ to 3′ direction: (i) a 5′ ITR; (ii) a first recombinant nucleotide sequence; (iii) a non-resolvable ITR; (iv) a second recombinant nucleotide sequence; and (v) a 3′ ITR, wherein the first and second recombinant nucleotide sequences are self-complementary.
 8. The viral vector of claim 7 where in the second recombinant nucleotide sequence comprises in the 5′ to 3′ direction: (i) a promoter; (ii) an RLBP1 coding sequence; and (iii) an SV40 polyA sequence.
 9. The viral vector of 8, wherein the nucleotide sequence of said promoter comprises SEQ ID NO:
 3. 10. The viral vector of claim 8 wherein the vector genome comprises nucleic acid sequences in the 5′ to 3′ direction of: SEQ ID NO: 36, 62, 63, 64, 65, 66, 1, 3, 4, 5, 6, 8, and
 9. 11. A viral vector comprising a vector genome capable of expressing a heterologous gene in RPE cells and Muller cells of the retina, said vector comprising a) an AAV8 or AAV2 capsid and b) said vector genome comprising an RLBP1 promoter operably linked to the heterologous gene, wherein said RLBP1 promoter has a sequence selected from SEQ ID NOs: 3 and
 10. 12. The viral vector of claim 11, wherein the vector genome is self-complementary.
 13. A composition comprising the viral vector of any of the preceding claims .
 14. The composition of claim 13 further comprising a pharmaceutically acceptable excipient.
 15. A method of expressing a heterologous gene in retinal cells, the method comprising contacting said retinal cells with a viral vector comprising: a) an AAV2 or AAV8 capsid, and b) a vector genome comprising an RLBP1 promoter of SEQ ID NO: 3 or SEQ ID NO: 10 operably linked to the heterologous gene.
 16. The method of claim 15, wherein the retinal cells are RPE cells and Muller cells.
 17. The method of claim 16, wherein the vector genome is a self-complementary genome.
 18. The method of any of claims 15-17, wherein the heterologous gene is RLBP1.
 19. A nucleic acid comprising a gene cassette, said gene cassette comprises, in the 5′ to 3′ direction: (i) a 5′ ITR or a non-resolvable ITR; (ii) a recombinant nucleotide sequence comprising an RLBP1 coding sequence; and (iii) a 3′ITR.
 20. The nucleic acid of claim 19 that is a plasmid.
 21. The nucleic acid of claim 19, wherein: (i) said 5′ ITR or said non-resolvable ITR have a nucleic acid sequence of SEQ ID NO: 2 or 1, respectively; (ii) said recombinant nucleic acid sequence comprises a promoter having a nucleic acid sequence selected from: SEQ ID NO: 3, 10, 11, 12 and 22 operably linked to said RLBP1 coding sequence having a nucleic acid sequence of SEQ ID NO: 3; or (ii) said 3′ ITR has a nucleic acid sequence of SEQ ID NO:
 9. 22. The nucleic acid of claim 19, wherein the gene cassette comprises a nucleic acid sequence selected from: SEQ ID NO: 51, 52, 53, 54, and
 55. 23. The nucleic acid of claim 19, further comprising the nucleic acid sequence selected from SEQ ID NO: 26, 27, 28, 29, 30 and
 50. 24. The nucleic acid of claim 19, wherein the gene cassette comprises, in the 5′ to 3′ direction, the sequences selected from: a) SEQ ID NO: 2, 10, 5, 6, 8, and 9, b) SEQ ID NO: 2, 11, 5, 6, 8, 14 and 9, c) SEQ ID NO: 2, 22, 5, 6, 8, 23 and 9, d) SEQ ID NO: 2, 3, 4, 5, 6, 8, 23 and 9, or e) SEQ ID NO: 1, 3, 4, 5, 6, 8, and
 9. 25. A method of treating a subject having RLBP1-associated retinal dystrophy, the method comprising administering to a subject the composition of claim
 13. 26. A method of improving the rate of dark adaption in a subject having RLBP1-associated retinal dystrophy, the method comprising administering to a subject the composition of claim
 13. 27. A method of expressing an RLBP1 coding sequence in RPE cells and Muller cells in the retina of a subject having RLBP1-associated retinal dystrophy, said method comprising the step of: contacting the retina of said subject with the viral vector of claim 6 or
 10. 28. The composition of claim 13 for use in treating a subject having RLBP1-associated retinal dystrophy.
 29. The composition of claim 13 for use in improving the rate of dark adaption in a subject having RLBP1-associated retinal dystrophy.
 30. The viral vector of claim 6 or 10 for use in expressing an RLBP1 coding sequence in RPE cells and Muller cells in the retina of a subject having RLBP1-associated retinal dystrophy. 